gamma-aminobutyric acid has been researched along with Chronic Disease in 294 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Gabapentin (a GABA analogue) is efficacious and often well tolerated in other chronic pain conditions." | 9.27 | GaPP2, a multicentre randomised controlled trial of the efficacy of gabapentin for the management of chronic pelvic pain in women: study protocol. ( Baranowski, A; Bhattacharya, S; Birch, J; Cheong, Y; Cregg, R; Daniels, J; Hewitt, CA; Horne, AW; Macfarlane, GJ; Middleton, L; Szubert, W; Tracey, I; Vincent, K; Williams, ACC, 2018) |
| " Adults with refractory chronic cough (>8 weeks' duration) without active respiratory disease or infection were randomly assigned to receive gabapentin (maximum tolerable daily dose of 1800 mg) or matching placebo for 10 weeks." | 9.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| " Gabapentin significantly improved cough-specific quality of life compared with placebo (between-group difference in LCQ score during treatment period 1·80, 95% CI 0·56-3·04; p=0·004; number needed to treat of 3·58)." | 9.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| "The treatment of refractory chronic cough with gabapentin is both effective and well tolerated." | 9.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| "Pregabalin, a high-affinity ligand for α2δ subunits of voltage-gated calcium channels, is a novel pharmacotherapy for chronic pain, partial seizures, and other disorders." | 9.15 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| "Using nonlinear mixed-effect modeling, 5,583 plasma pregabalin concentration-time samples from 1,723 subjects were analyzed: 2,868 samples from healthy volunteers or subjects with renal impairment (n = 123), 1,513 from patients with partial seizures (n = 626), and 1,202 from patients with chronic pain (n = 974)." | 9.15 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| "Pregabalin CL/F is related to CLcr, and this relationship is similar among healthy volunteers and patients with either partial seizures or chronic pain disorders." | 9.15 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| "To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)." | 9.14 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "The purpose of this, open-label, non-comparative study, was to evaluate the efficacy on quality of life and the efficacy of gabapentin monotherapy in patients with chronic radiculopathy." | 9.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "Thirty-five patients with radicular pain and diagnosed as L4, L5 or S1 radiculopathy were treated with oral gabapentin from a total of 300 mg per day once up to a total of 1800 mg per day divided in 3 doses for eight-week trial period." | 9.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "Gabapentin may provide benefits in terms of alleviation of pain and overall quality of life in patients with chronic radiculopathy." | 9.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception." | 9.12 | Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. ( Bergasa, NV; Engler, D; Ginsburg, IH; McGee, M, 2006) |
| "The aim of this study was to compare the efficacy and side effects of gabapentin, amitriptyline, and their combination in women with chronic pelvic pain." | 9.11 | Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study. ( Ellend, A; Frickey, N; Gleiss, A; Kozek-Langenecker, SA; Kress, HG; Sator-Katzenschlager, SM; Scharbert, G, 2005) |
| "Gabapentin alone or in combination with amitriptyline is better than amitriptyline alone in the treatment of female chronic pelvic pain." | 9.11 | Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study. ( Ellend, A; Frickey, N; Gleiss, A; Kozek-Langenecker, SA; Kress, HG; Sator-Katzenschlager, SM; Scharbert, G, 2005) |
| "To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin." | 9.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Significant improvements in BPI measures of pain intensity and pain relief were reported for all groups of patients after 2 weeks of lidocaine patch 5% treatment." | 9.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "A retrospective audit of the perceived efficacy and tolerability of adjunctive gabapentin (GBT) therapy in patients with intractable epilepsy was carried out." | 9.09 | An audit of the perceived efficacy and tolerability of gabapentin therapy in an out-patient cohort with chronic epilepsy. ( Duncan, JS; Langan, Y; Sander, JW, 1999) |
| "To assess the efficacy and safety of low doses of gabapentin in cases of chronic daily headache." | 9.09 | Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000) |
| "Despite the inherent limitations of such a small open trial, the authors concluded that ratings of excellent and good by two thirds of this population of patients with chronic daily headache should encourage the setup of a large double-blind, multicentric, placebo-controlled trial of low doses of gabapentin for chronic daily headache." | 9.09 | Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000) |
| "The authors investigate: (1) whether there is a lateral effect of hydrogen (1H) magnetic resonance (MR) spectroscopy observable metabolite ratios between the right and the left prefrontal lobe in chronic schizophrenia; (2) whether there is a change of proton metabolite ratios in chronic schizophrenia after neuroleptic treatment; (3) whether there is a relation between changes in 1H MR spectra and the clinical assessment of Brief Psychiatric Rating Scale (BPRS); and (4) to investigate a hypofrontality hypothesis in schizophrenia in terms of neurochemical aspects." | 9.08 | Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. ( Choe, BY; Lee, C; Lee, CW; Paik, IH; Shinn, KS; Suh, TS, 1996) |
| " Results of a clinical open trial with pivagabine (4-[(2,2-dimethyl-1-oxopropyl) amino]butanoic acid, CAS 69542-93-4, Tonerg) on 22 young patients affected by dysthymic disorders and on 38 older patients affected by adjustment disorders following different stressors (mourning, retirement and recovery in institutions of assistance) are reported." | 9.08 | Clinical evaluation of the efficacy of pivagabine in the treatment of mood and adjustment disorders. ( Gilotta, SM; Luca, S; Terranova, R, 1997) |
| "To substantiate a previously reported disturbance of gamma-aminobutyric acid (GABA) in chronic schizophrenia, plasma growth hormone (GH) response to a direct GABA agonist (baclofen, 10 mg) was assessed in 12 unmedicated chronic schizophrenic males and 10 sex- and age-matched healthy controls." | 9.06 | Baclofen-induced growth hormone secretion is blunted in chronic schizophrenics: neuroendocrine evidence for a GABA disturbance in schizophrenia. ( Forziati, D; Iovino, M; Maj, M; Monteleone, P; Steardo, L; Veltro, F, 1988) |
| "Recent developments in the treatment of cough include the use of speech pathology and pharmacotherapy with gabapentin." | 8.91 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "The effectiveness of neuromodulating medications such as gabapentin and pregabalin in the treatment of cough has been supported primarily through case series, case reports, prospective reviews and a double blind randomised controlled trial." | 8.91 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain and fibromyalgia." | 8.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "We identified randomised trials of gabapentin for chronic neuropathic pain or fibromyalgia by searching the databases MEDLINE (1966 to March 2014), EMBASE (1980 to 2014 week 10), and CENTRAL in The Cochrane Library (Issue 3 of 12, 2014)." | 8.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "Randomised, double-blind studies reporting the analgesic and adverse effects of gabapentin in neuropathic pain or fibromyalgia with assessment of pain intensity, pain relief, or both, using validated scales." | 8.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "gov, Google Scholar, and reference lists of articles and abstracts from conference proceedings, without language restriction for pregabalin treatment of Class III prostatitis and CP/CPPS." | 8.88 | Pregabalin for chronic prostatitis. ( Aboumarzouk, OM; Nelson, RL, 2012) |
| "Twenty-nine studies (3571 participants), studied gabapentin at daily doses of 1200 mg or more in 12 chronic pain conditions; 78% of participants were in studies of postherpetic neuralgia, painful diabetic neuropathy or mixed neuropathic pain." | 8.87 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; McQuay, HJ; Moore, RA; Wiffen, PJ, 2011) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Recent studies showed effectiveness of gabapentin in improving the pain control in patients with neuropathic cancer pain, already treated with opiates." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Given the significant benefits of gabapentin and the combination of gabapentin with opioids for the treatment of neuropathic pain, randomized clinical trials are needed to establish the role of these analgesic regimens for the treatment of neuropathic cancer pain." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Pregabalin has proven efficacy in neuropathic pain conditions and fibromyalgia." | 8.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "To assess analgesic efficacy and associated adverse events of pregabalin in acute and chronic pain." | 8.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "Randomised, double blind trials reporting on the analgesic effect of pregabalin, with subjective pain assessment by the patient as either the primary or a secondary outcome." | 8.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "There was no clear evidence of beneficial effects of pregabalin in established acute postoperative pain." | 8.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice." | 8.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "Randomised trials of gabapentin in acute, chronic or cancer pain were identified by MEDLINE (1966-Nov 2004), EMBASE (1994-Nov 2004), SIGLE (1980-Jan 2004) and the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 4, 2004)." | 8.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "Randomised trials reporting the analgesic effects of gabapentin in patients, with subjective pain assessment as either the primary or a secondary outcome." | 8.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "There is evidence to show that gabapentin is effective in neuropathic pain." | 8.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "Response to gabapentin was defined by physician-documented subjective patient report of improvement in cough symptoms." | 7.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| " Therapy was initiated in patients with chronic cough with gabapentin, 100 mg twice daily, which was titrated to response or adverse effects." | 7.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| "In patients with chronic cough suspected to be related to vagal neuropathy, the odds of response to gabapentin are higher with the presence of VFMA noted on videostroboscopy." | 7.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| "In the present work, we investigated the antinociceptive effect of gabapentin in a chronic myositis model and its interference in spinal glial cells." | 7.85 | Gabapentin decreases microglial cells and reverses bilateral hyperalgesia and allodynia in rats with chronic myositis. ( Chacur, M; Freitas, MF; Rocha, IR; Rosa, AS, 2017) |
| "Latrunculin A microperfusion of the hippocampus induces acute epileptic seizures and long-term biochemical changes leading to spontaneous seizures." | 7.80 | Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. ( Loureiro, AI; Sierra-Marcuño, G; Sierra-Paredes, G; Soares-da-Silva, P; Wright, LC, 2014) |
| "Oral administration of ESL (100 mg/kg), previous to latrunculin A microperfusion, completely prevented acute latrunculin A-induced seizures as well as chronic seizures and all EEG chronic signs of paroxysmal activity." | 7.80 | Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. ( Loureiro, AI; Sierra-Marcuño, G; Sierra-Paredes, G; Soares-da-Silva, P; Wright, LC, 2014) |
| "ESL treatment prevented acute latrunculin A-induced seizures as well as chronic seizures and all EEG chronic signs of paroxysmal activity, supporting a possible anti-epileptogenic effect of ESL in mice." | 7.80 | Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. ( Loureiro, AI; Sierra-Marcuño, G; Sierra-Paredes, G; Soares-da-Silva, P; Wright, LC, 2014) |
| "To analyze the survival and the changes of proportions of Calbindin, Calretinin and Parvalbumin positive neurons in mouse hippocampal CA area at chronic stage of Pilocarpine-induced epilepsy." | 7.79 | [Survival of calbindin, calretinin and parvalbumin positive neurons in mouse hippocampal CA area at chronic stage of pilocarpine-induced epilepsy]. ( Liu, J; Liu, Y; Tang, F, 2013) |
| "Calbindin, Calretinin and Parvalbumin immunofluoresence staining were done 2 months after Pilocarpine-induced epilepsy in mice or saline injection." | 7.79 | [Survival of calbindin, calretinin and parvalbumin positive neurons in mouse hippocampal CA area at chronic stage of pilocarpine-induced epilepsy]. ( Liu, J; Liu, Y; Tang, F, 2013) |
| "The changes of proportions of Calbindin, Calretinin and Parvalbumin positive neurons in the CA area of mouse hippocampus may be a factor in the ongoing epileptic activity at chronic stage of Pilocarpine-induced epilepsy." | 7.79 | [Survival of calbindin, calretinin and parvalbumin positive neurons in mouse hippocampal CA area at chronic stage of pilocarpine-induced epilepsy]. ( Liu, J; Liu, Y; Tang, F, 2013) |
| "The aim of this study was to assess the role of adding gabapentin (Neurontin) to the prescription of patients with opiate resistant pain as a result of critical limb ischaemia (CLI)." | 7.76 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "The study has demonstrated that gabapentin is a useful adjuvant in the management of CLI and leads to significant reductions in pain scores and improves night pain for most patients." | 7.76 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "The objective of this study was to develop a pharmacokinetic-pharmacodynamic (PK-PD) model of the static allodynia response to pregabalin with and without sildenafil in a chronic constriction injury model of neuropathic pain." | 7.76 | Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain. ( Bender, G; Bies, RR; Bramwell, S; Danhof, M; DeJongh, J; Field, MJ; Florian, JA; Marshall, S; Tan, KK, 2010) |
| "Despite widely replicated abnormalities of gamma-aminobutyric acid (GABA) neurons in schizophrenia postmortem, few studies have measured tissue GABA levels in vivo." | 7.76 | Elevated gamma-aminobutyric acid levels in chronic schizophrenia. ( Cohen, BM; McCarthy, J; Ongür, D; Prescot, AP; Renshaw, PF, 2010) |
| "We found elevations in GABA/creatine in the schizophrenia group compared with control subjects [F(1,65) = 4." | 7.76 | Elevated gamma-aminobutyric acid levels in chronic schizophrenia. ( Cohen, BM; McCarthy, J; Ongür, D; Prescot, AP; Renshaw, PF, 2010) |
| "Pregabalin is used for treatment of neuropathic pain conditions." | 7.74 | Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. ( Audette, KM; Maeda, Y; Sluka, KA; Yokoyama, T, 2007) |
| "This study shows that pregabalin reduces both cutaneous and muscle hyperalgesia in inflammatory and noninflammatory models of muscle pain." | 7.74 | Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. ( Audette, KM; Maeda, Y; Sluka, KA; Yokoyama, T, 2007) |
| "Pregabalin is often used for the treatment of chronic pain syndromes." | 7.74 | Pregabalin-induced generalized myoclonic status epilepticus in patients with chronic pain. ( Hamer, HM; Hattemer, K; Klein, KM; Knake, S; Oertel, WH; Rosenow, F; Wellek, A, 2007) |
| "This prospective, open-label study aimed to evaluate the efficacy of pregabalin treatment in patients suffering from trigeminal neuralgia with and without concomitant facial pain." | 7.74 | Efficacy of pregabalin in the treatment of trigeminal neuralgia. ( Diener, HC; Katsarava, Z; Maschke, M; Obermann, M; Sensen, K; Yoon, MS, 2008) |
| "The anticonvulsant gabapentin (GBP) has been shown effective for the treatment of neuropathic pain, although its mechanism of action remains unclear." | 7.73 | Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. ( Aiyar, J; Anker, N; Belley, M; Bristow, L; Campbell, B; Cohen, C; Park, KT; Ren, K; Stearns, B; Urban, MO, 2005) |
| "This study was designed to characterize, in anterior, mediobasal, and posterior hypothalamic and median eminence, the 24h changes of gamma aminobutyric acid (GABA) and taurine (TAU) contents in adult male rats and to analyze whether chronic hyperprolactinemia may affect these patterns." | 7.72 | Daily changes of GABA and taurine concentrations in various hypothalamic areas are affected by chronic hyperprolactinemia. ( Alvarez, MP; Cano, P; Castrillón, PO; Duvilanski, BH; Esquifino, AI, 2003) |
| " Chronic seizures were induced by amygdalar injection of kainic acid 60 days before death." | 7.71 | Collapse of extracellular glutamate regulation during epileptogenesis: down-regulation and functional failure of glutamate transporter function in rats with chronic seizures induced by kainic acid. ( Doi, T; Kamada, H; Mitsuyama, Y; Nakajima, A; Ohya-Nishiguchi, H; Tokumaru, J; Ueda, Y; Willmore, LJ; Yokoyama, H, 2001) |
| "Postmortem samples from individuals with schizophrenia (n = 13) and control subjects (n = 10) were investigated for binding of [(3)H]tiagabine to GABA transporter-1 GAT-1." | 7.71 | Increased [(3)H]tiagabine binding to GAT-1 in the cingulate cortex in schizophrenia. ( Blennow, K; Dandenell, AK; Davidsson, P; Marcusson, J; Sundman-Eriksson, I, 2002) |
| "To present two years of experience in the use of gabapentin for the alleviation of neuropathic pain in spinal cord injury patients." | 7.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Data were retrieved from the medical records of all spinal cord injury patients prescribed gabapentin for neuropathic pain." | 7.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Seventy-six per cent of patients receiving gabapentin reported a reduction in neuropathic pain." | 7.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Our experience suggests that gabapentin offers an effective therapeutic alternative for the alleviation of neuropathic pain following spinal cord injury." | 7.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "To compare the long-term retention of gabapentin (GBP), lamotrigine (LTG), and vigabatrin (VGB) by patients with chronic epilepsy and the reasons for treatment discontinuation." | 7.70 | The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. ( Chadwick, DW; Fenwick, PB; Mawer, GE; Sander, JW; Wong, IC, 1999) |
| "We sought to determine the long-term retention rates of lamotrigine (LTG), gabapentin (GBP), and topiramate (TPM) therapy for patients at a tertiary referral clinic for chronic, refractory epilepsy." | 7.70 | Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. ( Lhatoo, SD; Polizzi, G; Sander, JW; Wong, IC, 2000) |
| "High affinity [3H]gamma-aminobutyric acid (GABA) and [3H]L-glutamate uptake were determined in synaptosomes prepared from the cerebral cortex of dogs with congenital hepatic encephalopathy and control dogs." | 7.69 | L-glutamate and gamma-aminobutyric acid uptake in synaptosomes from the cerebral cortex of dogs with congenital chronic hepatic encephalopathy. ( Johnston, GA; Maddison, JE; Watson, WE, 1995) |
| "The average pretreatment pruritus score was 9." | 6.78 | Use of pregabalin in the management of chronic uremic pruritus. ( Grenader, T; Lifschitz, M; Shavit, L; Slotki, I, 2013) |
| "This pharmacostatistical model showed that: (1) pregabalin oral clearance (CL/F) was directly proportional to creatinine clearance (CLcr), but was independent of gender, race, age, female hormonal status, daily dose, and dosing regimen; (2) apparent volume of distribution was dependent on body weight and gender; (3) absorption rate was decreased when given with food; and (4) coadministration with marketed antiepileptic drugs (AEDs) had no significant effect on pregabalin CL/F." | 6.76 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| " Pregabalin dosage was increased from 150 to 600 mg/d during the first 4 weeks." | 6.75 | Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. ( Alexander, RB; Anderson, RU; Cen, L; Chuai, S; Krieger, JN; Kusek, JW; Landis, JR; Litwin, MS; McNaughton-Collins, M; Nickel, JC; Nyberg, LM; O'Leary, M; Pontari, MA; Propert, KJ; Schaeffer, AJ; Shoskes, DA; White, PC; Zeitlin, S, 2010) |
| " Patients in group B who were receiving gabapentin continued this treatment up to a maximum daily dosage of 2400 mg during the observation period." | 6.74 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "Multimodal pain is comprised of nociceptive/inflammatory and neuropathic components." | 6.74 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "Gabapentin was associated with an increase in mean HSA, in contrast to the placebo, which was associated with a decrease." | 6.72 | Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. ( Bergasa, NV; Engler, D; Ginsburg, IH; McGee, M, 2006) |
| "Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception." | 6.72 | Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. ( Bergasa, NV; Engler, D; Ginsburg, IH; McGee, M, 2006) |
| "The lidocaine patch 5% was found to be safe and well tolerated." | 6.71 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Patients with postherpetic neuralgia, painful diabetic neuropathy, or low back pain with partial responses (average daily pain intensity >4/10) to their current analgesic treatment regimen were included." | 6.71 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Gabapentin has been successfully used for a variety of chronic pain conditions and therefore may be of use in the treatment of chronic headache." | 6.69 | Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000) |
| "Baclofen and placebo were administered orally, in a double-blind design, and blood samples were collected before and 30, 60, 90, 120, 180, and 240 min after drug or placebo administration." | 6.66 | Baclofen-induced growth hormone secretion is blunted in chronic schizophrenics: neuroendocrine evidence for a GABA disturbance in schizophrenia. ( Forziati, D; Iovino, M; Maj, M; Monteleone, P; Steardo, L; Veltro, F, 1988) |
| "Chronic pruritus is a distressing symptom that is often refractory to treatment." | 6.53 | Gabapentin and pregabalin for the treatment of chronic pruritus. ( Kwatra, SG; Matsuda, KM; Schonfeld, AR; Sharma, D, 2016) |
| "Gabapentin has been shown to cause minimal to no toxicity in overdose." | 6.52 | A review on the efficacy and safety of gabapentin in the treatment of chronic cough. ( Ryan, NM, 2015) |
| "Recent developments in the treatment of cough include the use of speech pathology and pharmacotherapy with gabapentin." | 6.52 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "Chronic cough is regarded as a challenging clinical problem due to its frequency and often limited therapeutic options." | 6.52 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "Results might vary between different neuropathic pain conditions, and the amount of evidence for gabapentin in neuropathic pain conditions except postherpetic neuralgia and painful diabetic neuropathy, and in fibromyalgia, is very limited." | 6.50 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 6.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Gabapentin has been successfully used for the treatment of multiple neuropathic pain syndromes such as diabetic neuropathy and postherpetic neuralgia." | 6.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist." | 5.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| "Neuropathic pain has proven to be a difficult condition to treat, so investigational therapy has been sought that may prove useful, such as the use of sigma-1 antagonists." | 5.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| "Chronic cough is a debilitating, often multifactorial problem." | 5.46 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| "Chronic myositis was induced by injection of Complete Freund Adjuvant (CFA) into the right gastrocnemius (GS) muscle of rats and tests for evaluating mechanical hyperalgesia, thermal hyperalgesia and tactile allodynia were performed." | 5.46 | Gabapentin decreases microglial cells and reverses bilateral hyperalgesia and allodynia in rats with chronic myositis. ( Chacur, M; Freitas, MF; Rocha, IR; Rosa, AS, 2017) |
| "Gabapentin was commenced at 300 mg daily and titrated to 300 mg tds over 3 days." | 5.36 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "Pain was assessed by visual analogue scoring at baseline, 4, 7, 14 and 28 days." | 5.36 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "The static allodynia endpoint was modeled by using three population PD approaches: 1) the behavior of the injured paw using a three-category ordinal logistic regression model; 2) paw withdrawal threshold (PWT) (g) between the injured and uninjured paw using the Hill equation with a baseline function; and 3) the baseline normalized difference in PWT between the injured and uninjured paw." | 5.36 | Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain. ( Bender, G; Bies, RR; Bramwell, S; Danhof, M; DeJongh, J; Field, MJ; Florian, JA; Marshall, S; Tan, KK, 2010) |
| "Epilepsy is a serious neurological disorder in human beings and the long-term pathological events remain largely obscure." | 5.35 | Time-course of neuronal death in the mouse pilocarpine model of chronic epilepsy using Fluoro-Jade C staining. ( Chen, LW; Huang, YG; Liu, YH; Wang, L, 2008) |
| "Patients without concomitant facial pain showed better response rates (32 of 39, 82%) compared with patients with concomitant chronic facial pain (7 of 14, 50%, P = 0." | 5.35 | Efficacy of pregabalin in the treatment of trigeminal neuralgia. ( Diener, HC; Katsarava, Z; Maschke, M; Obermann, M; Sensen, K; Yoon, MS, 2008) |
| "Muscle hyperalgesia (withdrawal threshold to compression of the muscle) and cutaneous hyperalgesia of the paw (withdrawal threshold to von Frey filaments) were measured before and after induction of hyperalgesia and after treatment with pregabalin (saline, 10 to 100 mg/kg i." | 5.34 | Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. ( Audette, KM; Maeda, Y; Sluka, KA; Yokoyama, T, 2007) |
| "Chronic seizures were induced by amygdalar injection of kainic acid 60 days before death." | 5.31 | Collapse of extracellular glutamate regulation during epileptogenesis: down-regulation and functional failure of glutamate transporter function in rats with chronic seizures induced by kainic acid. ( Doi, T; Kamada, H; Mitsuyama, Y; Nakajima, A; Ohya-Nishiguchi, H; Tokumaru, J; Ueda, Y; Willmore, LJ; Yokoyama, H, 2001) |
| "Gabapentin treatment significantly and reversibly changed the responses, consistent with the attenuation of the abnormal sensory behavior, and the attenuated responses lasted for the duration of the drug effect (up to 6 h)." | 5.31 | Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. ( Hulsebosch, CE; McAdoo, DJ; Perez-Polo, JR; Taylor, CP; Westlund, KN; Xu, GY, 2000) |
| "Pain was assessed prior to and during treatment at 1, 3 and 6 months with a 10 cm visual analogue scale which ranged from 0 ('no pain') to 10 ('worst pain imaginable'), or by the documentation of a verbal description of pain." | 5.31 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| " Gabapentin (a GABA analogue) is efficacious and often well tolerated in other chronic pain conditions." | 5.27 | GaPP2, a multicentre randomised controlled trial of the efficacy of gabapentin for the management of chronic pelvic pain in women: study protocol. ( Baranowski, A; Bhattacharya, S; Birch, J; Cheong, Y; Cregg, R; Daniels, J; Hewitt, CA; Horne, AW; Macfarlane, GJ; Middleton, L; Szubert, W; Tracey, I; Vincent, K; Williams, ACC, 2018) |
| " Adults with refractory chronic cough (>8 weeks' duration) without active respiratory disease or infection were randomly assigned to receive gabapentin (maximum tolerable daily dose of 1800 mg) or matching placebo for 10 weeks." | 5.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| " Gabapentin significantly improved cough-specific quality of life compared with placebo (between-group difference in LCQ score during treatment period 1·80, 95% CI 0·56-3·04; p=0·004; number needed to treat of 3·58)." | 5.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| "The treatment of refractory chronic cough with gabapentin is both effective and well tolerated." | 5.16 | Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. ( Birring, SS; Gibson, PG; Ryan, NM, 2012) |
| "The purpose of this study was to evaluate the analgesic effects of perioperative gabapentin on postoperative acute and chronic pain after coronary artery bypass graft (CABG) surgery with median sternotomy and internal mammary artery harvesting." | 5.15 | The effects of gabapentin on acute and chronic postoperative pain after coronary artery bypass graft surgery. ( Onan, B; Selcuk, I; Sen, H; Turan, A; Ucak, A; Yilmaz, AT, 2011) |
| "Pregabalin, a high-affinity ligand for α2δ subunits of voltage-gated calcium channels, is a novel pharmacotherapy for chronic pain, partial seizures, and other disorders." | 5.15 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| "Using nonlinear mixed-effect modeling, 5,583 plasma pregabalin concentration-time samples from 1,723 subjects were analyzed: 2,868 samples from healthy volunteers or subjects with renal impairment (n = 123), 1,513 from patients with partial seizures (n = 626), and 1,202 from patients with chronic pain (n = 974)." | 5.15 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| "Pregabalin CL/F is related to CLcr, and this relationship is similar among healthy volunteers and patients with either partial seizures or chronic pain disorders." | 5.15 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| "To evaluate the adequacy of a low-dose combination of oxycodone and paracetamol (acetaminophen) in patients with multimodal, chronic, non-malignant pain using the Pain Management Index (PMI)." | 5.14 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "The purpose of this, open-label, non-comparative study, was to evaluate the efficacy on quality of life and the efficacy of gabapentin monotherapy in patients with chronic radiculopathy." | 5.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "Thirty-five patients with radicular pain and diagnosed as L4, L5 or S1 radiculopathy were treated with oral gabapentin from a total of 300 mg per day once up to a total of 1800 mg per day divided in 3 doses for eight-week trial period." | 5.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "Gabapentin may provide benefits in terms of alleviation of pain and overall quality of life in patients with chronic radiculopathy." | 5.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception." | 5.12 | Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. ( Bergasa, NV; Engler, D; Ginsburg, IH; McGee, M, 2006) |
| " Fifty patients scheduled for breast cancer surgery were blindly randomized to receive gabapentin, eutectic mixture of local anesthetics cream, and ropivacaine in the wound or three placebos." | 5.11 | Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer. ( Fassoulaki, A; Melemeni, A; Sarantopoulos, C; Triga, A, 2005) |
| "The aim of this study was to compare the efficacy and side effects of gabapentin, amitriptyline, and their combination in women with chronic pelvic pain." | 5.11 | Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study. ( Ellend, A; Frickey, N; Gleiss, A; Kozek-Langenecker, SA; Kress, HG; Sator-Katzenschlager, SM; Scharbert, G, 2005) |
| "Gabapentin alone or in combination with amitriptyline is better than amitriptyline alone in the treatment of female chronic pelvic pain." | 5.11 | Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study. ( Ellend, A; Frickey, N; Gleiss, A; Kozek-Langenecker, SA; Kress, HG; Sator-Katzenschlager, SM; Scharbert, G, 2005) |
| "To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin." | 5.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Significant improvements in BPI measures of pain intensity and pain relief were reported for all groups of patients after 2 weeks of lidocaine patch 5% treatment." | 5.10 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "A retrospective audit of the perceived efficacy and tolerability of adjunctive gabapentin (GBT) therapy in patients with intractable epilepsy was carried out." | 5.09 | An audit of the perceived efficacy and tolerability of gabapentin therapy in an out-patient cohort with chronic epilepsy. ( Duncan, JS; Langan, Y; Sander, JW, 1999) |
| "To assess the efficacy and safety of low doses of gabapentin in cases of chronic daily headache." | 5.09 | Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000) |
| "Despite the inherent limitations of such a small open trial, the authors concluded that ratings of excellent and good by two thirds of this population of patients with chronic daily headache should encourage the setup of a large double-blind, multicentric, placebo-controlled trial of low doses of gabapentin for chronic daily headache." | 5.09 | Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000) |
| " Data on 2724 subjects from 10 recently completed placebo-controlled clinical trials of pregabalin in diabetic neuropathy, postherpetic neuralgia, chronic low back pain, fibromyalgia, and osteoarthritis were used." | 5.09 | Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. ( Farrar, JT; LaMoreaux, L; Poole, MR; Werth, JL; Young, JP, 2001) |
| "The authors investigate: (1) whether there is a lateral effect of hydrogen (1H) magnetic resonance (MR) spectroscopy observable metabolite ratios between the right and the left prefrontal lobe in chronic schizophrenia; (2) whether there is a change of proton metabolite ratios in chronic schizophrenia after neuroleptic treatment; (3) whether there is a relation between changes in 1H MR spectra and the clinical assessment of Brief Psychiatric Rating Scale (BPRS); and (4) to investigate a hypofrontality hypothesis in schizophrenia in terms of neurochemical aspects." | 5.08 | Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. ( Choe, BY; Lee, C; Lee, CW; Paik, IH; Shinn, KS; Suh, TS, 1996) |
| " Results of a clinical open trial with pivagabine (4-[(2,2-dimethyl-1-oxopropyl) amino]butanoic acid, CAS 69542-93-4, Tonerg) on 22 young patients affected by dysthymic disorders and on 38 older patients affected by adjustment disorders following different stressors (mourning, retirement and recovery in institutions of assistance) are reported." | 5.08 | Clinical evaluation of the efficacy of pivagabine in the treatment of mood and adjustment disorders. ( Gilotta, SM; Luca, S; Terranova, R, 1997) |
| "To substantiate a previously reported disturbance of gamma-aminobutyric acid (GABA) in chronic schizophrenia, plasma growth hormone (GH) response to a direct GABA agonist (baclofen, 10 mg) was assessed in 12 unmedicated chronic schizophrenic males and 10 sex- and age-matched healthy controls." | 5.06 | Baclofen-induced growth hormone secretion is blunted in chronic schizophrenics: neuroendocrine evidence for a GABA disturbance in schizophrenia. ( Forziati, D; Iovino, M; Maj, M; Monteleone, P; Steardo, L; Veltro, F, 1988) |
| "The hypothesis of a gamma-aminobutyric acid (GABA) involvement in the pathophysiology of schizophrenia has been recently proposed but not confirmed." | 5.06 | Growth hormone response to sodium valproate in chronic schizophrenia. ( Iovino, M; Maj, M; Monteleone, P; Steardo, L, 1986) |
| " Most studies used oral gabapentin or gabapentin encarbil at doses of 1200 mg or more daily in different neuropathic pain conditions, predominantly postherpetic neuralgia and painful diabetic neuropathy." | 4.95 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| "Gabapentin at doses of 1800 mg to 3600 mg daily (1200 mg to 3600 mg gabapentin encarbil) can provide good levels of pain relief to some people with postherpetic neuralgia and peripheral diabetic neuropathy." | 4.95 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| "With anticonvulsant, anxiolytic, and analgesic properties, pregabalin has been evaluated for neuropathic pain and fibromyalgia (FM)." | 4.91 | A systematic review of pharmacoeconomic studies for pregabalin. ( Huelin, R; Khankhel, Z; Mould, J; Parker, L; Wasiak, R, 2015) |
| "Recent developments in the treatment of cough include the use of speech pathology and pharmacotherapy with gabapentin." | 4.91 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "The effectiveness of neuromodulating medications such as gabapentin and pregabalin in the treatment of cough has been supported primarily through case series, case reports, prospective reviews and a double blind randomised controlled trial." | 4.91 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "To assess the analgesic efficacy and adverse effects of gabapentin in chronic neuropathic pain and fibromyalgia." | 4.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "We identified randomised trials of gabapentin for chronic neuropathic pain or fibromyalgia by searching the databases MEDLINE (1966 to March 2014), EMBASE (1980 to 2014 week 10), and CENTRAL in The Cochrane Library (Issue 3 of 12, 2014)." | 4.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "Randomised, double-blind studies reporting the analgesic and adverse effects of gabapentin in neuropathic pain or fibromyalgia with assessment of pain intensity, pain relief, or both, using validated scales." | 4.90 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "The goal of this systematic review was to examine the evidence for the use of the neuromodulating agents, amitriptyline, gabapentin, pregabalin, and baclofen, in the management of chronic, idiopathic cough patients." | 4.89 | Use of specific neuromodulators in the treatment of chronic, idiopathic cough: a systematic review. ( Cohen, SM; Misono, S, 2013) |
| "Benefit from neuromodulator treatment with amitriptyline, gabapentin, pregabalin, and baclofen in chronic, idiopathic cough patients was demonstrated." | 4.89 | Use of specific neuromodulators in the treatment of chronic, idiopathic cough: a systematic review. ( Cohen, SM; Misono, S, 2013) |
| "gov, Google Scholar, and reference lists of articles and abstracts from conference proceedings, without language restriction for pregabalin treatment of Class III prostatitis and CP/CPPS." | 4.88 | Pregabalin for chronic prostatitis. ( Aboumarzouk, OM; Nelson, RL, 2012) |
| "Twenty-nine studies (3571 participants), studied gabapentin at daily doses of 1200 mg or more in 12 chronic pain conditions; 78% of participants were in studies of postherpetic neuralgia, painful diabetic neuropathy or mixed neuropathic pain." | 4.87 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; McQuay, HJ; Moore, RA; Wiffen, PJ, 2011) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Recent studies showed effectiveness of gabapentin in improving the pain control in patients with neuropathic cancer pain, already treated with opiates." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Given the significant benefits of gabapentin and the combination of gabapentin with opioids for the treatment of neuropathic pain, randomized clinical trials are needed to establish the role of these analgesic regimens for the treatment of neuropathic cancer pain." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Pregabalin has proven efficacy in neuropathic pain conditions and fibromyalgia." | 4.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "To assess analgesic efficacy and associated adverse events of pregabalin in acute and chronic pain." | 4.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "Randomised, double blind trials reporting on the analgesic effect of pregabalin, with subjective pain assessment by the patient as either the primary or a secondary outcome." | 4.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "There was no clear evidence of beneficial effects of pregabalin in established acute postoperative pain." | 4.85 | Pregabalin for acute and chronic pain in adults. ( Derry, S; McQuay, HJ; Moore, RA; Straube, S; Wiffen, PJ, 2009) |
| "In recent years, anticonvulsant drugs (AEDs) have been considered promising drugs in the prevention of migraine and other forms of headache, based on their action on the metabolism of gamma-aminobutyric acid (GABA) and glutamate." | 4.82 | Antiepileptic drugs in the treatment of chronic headaches. ( Agostoni, E; Frigerio, R; Santoro, P, 2003) |
| "To evaluate the analgesic effectiveness and adverse effects of gabapentin for pain management in clinical practice." | 4.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "Randomised trials of gabapentin in acute, chronic or cancer pain were identified by MEDLINE (1966-Nov 2004), EMBASE (1994-Nov 2004), SIGLE (1980-Jan 2004) and the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 4, 2004)." | 4.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "Randomised trials reporting the analgesic effects of gabapentin in patients, with subjective pain assessment as either the primary or a secondary outcome." | 4.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| "There is evidence to show that gabapentin is effective in neuropathic pain." | 4.82 | Gabapentin for acute and chronic pain. ( Edwards, JE; McQuay, HJ; Moore, RA; Wiffen, PJ, 2005) |
| " However, the neuroprotective effects and the mechanism of action of PNU-282987, an α7-nAChR agonist, in a chronic in vivo rat glaucoma model are poorly understood." | 3.85 | Alpha7 nicotinic acetylcholine receptor agonist promotes retinal ganglion cell function via modulating GABAergic presynaptic activity in a chronic glaucomatous model. ( Cheng, Y; Li, G; Wu, J; Yang, B; Zhang, R; Zhang, S; Zhou, X, 2017) |
| "Response to gabapentin was defined by physician-documented subjective patient report of improvement in cough symptoms." | 3.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| " Therapy was initiated in patients with chronic cough with gabapentin, 100 mg twice daily, which was titrated to response or adverse effects." | 3.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| "In patients with chronic cough suspected to be related to vagal neuropathy, the odds of response to gabapentin are higher with the presence of VFMA noted on videostroboscopy." | 3.85 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| "In the present work, we investigated the antinociceptive effect of gabapentin in a chronic myositis model and its interference in spinal glial cells." | 3.85 | Gabapentin decreases microglial cells and reverses bilateral hyperalgesia and allodynia in rats with chronic myositis. ( Chacur, M; Freitas, MF; Rocha, IR; Rosa, AS, 2017) |
| " Based on this, the aim of the present study was to investigate the effect of magnesium on the level of glutamic acid decarboxylase-67kDa (GAD-67) in the different brain areas in the chronic mild stress (CMS) and olfactory bulbectomy (OB) models of depression in rats." | 3.83 | Brain glutamic acid decarboxylase-67kDa alterations induced by magnesium treatment in olfactory bulbectomy and chronic mild stress models in rats. ( Nowak, G; Pochwat, B; Szewczyk, B, 2016) |
| "Latrunculin A microperfusion of the hippocampus induces acute epileptic seizures and long-term biochemical changes leading to spontaneous seizures." | 3.80 | Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. ( Loureiro, AI; Sierra-Marcuño, G; Sierra-Paredes, G; Soares-da-Silva, P; Wright, LC, 2014) |
| "Oral administration of ESL (100 mg/kg), previous to latrunculin A microperfusion, completely prevented acute latrunculin A-induced seizures as well as chronic seizures and all EEG chronic signs of paroxysmal activity." | 3.80 | Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. ( Loureiro, AI; Sierra-Marcuño, G; Sierra-Paredes, G; Soares-da-Silva, P; Wright, LC, 2014) |
| "ESL treatment prevented acute latrunculin A-induced seizures as well as chronic seizures and all EEG chronic signs of paroxysmal activity, supporting a possible anti-epileptogenic effect of ESL in mice." | 3.80 | Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. ( Loureiro, AI; Sierra-Marcuño, G; Sierra-Paredes, G; Soares-da-Silva, P; Wright, LC, 2014) |
| "To analyze the survival and the changes of proportions of Calbindin, Calretinin and Parvalbumin positive neurons in mouse hippocampal CA area at chronic stage of Pilocarpine-induced epilepsy." | 3.79 | [Survival of calbindin, calretinin and parvalbumin positive neurons in mouse hippocampal CA area at chronic stage of pilocarpine-induced epilepsy]. ( Liu, J; Liu, Y; Tang, F, 2013) |
| "Calbindin, Calretinin and Parvalbumin immunofluoresence staining were done 2 months after Pilocarpine-induced epilepsy in mice or saline injection." | 3.79 | [Survival of calbindin, calretinin and parvalbumin positive neurons in mouse hippocampal CA area at chronic stage of pilocarpine-induced epilepsy]. ( Liu, J; Liu, Y; Tang, F, 2013) |
| "The changes of proportions of Calbindin, Calretinin and Parvalbumin positive neurons in the CA area of mouse hippocampus may be a factor in the ongoing epileptic activity at chronic stage of Pilocarpine-induced epilepsy." | 3.79 | [Survival of calbindin, calretinin and parvalbumin positive neurons in mouse hippocampal CA area at chronic stage of pilocarpine-induced epilepsy]. ( Liu, J; Liu, Y; Tang, F, 2013) |
| "The aim of this study was to assess the role of adding gabapentin (Neurontin) to the prescription of patients with opiate resistant pain as a result of critical limb ischaemia (CLI)." | 3.76 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "The study has demonstrated that gabapentin is a useful adjuvant in the management of CLI and leads to significant reductions in pain scores and improves night pain for most patients." | 3.76 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "The objective of this study was to develop a pharmacokinetic-pharmacodynamic (PK-PD) model of the static allodynia response to pregabalin with and without sildenafil in a chronic constriction injury model of neuropathic pain." | 3.76 | Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain. ( Bender, G; Bies, RR; Bramwell, S; Danhof, M; DeJongh, J; Field, MJ; Florian, JA; Marshall, S; Tan, KK, 2010) |
| "Despite widely replicated abnormalities of gamma-aminobutyric acid (GABA) neurons in schizophrenia postmortem, few studies have measured tissue GABA levels in vivo." | 3.76 | Elevated gamma-aminobutyric acid levels in chronic schizophrenia. ( Cohen, BM; McCarthy, J; Ongür, D; Prescot, AP; Renshaw, PF, 2010) |
| "We found elevations in GABA/creatine in the schizophrenia group compared with control subjects [F(1,65) = 4." | 3.76 | Elevated gamma-aminobutyric acid levels in chronic schizophrenia. ( Cohen, BM; McCarthy, J; Ongür, D; Prescot, AP; Renshaw, PF, 2010) |
| "Pregabalin is used for treatment of neuropathic pain conditions." | 3.74 | Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. ( Audette, KM; Maeda, Y; Sluka, KA; Yokoyama, T, 2007) |
| "This study shows that pregabalin reduces both cutaneous and muscle hyperalgesia in inflammatory and noninflammatory models of muscle pain." | 3.74 | Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. ( Audette, KM; Maeda, Y; Sluka, KA; Yokoyama, T, 2007) |
| "Although this is a small study, it appears that gabapentin and nortriptyline are effective in the treatment of idiopathic chronic orchialgia but not post-vasectomy pain." | 3.74 | Chronic orchialgia: consider gabapentin or nortriptyline before considering surgery. ( Lee, LK; Miller, B; Sinclair, AM, 2007) |
| "6% of patients commenced on nortriptyline had a greater than 50% improvement in pain." | 3.74 | Chronic orchialgia: consider gabapentin or nortriptyline before considering surgery. ( Lee, LK; Miller, B; Sinclair, AM, 2007) |
| " The case presentation illustrates the role of pregabalin in successful medical management of this chronic pain disorder, as well as the management of common psychiatric morbidities associated with this condition." | 3.74 | Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia. ( Jerome, L, 2007) |
| "Pregabalin is often used for the treatment of chronic pain syndromes." | 3.74 | Pregabalin-induced generalized myoclonic status epilepticus in patients with chronic pain. ( Hamer, HM; Hattemer, K; Klein, KM; Knake, S; Oertel, WH; Rosenow, F; Wellek, A, 2007) |
| "This prospective, open-label study aimed to evaluate the efficacy of pregabalin treatment in patients suffering from trigeminal neuralgia with and without concomitant facial pain." | 3.74 | Efficacy of pregabalin in the treatment of trigeminal neuralgia. ( Diener, HC; Katsarava, Z; Maschke, M; Obermann, M; Sensen, K; Yoon, MS, 2008) |
| "To determine whether altered central and/or peripheral gamma-aminobutyric acid (GABA)ergic mechanisms acting in GABA(A) receptors contribute to the abnormal ventilatory response to acute and sustained hypoxia in obese Zucker rats." | 3.73 | GABAergic modulation of ventilatory response to acute and sustained hypoxia in obese Zucker rats. ( Huang, CY; Lee, SD; Lin, TB; Lo, MJ; Ting, H, 2005) |
| "The anticonvulsant gabapentin (GBP) has been shown effective for the treatment of neuropathic pain, although its mechanism of action remains unclear." | 3.73 | Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. ( Aiyar, J; Anker, N; Belley, M; Bristow, L; Campbell, B; Cohen, C; Park, KT; Ren, K; Stearns, B; Urban, MO, 2005) |
| "This study was designed to characterize, in anterior, mediobasal, and posterior hypothalamic and median eminence, the 24h changes of gamma aminobutyric acid (GABA) and taurine (TAU) contents in adult male rats and to analyze whether chronic hyperprolactinemia may affect these patterns." | 3.72 | Daily changes of GABA and taurine concentrations in various hypothalamic areas are affected by chronic hyperprolactinemia. ( Alvarez, MP; Cano, P; Castrillón, PO; Duvilanski, BH; Esquifino, AI, 2003) |
| "GABA and glycine are inhibitory neurotransmitters used by many neurons in the spinal dorsal horn, and intrathecal administration of GABA(A) and glycine receptor antagonists produces behavioural signs of allodynia, suggesting that these transmitters have an important role in spinal pain mechanisms." | 3.72 | Selective loss of spinal GABAergic or glycinergic neurons is not necessary for development of thermal hyperalgesia in the chronic constriction injury model of neuropathic pain. ( Hughes, DI; Maxwell, DJ; Polgár, E; Puskár, Z; Riddell, JS; Todd, AJ, 2003) |
| "A pharmacokinetic-pharmacodynamic (PK/PD) model relating pain relief to gabapentin plasma concentrations was derived from a phase 3 study." | 3.72 | The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain. ( Cook, JA; Ewy, WE; Lockwood, PA; Mandema, JW, 2003) |
| "A series of mutual prodrugs derived from gabapentin, pregabalin, memantine, venlafaxine were synthesized and their pharmacological properties to treat neuropathic pain were investigated in a rat model of chronic sciatic nerve constriction injury (CCI)." | 3.72 | Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury. ( Bo-Hua, Z; He, L; Hong-Ju, Y; Jun-Wei, W; Nan, Z; Wei-Guo, S; Wei-Xiu, Y; Zhe-Hui, G; Zheng-Hua, G; Zhi-Pu, L; Zhong-Wei, J, 2004) |
| " Chronic seizures were induced by amygdalar injection of kainic acid 60 days before death." | 3.71 | Collapse of extracellular glutamate regulation during epileptogenesis: down-regulation and functional failure of glutamate transporter function in rats with chronic seizures induced by kainic acid. ( Doi, T; Kamada, H; Mitsuyama, Y; Nakajima, A; Ohya-Nishiguchi, H; Tokumaru, J; Ueda, Y; Willmore, LJ; Yokoyama, H, 2001) |
| "Postmortem samples from individuals with schizophrenia (n = 13) and control subjects (n = 10) were investigated for binding of [(3)H]tiagabine to GABA transporter-1 GAT-1." | 3.71 | Increased [(3)H]tiagabine binding to GAT-1 in the cingulate cortex in schizophrenia. ( Blennow, K; Dandenell, AK; Davidsson, P; Marcusson, J; Sundman-Eriksson, I, 2002) |
| "To present two years of experience in the use of gabapentin for the alleviation of neuropathic pain in spinal cord injury patients." | 3.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Data were retrieved from the medical records of all spinal cord injury patients prescribed gabapentin for neuropathic pain." | 3.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Seventy-six per cent of patients receiving gabapentin reported a reduction in neuropathic pain." | 3.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Our experience suggests that gabapentin offers an effective therapeutic alternative for the alleviation of neuropathic pain following spinal cord injury." | 3.71 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "This report describes the long-term follow-up of 56 patients with refractory partial epilepsy who, within 3 months of vigabatrin add-on therapy (3 g/day), showed a reduction in monthly seizure frequency of more than 50%." | 3.70 | Long-term treatment with vigabatrin - 10 years of clinical experience. ( Mumford, JP; Riekkinen, PJ; Salmenperä, T; Ylinen, A, 1999) |
| "To compare the long-term retention of gabapentin (GBP), lamotrigine (LTG), and vigabatrin (VGB) by patients with chronic epilepsy and the reasons for treatment discontinuation." | 3.70 | The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. ( Chadwick, DW; Fenwick, PB; Mawer, GE; Sander, JW; Wong, IC, 1999) |
| "We sought to determine the long-term retention rates of lamotrigine (LTG), gabapentin (GBP), and topiramate (TPM) therapy for patients at a tertiary referral clinic for chronic, refractory epilepsy." | 3.70 | Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. ( Lhatoo, SD; Polizzi, G; Sander, JW; Wong, IC, 2000) |
| "High affinity [3H]gamma-aminobutyric acid (GABA) and [3H]L-glutamate uptake were determined in synaptosomes prepared from the cerebral cortex of dogs with congenital hepatic encephalopathy and control dogs." | 3.69 | L-glutamate and gamma-aminobutyric acid uptake in synaptosomes from the cerebral cortex of dogs with congenital chronic hepatic encephalopathy. ( Johnston, GA; Maddison, JE; Watson, WE, 1995) |
| "The novel anti-epileptic drugs lamotrigine, felbamate and gabapentin were compared in rat experimental models of acute (tail flick) and chronic pain: the chronic constriction injury and spinal nerve ligation models." | 3.69 | The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. ( Fontana, DJ; Gogas, KR; Hedley, LR; Hunter, JC; Jacobson, LO; Kassotakis, L; Thompson, J, 1997) |
| "The alteration in circulating levels of PRL, GH, TSH, and cortisol was studied after the oral administration of muscimol (3-hydroxy-5-aminomethylisoxazole) to human subjects with Huntington's disease (n = 4) and chronic schizophrenia (n = 5)." | 3.66 | Stimulation of prolactin and growth hormone secretion by muscimol, a gamma-aminobutyric acid agonist. ( Chase, TN; Frohman, LA; Neophytides, A; Tamminga, CA, 1978) |
| "The average pretreatment pruritus score was 9." | 2.78 | Use of pregabalin in the management of chronic uremic pruritus. ( Grenader, T; Lifschitz, M; Shavit, L; Slotki, I, 2013) |
| "The assessment of postoperative pain at the 1- and 3-month follow-ups was performed using a numeric rating scale." | 2.76 | The effects of gabapentin on acute and chronic postoperative pain after coronary artery bypass graft surgery. ( Onan, B; Selcuk, I; Sen, H; Turan, A; Ucak, A; Yilmaz, AT, 2011) |
| "This pharmacostatistical model showed that: (1) pregabalin oral clearance (CL/F) was directly proportional to creatinine clearance (CLcr), but was independent of gender, race, age, female hormonal status, daily dose, and dosing regimen; (2) apparent volume of distribution was dependent on body weight and gender; (3) absorption rate was decreased when given with food; and (4) coadministration with marketed antiepileptic drugs (AEDs) had no significant effect on pregabalin CL/F." | 2.76 | Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. ( Bockbrader, HN; Burger, P; Corrigan, BW; Knapp, L, 2011) |
| " Pregabalin dosage was increased from 150 to 600 mg/d during the first 4 weeks." | 2.75 | Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial. ( Alexander, RB; Anderson, RU; Cen, L; Chuai, S; Krieger, JN; Kusek, JW; Landis, JR; Litwin, MS; McNaughton-Collins, M; Nickel, JC; Nyberg, LM; O'Leary, M; Pontari, MA; Propert, KJ; Schaeffer, AJ; Shoskes, DA; White, PC; Zeitlin, S, 2010) |
| "Assessment of postoperative pain at 1, 3 and 6 months was carried out with an 11-point numerical rating scale; 0 indicating 'no pain' and 10 indicating 'worst pain imaginable'." | 2.74 | The effects of gabapentin on acute and chronic pain after inguinal herniorrhaphy. ( Dağli, G; Inangil, G; Ozkan, S; Sen, H; Senol, MG; Sizlan, A; Sücüllü, I; Yanarateş, O, 2009) |
| " Patients in group B who were receiving gabapentin continued this treatment up to a maximum daily dosage of 2400 mg during the observation period." | 2.74 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "Multimodal pain is comprised of nociceptive/inflammatory and neuropathic components." | 2.74 | Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study. ( Bertini, L; Carucci, A; Gatti, A; Mammucari, M; Occhioni, R; Sabato, AF, 2009) |
| "MDD and PTSD patients present abnormalities in the HPA axis regulation, such as altered cortisol levels or failure to suppress cortisol release in the dexamethasone suppression test." | 2.72 | The Role of HPA Axis and Allopregnanolone on the Neurobiology of Major Depressive Disorders and PTSD. ( Almeida, FB; Barros, HMT; Pinna, G, 2021) |
| "Gabapentin was associated with an increase in mean HSA, in contrast to the placebo, which was associated with a decrease." | 2.72 | Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. ( Bergasa, NV; Engler, D; Ginsburg, IH; McGee, M, 2006) |
| "Pruritus is defined as the second order of nociception, the first being pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to experience nociception." | 2.72 | Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. ( Bergasa, NV; Engler, D; Ginsburg, IH; McGee, M, 2006) |
| "Chronic neuropathic pain was associated with motor cortex disinhibition, suggesting impaired GABAergic neurotransmission related to some aspects of pain or to underlying sensory or motor disturbances." | 2.72 | Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain. ( Drouot, X; Keravel, Y; Lefaucheur, JP; Ménard-Lefaucheur, I; Nguyen, JP, 2006) |
| "The lidocaine patch 5% was found to be safe and well tolerated." | 2.71 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Patients with postherpetic neuralgia, painful diabetic neuropathy, or low back pain with partial responses (average daily pain intensity >4/10) to their current analgesic treatment regimen were included." | 2.71 | Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. ( Drass, M; Nalamachu, S; Patel, N; White, WT, 2003) |
| "Chronic neuropathic pain occurs in 10-15% of patients with neuroborreliosis and is difficult to treat." | 2.71 | Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage lyme borreliosis: a pilot study. ( Hofmann, H; Ring, J; Weissenbacher, S, 2005) |
| "Fifty patients scheduled for breast cancer surgery were blindly randomized to receive gabapentin, eutectic mixture of local anesthetics cream, and ropivacaine in the wound or three placebos." | 2.71 | Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer. ( Fassoulaki, A; Melemeni, A; Sarantopoulos, C; Triga, A, 2005) |
| "Gabapentin has been successfully used for a variety of chronic pain conditions and therefore may be of use in the treatment of chronic headache." | 2.69 | Low doses of gabapentin may be helpful in the management of chronic daily headache. ( Carrazana, EJ; Fragoso, YD, 2000) |
| "Tonic SCS concurrently initiates neuropathic pain modulation through a supraspinal-spinal feedback loop and serotonergic descending fibers." | 2.66 | Mechanisms and mode of action of spinal cord stimulation in chronic neuropathic pain. ( Heijmans, L; Joosten, EA, 2020) |
| "Baclofen and placebo were administered orally, in a double-blind design, and blood samples were collected before and 30, 60, 90, 120, 180, and 240 min after drug or placebo administration." | 2.66 | Baclofen-induced growth hormone secretion is blunted in chronic schizophrenics: neuroendocrine evidence for a GABA disturbance in schizophrenia. ( Forziati, D; Iovino, M; Maj, M; Monteleone, P; Steardo, L; Veltro, F, 1988) |
| "Gabapentin is commonly used to treat neuropathic pain (pain due to nerve damage)." | 2.55 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| "Evidence for other types of neuropathic pain is very limited." | 2.55 | Gabapentin for chronic neuropathic pain in adults. ( Bell, RF; Derry, S; Moore, RA; Phillips, T; Rice, AS; Tölle, TR; Wiffen, PJ, 2017) |
| "Chronic pruritus is a distressing symptom that is often refractory to treatment." | 2.53 | Gabapentin and pregabalin for the treatment of chronic pruritus. ( Kwatra, SG; Matsuda, KM; Schonfeld, AR; Sharma, D, 2016) |
| "In contrast, medical costs for neuropathic pain did not significantly differ after initiation of pregabalin vs." | 2.52 | A systematic review of pharmacoeconomic studies for pregabalin. ( Huelin, R; Khankhel, Z; Mould, J; Parker, L; Wasiak, R, 2015) |
| "Economic studies of pregabalin in neuropathic pain and FM indicate some results favorable to other forms of care, but heterogeneity among study designs and populations hinder comparisons." | 2.52 | A systematic review of pharmacoeconomic studies for pregabalin. ( Huelin, R; Khankhel, Z; Mould, J; Parker, L; Wasiak, R, 2015) |
| "Gabapentin has been shown to cause minimal to no toxicity in overdose." | 2.52 | A review on the efficacy and safety of gabapentin in the treatment of chronic cough. ( Ryan, NM, 2015) |
| "Recent developments in the treatment of cough include the use of speech pathology and pharmacotherapy with gabapentin." | 2.52 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "Chronic cough is regarded as a challenging clinical problem due to its frequency and often limited therapeutic options." | 2.52 | Gabapentin in chronic cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "Chronic refractory cough has factors in common with laryngeal hypersensitivity syndromes and chronic pain syndromes, and these similarities help to shed light on the pathophysiology of the condition." | 2.52 | Management of chronic refractory cough. ( Gibson, PG; Vertigan, AE, 2015) |
| "Results might vary between different neuropathic pain conditions, and the amount of evidence for gabapentin in neuropathic pain conditions except postherpetic neuralgia and painful diabetic neuropathy, and in fibromyalgia, is very limited." | 2.50 | Gabapentin for chronic neuropathic pain and fibromyalgia in adults. ( Derry, S; Moore, RA; Rice, AS; Toelle, T; Wiffen, PJ, 2014) |
| "Tinnitus is the perception of sound or noise in the absence of an external or internal acoustic stimulation." | 2.47 | Anticonvulsants for tinnitus. ( Hoekstra, CE; Rovers, MM; Rynja, SP; van Zanten, GA, 2011) |
| "Migraine and headache studies are excluded in this revision." | 2.46 | WITHDRAWN. Anticonvulsant drugs for acute and chronic pain. ( Carroll, D; Collins, S; Jadad, A; McQuay, HJ; Moore, RA; Wiffen, PJ, 2010) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 2.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Gabapentin has been successfully used for the treatment of multiple neuropathic pain syndromes such as diabetic neuropathy and postherpetic neuralgia." | 2.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Multimodal postoperative pain management targeted at diminishing harmful outcomes should include pregabalin in cases that need opioid reduction and when the risk of developing chronic neuropathic postsurgical pain is present." | 2.46 | Pregabalin for the treatment of postsurgical pain. ( Durkin, B; Glass, P; Page, C, 2010) |
| "Chronic pain is now viewed as a biopsychosocial phenomenon, in which biological, psychological, and social factors are at work." | 2.44 | Practical management strategies for the chronic pain patient. ( Forde, G; Stanos, S, 2007) |
| "Some mechanisms of the development of neuropathic pain have been proposed; 1) sprouting of A beta fibers to the superficial layer of the dorsal horn, 2) ectopic discharge in the dorsal root ganglion and/or in neuroma at the nerve stump, 3) spinal sensitization." | 2.44 | [Mechanisms of the development of neuropathic pain and its treatment]. ( Yamamoto, T, 2008) |
| "Neuropathic pain has been known to be refractory to traditional analgesics, such as opioids and non-steroidal anti-inflammatoy drugs." | 2.44 | [Mechanisms of the development of neuropathic pain and its treatment]. ( Yamamoto, T, 2008) |
| "neuropathic pain) is not very satisfactorily managed." | 2.44 | [Central and peripheral mechanisms in antinociception: current and future perspectives]. ( Fürst, Z, 2008) |
| "Gabapentin is a second generation anticonvulsant that is effective in the treatment of chronic neuropathic pain." | 2.44 | Gabapentin: a multimodal perioperative drug? ( Irwin, MG; Kong, VK, 2007) |
| "Persistent hiccups have been reported to occur occasionally during rehabilitation hospitalizations." | 2.44 | Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature. ( Browne, BA; Schuchmann, JA, 2007) |
| "Migraine and headache studies are excluded in this revision." | 2.43 | Anticonvulsant drugs for acute and chronic pain. ( Carroll, D; Collins, S; Jadad, A; McQuay, H; Moore, A; Wiffen, P, 2005) |
| " Thus, monitoring and dosage adjustment are required, without discontinuation of the drug." | 2.43 | Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. ( Argyra, E; Moka, E; Siafaka, I; Vadalouca, A; Vrachnou, E, 2006) |
| "Treatment decisions for patients with neuropathic pain can be difficult." | 2.43 | Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. ( Argyra, E; Moka, E; Siafaka, I; Vadalouca, A; Vrachnou, E, 2006) |
| "Neuropathic pain is defined as pain caused by a lesion in the nervous system and is common in clinical practice." | 2.43 | Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. ( Argyra, E; Moka, E; Siafaka, I; Vadalouca, A; Vrachnou, E, 2006) |
| "Managing patients with chronic neuropathic pain is a common clinical challenge due to variability in individual symptoms, mechanisms, and treatment responses." | 2.42 | Diagnosis and management of neuropathic pain: a balanced approach to treatment. ( Nicholson, BD, 2003) |
| "Diagnosis and management of neuropathic pain syndromes is challenging." | 2.42 | Diagnosis and management of neuropathic pain: a balanced approach to treatment. ( Nicholson, BD, 2003) |
| "Lamotrigine has demonstrated efficacy in delaying time to depressive relapse." | 2.42 | Rethinking the treatment paradigm for bipolar depression: the importance of long-term management. ( Baldassano, CF; Ballas, CA; O'Reardon, JP, 2004) |
| "Stroke is a leading cause of adult disability owing largely to motor impairment and loss of function." | 1.51 | The Influence of Primary Motor Cortex Inhibition on Upper Limb Impairment and Function in Chronic Stroke: A Multimodal Study. ( Ackerley, SJ; Barber, PA; Byblow, WD; Cirillo, J; Mooney, RA; Rajeswaran, DK; Stinear, CM, 2019) |
| "Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist." | 1.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| "Neuropathic pain has proven to be a difficult condition to treat, so investigational therapy has been sought that may prove useful, such as the use of sigma-1 antagonists." | 1.46 | Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; López-Muñoz, FJ, 2017) |
| "Chronic cough is a debilitating, often multifactorial problem." | 1.46 | Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough. ( Dibildox, D; Giliberto, JP; Merati, A, 2017) |
| "Gabapentin was used by 45% as first-, second-, or third-line treatment." | 1.46 | International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis. ( Bieber, BA; Ecder, T; Graham-Brown, M; Hasegawa, T; Kleophas, W; Larkina, M; Pisoni, RL; Rayner, HC; Robinson, BM; Tentori, F; van der Veer, SN; Wang, M, 2017) |
| "Chronic myositis was induced by injection of Complete Freund Adjuvant (CFA) into the right gastrocnemius (GS) muscle of rats and tests for evaluating mechanical hyperalgesia, thermal hyperalgesia and tactile allodynia were performed." | 1.46 | Gabapentin decreases microglial cells and reverses bilateral hyperalgesia and allodynia in rats with chronic myositis. ( Chacur, M; Freitas, MF; Rocha, IR; Rosa, AS, 2017) |
| "Fetal intrauterine growth restriction generates chronic hypoxia due to placental insufficiency." | 1.42 | Altered levels of brain neurotransmitter from new born rabbits with intrauterine restriction. ( Cortés-Camberos, AJ; Díaz, NF; Flores-Herrera, H; García-López, G; González-Jiménez, M; Hernández-Andrade, E; Molina-Hernández, A; Santamaría, A, 2015) |
| "Cyclothiazide (CTZ) has been reported to simultaneously enhance glutamate receptor excitation and inhibit GABAA receptor inhibition, and in turn it evokes epileptiform activities in hippocampal neurons." | 1.40 | Downregulated GABA and BDNF-TrkB pathway in chronic cyclothiazide seizure model. ( Cheng, Z; Kong, S; Liu, J; Wang, Y, 2014) |
| "However, whether CTZ induced seizure rats could develop to have recurrent seizure still remains unknown." | 1.40 | Downregulated GABA and BDNF-TrkB pathway in chronic cyclothiazide seizure model. ( Cheng, Z; Kong, S; Liu, J; Wang, Y, 2014) |
| "The effect of disc degeneration on behavioral measures of chronic pain has not been evaluated in this model." | 1.37 | Behavioral signs of chronic back pain in the SPARC-null mouse. ( Millecamps, M; Sage, EH; Stone, LS; Tajerian, M, 2011) |
| "Gabapentin failed to suppress the scratching behavior induced by the intradermal injection of compound 48/80 in normal mice." | 1.37 | Gabapentin and pregabalin inhibit the itch-associated response induced by the repeated application of oxazolone in mice. ( Manabe, H; Matsumoto, Y; Miura, H; Tsukumo, Y; Yano, H, 2011) |
| "Causes of symptomatic glossopharyngeal neuralgia can be tumors, infarction or trauma." | 1.37 | [Glossopharyngeal neuralgia after resection of a glossopharyngeal schwannoma]. ( Graf, BM; Kleinjung, T; Lassen, CL; Strutz, J; Wiese, CH, 2011) |
| "Glossopharyngeal neuralgia is a rare condition and the origin is mostly idiopathic." | 1.37 | [Glossopharyngeal neuralgia after resection of a glossopharyngeal schwannoma]. ( Graf, BM; Kleinjung, T; Lassen, CL; Strutz, J; Wiese, CH, 2011) |
| "In rats with four ligatures, prominent mechanical allodynia and thermal hyperalgesia developed; these behavioral signs were not prominent in rats with two ligatures." | 1.37 | Pharmacological and behavioral characterization of the saphenous chronic constriction injury model of neuropathic pain in rats. ( Buldum, D; Gunduz, O; Guven, R; Oltulu, C; Ulugol, A, 2011) |
| "Then, behavioral signs of neuropathic pain were observed for 8 weeks." | 1.37 | Pharmacological and behavioral characterization of the saphenous chronic constriction injury model of neuropathic pain in rats. ( Buldum, D; Gunduz, O; Guven, R; Oltulu, C; Ulugol, A, 2011) |
| "Chronic pain is a common neurological disease involving lasting, multifaceted maladaptations ranging from gene modulation to synaptic dysfunction and emotional disorders." | 1.37 | Epigenetic suppression of GAD65 expression mediates persistent pain. ( Bie, B; Cai, YQ; Pan, ZZ; Zhang, Z; Zou, F, 2011) |
| "Tobacco smoking and depression are strongly associated, but the possible effects of SHS have not been evaluated." | 1.36 | Secondhand smoke exposure and depressive symptoms. ( Arheart, KL; Bandiera, FC; Caban-Martinez, AJ; Davila, EP; Dietz, NA; Fleming, LE; Leblanc, WG; Lee, DJ; Lewis, JE; McCollister, K; Serdar, B, 2010) |
| "Gabapentin was commenced at 300 mg daily and titrated to 300 mg tds over 3 days." | 1.36 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "Pain was assessed by visual analogue scoring at baseline, 4, 7, 14 and 28 days." | 1.36 | Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study. ( Lewis, MH; Morris-Stiff, G, 2010) |
| "The static allodynia endpoint was modeled by using three population PD approaches: 1) the behavior of the injured paw using a three-category ordinal logistic regression model; 2) paw withdrawal threshold (PWT) (g) between the injured and uninjured paw using the Hill equation with a baseline function; and 3) the baseline normalized difference in PWT between the injured and uninjured paw." | 1.36 | Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain. ( Bender, G; Bies, RR; Bramwell, S; Danhof, M; DeJongh, J; Field, MJ; Florian, JA; Marshall, S; Tan, KK, 2010) |
| "Chronic migraine is an important public health problem." | 1.36 | Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials. ( D'Amico, D, 2010) |
| "Neuropathic pain is a common problem following spinal cord injury (SCI)." | 1.36 | Role of NKCC1 and KCC2 in the development of chronic neuropathic pain following spinal cord injury. ( Ahmed, MM; Hasbargen, T; Kahle, KT; Li, L; Miranpuri, G; Resnick, D; Sun, D, 2010) |
| "CCI also evoked mechanical allodynia that was fully developed on a week post-operation, but showed no recovery for at least 8 weeks." | 1.35 | Pharmacological characteristics of the hind paw weight bearing difference induced by chronic constriction injury of the sciatic nerve in rats. ( Kurebayashi, Y; Nakazato-Imasato, E, 2009) |
| "Epilepsy is a serious neurological disorder in human beings and the long-term pathological events remain largely obscure." | 1.35 | Time-course of neuronal death in the mouse pilocarpine model of chronic epilepsy using Fluoro-Jade C staining. ( Chen, LW; Huang, YG; Liu, YH; Wang, L, 2008) |
| "Anxiety and depression are often also present." | 1.35 | Fibromyalgia: poorly understood; treatments are disappointing. ( , 2009) |
| "(1) Fibromyalgia is characterised by a range of symptoms that include muscle pain, fatigue and sleep disorders." | 1.35 | Fibromyalgia: poorly understood; treatments are disappointing. ( , 2009) |
| "Patients without concomitant facial pain showed better response rates (32 of 39, 82%) compared with patients with concomitant chronic facial pain (7 of 14, 50%, P = 0." | 1.35 | Efficacy of pregabalin in the treatment of trigeminal neuralgia. ( Diener, HC; Katsarava, Z; Maschke, M; Obermann, M; Sensen, K; Yoon, MS, 2008) |
| "Pelvic pain was detected 5 days after antigen instillation and was sustained beyond 30 days, indicating the development of chronic pain." | 1.35 | Experimental autoimmune prostatitis induces chronic pelvic pain. ( Rudick, CN; Schaeffer, AJ; Thumbikat, P, 2008) |
| "Muscle hyperalgesia (withdrawal threshold to compression of the muscle) and cutaneous hyperalgesia of the paw (withdrawal threshold to von Frey filaments) were measured before and after induction of hyperalgesia and after treatment with pregabalin (saline, 10 to 100 mg/kg i." | 1.34 | Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. ( Audette, KM; Maeda, Y; Sluka, KA; Yokoyama, T, 2007) |
| "Chronic transauricular kindled seizure was induced by repeated application of initially subconvulsive electrical stimulation (40 mA, 0." | 1.34 | [Effects of acute maximal electroshock and chronic transauricular kindled seizures on learning abilities in Sprague-Dawley rats]. ( Chen, Z; Li, Q; Wu, DC; Zhang, Q, 2007) |
| "Chronic transauricular kindled seizures induced CA1 neuron damage and a decrease in histamine levels in the hippocampus." | 1.34 | [Effects of acute maximal electroshock and chronic transauricular kindled seizures on learning abilities in Sprague-Dawley rats]. ( Chen, Z; Li, Q; Wu, DC; Zhang, Q, 2007) |
| "Different types of kindling seizure produce different effects on cognitive behavior: (1) an acute MES impairs learning ability, which may be associated with an abnormal plasticity and an increase of GABA in the hippocampus; (2) the chronic transauricular kindled seizure impairs retrieval memory mainly, which may be related to CA1 neuron damage and a decrease in histaminergic activity in the hippocampus." | 1.34 | [Effects of acute maximal electroshock and chronic transauricular kindled seizures on learning abilities in Sprague-Dawley rats]. ( Chen, Z; Li, Q; Wu, DC; Zhang, Q, 2007) |
| "Six children with cerebral palsy are presented who developed neuropathic pain following multilevel orthopedic surgery." | 1.33 | Neuropathic pain following multilevel surgery in children with cerebral palsy: a case series and review. ( Lauder, GR; White, MC, 2005) |
| "Gabapentin is an anticonvulsant that successfully treats many neuropathic pain syndromes, although the mechanism of its antihyperalgesic action remains elusive." | 1.33 | Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. ( Coderre, TJ; Kumar, N; Lefebvre, CD; Yu, JS, 2005) |
| "The severe burning pain, deep pressure-like pain, and deep mechanical allodynia, which presented over the contralateral side to the TBI, were successfully relieved with motor cortex stimulation (MCS)." | 1.33 | Motor cortex stimulation for central pain following a traumatic brain injury. ( Choi, ES; Hong, JT; Lee, SW; Son, BC; Sung, JH, 2006) |
| "We studied 14 chronic migraine patients, with or without depression, compared to age-and sex-matched controls." | 1.33 | Cerebrospinal fluid GABA levels in chronic migraine with and without depression. ( Alonso, EO; Cavalheiro, EA; Faulhaber, MH; Naffah-Mazacoratti, MG; Peres, MF; Senne Soares, CA; Vieira, DS; Zukerman, E, 2006) |
| "Patients with hepatic encephalopathy show altered motor function, psychomotor slowing and hypokinesia." | 1.33 | Hypolocomotion in rats with chronic liver failure is due to increased glutamate and activation of metabotropic glutamate receptors in substantia nigra. ( Cauli, O; Erceg, S; Felipo, V; Llansola, M, 2006) |
| "Gabapentin has been shown to be useful in treatment of different conditions which may be caused by increased neuronal excitability." | 1.32 | Treatment of chronic neuropathic pain after traumatic central cervical cord lesion with gabapentin. ( Haller, H; Leblhuber, F; Schmidhammer, R; Trenkler, J, 2003) |
| "Very low birth weight (VLBW) and fetal growth restriction are associated with increased risks of long-term visual impairments, including alterations to contrast sensitivity, a parameter mediated in part by dopaminergic amacrine cells." | 1.32 | Chronic placental insufficiency affects retinal development in the guinea pig. ( Briscoe, T; Caddy, J; Dieni, S; Lambert, G; Loeliger, M; Rees, S; Rehn, A, 2004) |
| " The norepinephrine dose-response curve was shifted to the left with dehydration, revealing an increase in norepinephrine sensitivity." | 1.32 | Dehydration-induced synaptic plasticity in magnocellular neurons of the hypothalamic supraoptic nucleus. ( Di, S; Tasker, JG, 2004) |
| "Thus, dehydration leads to an increase in glutamate and GABA release onto supraoptic magnocellular neurons as well as a marked enhancement of the facilitatory effect of norepinephrine on glutamate release and inhibitory effect on GABA release." | 1.32 | Dehydration-induced synaptic plasticity in magnocellular neurons of the hypothalamic supraoptic nucleus. ( Di, S; Tasker, JG, 2004) |
| "Chronic seizures were induced by amygdalar injection of kainic acid 60 days before death." | 1.31 | Collapse of extracellular glutamate regulation during epileptogenesis: down-regulation and functional failure of glutamate transporter function in rats with chronic seizures induced by kainic acid. ( Doi, T; Kamada, H; Mitsuyama, Y; Nakajima, A; Ohya-Nishiguchi, H; Tokumaru, J; Ueda, Y; Willmore, LJ; Yokoyama, H, 2001) |
| "Gabapentin treatment significantly and reversibly changed the responses, consistent with the attenuation of the abnormal sensory behavior, and the attenuated responses lasted for the duration of the drug effect (up to 6 h)." | 1.31 | Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin. ( Hulsebosch, CE; McAdoo, DJ; Perez-Polo, JR; Taylor, CP; Westlund, KN; Xu, GY, 2000) |
| "Lactic acidosis has been implicated; however, increases in the excitotoxic amino acid glutamate, which correlate with increased neuronal damage, may be the cause for the increased damage seen in hyperglycemic stroke." | 1.31 | The effect of streptozotocin-induced diabetes on the release of excitotoxic and other amino acids from the ischemic rat cerebral cortex. ( Diaz, FG; Guyot, LL; O'Regan, MH; Phillis, JW; Song, D, 2001) |
| "SCI gabapentin-treated rats did not display differences in total rearing time until PSD 28 and a significant difference in total activity of all measured parameters was not seen until PSD 60." | 1.31 | Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury. ( Grady, JJ; Hulsebosch, CE; Mills, CD, 2001) |
| "Gabapentin was effective in approximately 50% of pretreated patients with intractable pain." | 1.31 | [Gabapentin in the treatment of chronic intractable pain]. ( Gustorff, B; Kress, HG; Nahlik, G; Spacek, A, 2002) |
| "Gabapentin has been shown to reduce pain associated with diabetic neuropathia and postherpetic neuralgia." | 1.31 | [Gabapentin in the treatment of chronic intractable pain]. ( Gustorff, B; Kress, HG; Nahlik, G; Spacek, A, 2002) |
| "Pain was assessed prior to and during treatment at 1, 3 and 6 months with a 10 cm visual analogue scale which ranged from 0 ('no pain') to 10 ('worst pain imaginable'), or by the documentation of a verbal description of pain." | 1.31 | Gabapentin for neuropathic pain following spinal cord injury. ( Brown, DJ; Cooper, N; Frauman, AG; Hill, ST; Kirsa, SW; Lim, TC; To, TP, 2002) |
| "Paradoxically, GABA agonists increased seizure occurrence while GABA antagonists decreased seizure occurrence." | 1.28 | Paradoxical role of GABA in a chronic model of petit mal (absence)-like epilepsy in the rat. ( Bierkamper, GG; Smith, KA, 1990) |
| "Muscimol was chronically administrated to the third ventricle of thalamic pigeons by means of osmotic minipumps at the rate of 0." | 1.27 | Effects of chronic intracerebroventricular GABAergic treatment on basal and chronic or acute stress-induced adrenocortical activities in the thalamic pigeon. ( Baylé, JD; Ramade, F, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (7.82) | 18.7374 |
| 1990's | 27 (9.18) | 18.2507 |
| 2000's | 134 (45.58) | 29.6817 |
| 2010's | 103 (35.03) | 24.3611 |
| 2020's | 7 (2.38) | 2.80 |
| Authors | Studies |
|---|---|
| Pankowska, A | 1 |
| Chudzik, A | 1 |
| Słowik, T | 1 |
| Łazorczyk, A | 1 |
| Kochalska, K | 1 |
| Andres-Mach, M | 1 |
| Lam, WW | 1 |
| Pietura, R | 1 |
| Rola, R | 1 |
| Stanisz, GJ | 1 |
| Orzyłowska, A | 1 |
| Dhanani, LY | 1 |
| Totton, RR | 1 |
| Jara-Quijada, E | 1 |
| Pérez-Won, M | 1 |
| Tabilo-Munizaga, G | 1 |
| Lemus-Mondaca, R | 1 |
| González-Cavieres, L | 1 |
| Palma-Acevedo, A | 1 |
| Herrera-Lavados, C | 1 |
| Milovanovic, S | 1 |
| Grzegorczyk, A | 1 |
| Świątek, Ł | 1 |
| Grzęda, A | 1 |
| Dębczak, A | 1 |
| Tyskiewicz, K | 1 |
| Konkol, M | 1 |
| Li, Y | 3 |
| Chang, P | 1 |
| Sankaran, S | 1 |
| Jang, H | 1 |
| Nie, Y | 1 |
| Zeng, A | 1 |
| Hussain, S | 1 |
| Wu, JY | 1 |
| Chen, X | 3 |
| Shi, L | 2 |
| Senapati, A | 1 |
| Chetri, BK | 1 |
| Mitra, S | 1 |
| Shelke, RG | 1 |
| Rangan, L | 1 |
| Chauhan, AS | 1 |
| Tiwari, M | 1 |
| Indoliya, Y | 1 |
| Mishra, SK | 1 |
| Lavania, UC | 1 |
| Chauhan, PS | 1 |
| Chakrabarty, D | 1 |
| Tripathi, RD | 1 |
| Akaputra, R | 1 |
| Hatta, M | 1 |
| Massi, MN | 1 |
| Djaharuddin, I | 1 |
| Bukhari, A | 1 |
| Aminuddin, A | 1 |
| Santoso, A | 1 |
| Natzir, R | 1 |
| Bahar, B | 1 |
| Fachri, M | 1 |
| Farsida, F | 1 |
| Fathimah, A | 1 |
| Ubaidah, FM | 1 |
| Sridiana, E | 1 |
| Dwiyanti, R | 1 |
| Syukri, A | 1 |
| Junita, AR | 1 |
| Febrianti, A | 1 |
| Primaguna, MR | 1 |
| Azhar, A | 1 |
| Rajaure, YS | 1 |
| Thapa, B | 1 |
| Budhathoki, L | 1 |
| Rana, SR | 1 |
| Khadka, M | 1 |
| Batchu, UR | 1 |
| Surapaneni, JR | 1 |
| Cheemalamarri, C | 1 |
| Mandava, K | 1 |
| Puvvada, N | 1 |
| Shetty, PR | 1 |
| Mv, S | 1 |
| Ranjbarian, P | 1 |
| Goudarzi, F | 1 |
| Akya, A | 1 |
| Heidarinia, H | 1 |
| Farasat, A | 1 |
| Rostamian, M | 1 |
| Suri, K | 1 |
| Rajput, N | 1 |
| Sharma, P | 1 |
| Omble, AD | 1 |
| Kulkarni, K | 1 |
| Gahlay, GK | 1 |
| Fernandez Garcia, E | 1 |
| Paudel, U | 1 |
| Noji, MC | 1 |
| Bowman, CE | 1 |
| Rustgi, AK | 1 |
| Pitarresi, JR | 1 |
| Wellen, KE | 1 |
| Arany, Z | 1 |
| Weissenrieder, JS | 1 |
| Foskett, JK | 1 |
| Lee, MS | 1 |
| Han, HJ | 1 |
| Choi, TI | 1 |
| Lee, KH | 1 |
| Baasankhuu, A | 1 |
| Kim, HT | 1 |
| Kim, CH | 1 |
| Redd, PS | 1 |
| Payero, L | 1 |
| Gilbert, DM | 1 |
| Page, CA | 1 |
| King, R | 1 |
| McAssey, EV | 1 |
| Bodie, D | 1 |
| Diaz, S | 1 |
| Hancock, CN | 1 |
| Lee, HS | 1 |
| Jung, S | 1 |
| Lee, SW | 2 |
| Kim, YT | 1 |
| Lee, J | 1 |
| Ren, T | 1 |
| Yu, Z | 1 |
| Yu, H | 1 |
| Deng, K | 1 |
| Wang, Z | 1 |
| Li, X | 1 |
| Wang, H | 3 |
| Wang, L | 3 |
| Xu, Y | 2 |
| Lascano, J | 1 |
| Riley, L | 1 |
| Khodayari, N | 1 |
| Brantly, M | 1 |
| Gupta, R | 1 |
| Pradhan, J | 1 |
| Haldar, A | 1 |
| Murapaka, C | 1 |
| Chandra Mondal, P | 1 |
| Gao, R | 1 |
| Dai, TY | 1 |
| Meng, Z | 1 |
| Sun, XF | 1 |
| Liu, DX | 1 |
| Shi, MM | 1 |
| Li, HR | 1 |
| Kang, X | 1 |
| Bi, B | 1 |
| Zhang, YT | 1 |
| Xu, TW | 1 |
| Yan, JM | 1 |
| Jiang, Q | 1 |
| Helmchen, G | 1 |
| Guo, H | 1 |
| Xiang, W | 1 |
| Fang, Y | 1 |
| Li, J | 5 |
| Lin, Y | 1 |
| An, X | 1 |
| Jiang, D | 1 |
| Cao, Q | 1 |
| Xu, F | 1 |
| Shiigi, H | 1 |
| Wang, W | 1 |
| Chen, Z | 2 |
| Akosman, I | 1 |
| Kumar, N | 2 |
| Mortenson, R | 1 |
| Lans, A | 1 |
| De La Garza Ramos, R | 1 |
| Eleswarapu, A | 1 |
| Yassari, R | 1 |
| Fourman, MS | 1 |
| Jana, S | 1 |
| Evans, EGB | 1 |
| Jang, HS | 1 |
| Zhang, S | 3 |
| Zhang, H | 2 |
| Rajca, A | 1 |
| Gordon, SE | 1 |
| Zagotta, WN | 1 |
| Stoll, S | 1 |
| Mehl, RA | 1 |
| Miller, S | 1 |
| Lee, DA | 1 |
| Muhimpundu, S | 1 |
| Maxwell, CA | 1 |
| Liu, Z | 1 |
| Shen, F | 1 |
| Tong, Q | 1 |
| Tang, M | 1 |
| Peng, M | 1 |
| Jiao, Z | 1 |
| Jiang, Y | 1 |
| Ao, L | 1 |
| Fu, W | 1 |
| Lv, X | 1 |
| Jiang, G | 1 |
| Hou, L | 1 |
| Tu, WC | 1 |
| McManamen, AM | 1 |
| Su, X | 1 |
| Jeacopello, I | 1 |
| Takezawa, MG | 1 |
| Hieber, DL | 1 |
| Hassan, GW | 1 |
| Lee, UN | 1 |
| Anana, EV | 1 |
| Locknane, MP | 1 |
| Stephenson, MW | 1 |
| Shinkawa, VAM | 1 |
| Wald, ER | 1 |
| DeMuri, GP | 1 |
| Adams, KN | 1 |
| Berthier, E | 1 |
| Thongpang, S | 1 |
| Theberge, AB | 1 |
| Jiang, L | 1 |
| Li, Z | 1 |
| Dong, Q | 1 |
| Rong, X | 1 |
| Dong, G | 1 |
| Huang, J | 1 |
| Liang, Y | 1 |
| Sun, S | 1 |
| Zhang, R | 2 |
| Miao, Z | 1 |
| Senju, C | 1 |
| Nakazawa, Y | 1 |
| Oso, T | 1 |
| Shimada, M | 1 |
| Kato, K | 1 |
| Matsuse, M | 1 |
| Tsujimoto, M | 1 |
| Masaki, T | 1 |
| Miyazaki, Y | 1 |
| Fukushima, S | 1 |
| Tateishi, S | 1 |
| Utani, A | 1 |
| Murota, H | 1 |
| Tanaka, K | 1 |
| Mitsutake, N | 1 |
| Moriwaki, S | 1 |
| Nishigori, C | 1 |
| Ogi, T | 1 |
| Liu, C | 1 |
| Zhang, X | 1 |
| Wang, B | 1 |
| Luo, Z | 1 |
| Qian, D | 1 |
| Liu, J | 4 |
| Waterhouse, GIN | 1 |
| Barbosa, M | 1 |
| Marques-Sá, J | 1 |
| Carvalho, C | 1 |
| Fernandes, V | 1 |
| Grilli, D | 1 |
| Smetana, V | 1 |
| Ahmed, SJ | 1 |
| Shtender, V | 1 |
| Pani, M | 1 |
| Manfrinetti, P | 1 |
| Mudring, AV | 1 |
| Kuang, Y | 1 |
| Yang, D | 1 |
| Gai, S | 1 |
| He, F | 1 |
| An, B | 1 |
| Yang, P | 1 |
| Notini, L | 1 |
| Schulz, K | 1 |
| Kubeneck, LJ | 1 |
| Grigg, ARC | 1 |
| Rothwell, KA | 1 |
| Fantappiè, G | 1 |
| ThomasArrigo, LK | 1 |
| Kretzschmar, R | 1 |
| Siswanto, FM | 1 |
| Okukawa, K | 1 |
| Tamura, A | 1 |
| Oguro, A | 1 |
| Imaoka, S | 1 |
| Kim, CG | 1 |
| Jung, M | 1 |
| Kim, HS | 2 |
| Lee, CK | 1 |
| Jeung, HC | 1 |
| Koo, DH | 1 |
| Bae, WK | 1 |
| Zang, DY | 1 |
| Kim, BJ | 1 |
| Kim, H | 1 |
| Yun, UJ | 1 |
| Che, J | 1 |
| Park, S | 1 |
| Kim, TS | 1 |
| Kwon, WS | 1 |
| Park, J | 1 |
| Cho, SW | 1 |
| Nam, CM | 1 |
| Chung, HC | 1 |
| Rha, SY | 1 |
| Colombo, N | 1 |
| Van Gorp, T | 1 |
| Matulonis, UA | 1 |
| Oaknin, A | 1 |
| Grisham, RN | 1 |
| Fleming, GF | 1 |
| Olawaiye, AB | 1 |
| Nguyen, DD | 1 |
| Greenstein, AE | 1 |
| Custodio, JM | 1 |
| Pashova, HI | 1 |
| Tudor, IC | 1 |
| Lorusso, D | 1 |
| Zhou, F | 1 |
| Jiang, Z | 1 |
| Liang, H | 1 |
| Ru, S | 1 |
| Bettiol, AA | 1 |
| Gao, W | 1 |
| Lipsyc-Sharf, M | 1 |
| Jain, E | 1 |
| Collins, LC | 1 |
| Rosenberg, SM | 1 |
| Ruddy, KJ | 1 |
| Tamimi, RM | 1 |
| Schapira, L | 1 |
| Come, SE | 1 |
| Peppercorn, JM | 1 |
| Borges, VF | 1 |
| Warner, E | 1 |
| Snow, C | 1 |
| Krop, IE | 1 |
| Kim, D | 1 |
| Weiss, J | 1 |
| Zanudo, JGT | 1 |
| Partridge, AH | 1 |
| Wagle, N | 1 |
| Waks, AG | 1 |
| Moskowitz, A | 1 |
| Berg, KM | 1 |
| Grossestreuer, AV | 1 |
| Balaji, L | 1 |
| Liu, X | 1 |
| Cocchi, MN | 1 |
| Chase, M | 1 |
| Gong, MN | 1 |
| Gong, J | 1 |
| Parikh, SM | 1 |
| Ngo, L | 1 |
| Berlin, N | 1 |
| Donnino, MW | 1 |
| Zhou, Y | 1 |
| Chen, Q | 1 |
| Zhong, S | 1 |
| Liu, H | 2 |
| Koh, K | 1 |
| Chen, H | 1 |
| He, J | 1 |
| Chen, J | 1 |
| Liu, S | 1 |
| Lin, L | 1 |
| Zhang, Y | 2 |
| Xiao, S | 2 |
| Cao, S | 1 |
| Yan, B | 2 |
| Deng, J | 1 |
| Gu, J | 1 |
| Tao, Y | 1 |
| Huang, C | 1 |
| Lai, C | 1 |
| Yong, Q | 1 |
| Shen, Y | 1 |
| Gong, Z | 1 |
| Cao, J | 1 |
| Mao, W | 1 |
| Yao, Y | 1 |
| Zhao, J | 1 |
| Li, Q | 2 |
| Liu, K | 1 |
| Liu, B | 1 |
| Feng, S | 1 |
| Chandran, V | 1 |
| Kunjan, C | 1 |
| Veerapandian, V | 1 |
| Kannan, R | 1 |
| Zhang, T | 2 |
| von Gunten, U | 1 |
| Caruso, FR | 1 |
| Goulart, CDL | 1 |
| Jr, JCB | 1 |
| de Oliveira, CR | 1 |
| Mendes, RG | 1 |
| Arena, R | 1 |
| Borghi-Silva, A | 1 |
| Carrasco-Nuñes, N | 1 |
| Romano, M | 1 |
| Cabeza, M | 1 |
| Jiang, B | 1 |
| Chen, D | 1 |
| Zhao, C | 1 |
| Ma, Y | 1 |
| Yang, W | 1 |
| Shen, X | 1 |
| Satheeshkumar, K | 1 |
| Saravanakumar, P | 1 |
| Kalavathi, A | 1 |
| Vennila, KN | 1 |
| Elango, KP | 1 |
| Mues Genannt Koers, L | 1 |
| Prevost, D | 1 |
| Paulssen, E | 1 |
| Hoehr, C | 1 |
| Ulhassan, Z | 1 |
| Yang, S | 1 |
| He, D | 1 |
| Khan, AR | 1 |
| Salam, A | 1 |
| Azhar, W | 1 |
| Muhammad, S | 1 |
| Ali, S | 1 |
| Hamid, Y | 1 |
| Khan, I | 1 |
| Sheteiwy, MS | 1 |
| Zhou, W | 1 |
| Wang, X | 1 |
| Xie, Q | 1 |
| Wang, Y | 4 |
| Lü, H | 1 |
| Fu, M | 1 |
| Wang, D | 1 |
| Sun, H | 1 |
| Zhu, Y | 1 |
| Shen, Z | 1 |
| Zhu, X | 1 |
| Yao, PA | 1 |
| Zhang, C | 1 |
| Yu, W | 1 |
| Wu, Z | 1 |
| Sun, J | 1 |
| Xu, C | 1 |
| Du, J | 1 |
| He, X | 1 |
| Fang, J | 1 |
| Shao, X | 1 |
| Ma, K | 1 |
| Wang, S | 2 |
| Song, X | 1 |
| Dong, Z | 1 |
| Han, X | 1 |
| Li, H | 1 |
| Rahaman, A | 1 |
| Baloch, Z | 1 |
| Qin, X | 1 |
| He, Y | 2 |
| Wang, N | 1 |
| Zou, JX | 1 |
| Zhang, YM | 1 |
| Cao, JL | 1 |
| Pan, BX | 2 |
| Zhang, WH | 1 |
| Sun, T | 2 |
| Luo, L | 1 |
| Tian, QQ | 1 |
| Wang, WJ | 1 |
| Liu, QQ | 1 |
| Yang, L | 1 |
| Zhang, K | 1 |
| Zhang, W | 1 |
| Zhao, MG | 1 |
| Yang, Q | 1 |
| Heijmans, L | 1 |
| Joosten, EA | 1 |
| Yu, F | 1 |
| Xu, H | 1 |
| Chen, M | 1 |
| Guo, L | 1 |
| Zhou, C | 1 |
| Wang, F | 1 |
| Yu, J | 1 |
| Wu, B | 1 |
| Almeida, FB | 1 |
| Pinna, G | 1 |
| Barros, HMT | 1 |
| Lee, HG | 1 |
| Grossman, SK | 1 |
| Valdes-Rodriguez, R | 1 |
| Berenato, F | 1 |
| Korbutov, J | 1 |
| Chan, YH | 1 |
| Lavery, MJ | 1 |
| Yosipovitch, G | 2 |
| Zhou, X | 1 |
| Cheng, Y | 1 |
| Li, G | 1 |
| Yang, B | 1 |
| Wu, J | 1 |
| Qiuxia, Z | 1 |
| Xinlong, M | 1 |
| Yilong, Y | 1 |
| Hui, Z | 1 |
| Yali, W | 1 |
| Xiaoquan, Y | 1 |
| Lei, W | 1 |
| Jiahui, C | 1 |
| Haiyan, Z | 1 |
| Wiffen, PJ | 7 |
| Derry, S | 4 |
| Bell, RF | 1 |
| Rice, AS | 2 |
| Tölle, TR | 1 |
| Phillips, T | 1 |
| Moore, RA | 7 |
| Espinosa-Juárez, JV | 1 |
| Jaramillo-Morales, OA | 1 |
| López-Muñoz, FJ | 1 |
| Kohse, EK | 1 |
| Hollmann, MW | 1 |
| Bardenheuer, HJ | 1 |
| Kessler, J | 1 |
| Giliberto, JP | 2 |
| Dibildox, D | 1 |
| Merati, A | 1 |
| Rayner, HC | 1 |
| Larkina, M | 1 |
| Wang, M | 2 |
| Graham-Brown, M | 1 |
| van der Veer, SN | 1 |
| Ecder, T | 1 |
| Hasegawa, T | 1 |
| Kleophas, W | 1 |
| Bieber, BA | 1 |
| Tentori, F | 1 |
| Robinson, BM | 1 |
| Pisoni, RL | 1 |
| Bittencourt, S | 1 |
| Ferrazoli, E | 1 |
| Valente, MF | 1 |
| Romariz, S | 1 |
| Janisset, NRLL | 1 |
| Macedo, CE | 1 |
| Antonio, BB | 1 |
| Barros, V | 1 |
| Mundim, M | 1 |
| Porcionatto, M | 1 |
| Aarão, MC | 1 |
| Miranda, MF | 1 |
| Rodrigues, AM | 1 |
| de Almeida, AG | 1 |
| Longo, BM | 1 |
| Mello, LE | 2 |
| Hoggard, M | 1 |
| Nocera, A | 1 |
| Biswas, K | 1 |
| Taylor, MW | 1 |
| Douglas, RG | 1 |
| Bleier, BS | 1 |
| Miao, J | 1 |
| Aboagye, DE | 1 |
| Chulpayev, B | 1 |
| Liu, L | 1 |
| Ishkanian, G | 1 |
| Kolanuvada, B | 1 |
| Alaie, D | 1 |
| Petrillo, RL | 1 |
| Vincent, K | 1 |
| Baranowski, A | 1 |
| Bhattacharya, S | 1 |
| Birch, J | 1 |
| Cheong, Y | 1 |
| Cregg, R | 1 |
| Daniels, J | 1 |
| Hewitt, CA | 1 |
| Macfarlane, GJ | 1 |
| Middleton, L | 1 |
| Szubert, W | 1 |
| Tracey, I | 1 |
| Williams, ACC | 1 |
| Horne, AW | 1 |
| Reszke, R | 1 |
| Szepietowski, JC | 1 |
| Mooney, RA | 1 |
| Ackerley, SJ | 1 |
| Rajeswaran, DK | 1 |
| Cirillo, J | 1 |
| Barber, PA | 1 |
| Stinear, CM | 1 |
| Byblow, WD | 1 |
| Chun, E | 1 |
| Bumanglag, AV | 1 |
| Burke, SN | 1 |
| Sloviter, RS | 1 |
| Severance, EG | 1 |
| Viscidi, RP | 1 |
| Yolken, RH | 1 |
| Xiao, J | 1 |
| Bernhard, JD | 1 |
| Liu, Y | 1 |
| Tang, F | 1 |
| Fostini, AC | 1 |
| Girolomoni, G | 1 |
| Tessari, G | 1 |
| Jo, A | 1 |
| Heo, C | 1 |
| Schwartz, TH | 1 |
| Suh, M | 1 |
| Kong, S | 1 |
| Cheng, Z | 1 |
| Liu, ZP | 1 |
| Song, C | 1 |
| Xu, XB | 1 |
| Pan, HQ | 1 |
| Chen, WB | 1 |
| Peng, WJ | 1 |
| Toelle, T | 1 |
| Kim, SY | 1 |
| Lee, DW | 1 |
| -Kim, H | 1 |
| Bang, E | 1 |
| Chae, JH | 1 |
| Choe, BY | 2 |
| Parker, L | 1 |
| Huelin, R | 1 |
| Khankhel, Z | 1 |
| Wasiak, R | 1 |
| Mould, J | 1 |
| Kalita, J | 1 |
| Kohat, AK | 1 |
| Misra, UK | 1 |
| Bhoi, SK | 1 |
| Wu, CH | 1 |
| Gunasekara, K | 1 |
| Hull, JH | 1 |
| Bikov, A | 1 |
| Morris, AJ | 1 |
| Usmani, OS | 1 |
| Hernández-Andrade, E | 1 |
| Cortés-Camberos, AJ | 1 |
| Díaz, NF | 1 |
| Flores-Herrera, H | 1 |
| García-López, G | 1 |
| González-Jiménez, M | 1 |
| Santamaría, A | 1 |
| Molina-Hernández, A | 1 |
| Ryan, NM | 2 |
| Shao, B | 1 |
| Zhou, YL | 1 |
| Lin, YS | 1 |
| MacKenzie, G | 2 |
| Maguire, J | 2 |
| Sierra-Paredes, G | 1 |
| Loureiro, AI | 1 |
| Wright, LC | 1 |
| Sierra-Marcuño, G | 1 |
| Soares-da-Silva, P | 1 |
| Chutko, LS | 1 |
| Surushkina, SIu | 1 |
| Iakovenko, EA | 1 |
| Nikishena, IS | 1 |
| Anisimova, TI | 1 |
| Bondarchuk, IuL | 1 |
| Inkpen, H | 1 |
| Soukupova, M | 1 |
| Binaschi, A | 1 |
| Falcicchia, C | 1 |
| Palma, E | 1 |
| Roncon, P | 1 |
| Zucchini, S | 1 |
| Simonato, M | 1 |
| Gibson, PG | 3 |
| Vertigan, AE | 2 |
| Parekh, PJ | 1 |
| Balart, LA | 1 |
| Nakazato-Imasato, E | 2 |
| Kurebayashi, Y | 1 |
| Long, Q | 1 |
| Hei, Y | 1 |
| Luo, Q | 1 |
| Tian, Y | 1 |
| Yang, J | 1 |
| Wei, L | 1 |
| Liu, W | 1 |
| Bonnet, U | 1 |
| Ossowski, A | 1 |
| Schubert, M | 1 |
| Gall, H | 1 |
| Steinkamp, I | 1 |
| Richter, LE | 1 |
| Khalil-Boutros, Y | 1 |
| Nefedev, A | 1 |
| Kuhlmann, R | 1 |
| Nascimento-Alves, P | 1 |
| Fernandes-Silva, H | 1 |
| Aragão-Homem, C | 1 |
| Geraldes, R | 1 |
| Fonseca, AC | 1 |
| Robertson, KL | 1 |
| Marshman, LA | 1 |
| Lee, V | 1 |
| Hooper, A | 1 |
| Matsuda, KM | 1 |
| Sharma, D | 1 |
| Schonfeld, AR | 1 |
| Kwatra, SG | 1 |
| McKlveen, JM | 1 |
| Morano, RL | 1 |
| Fitzgerald, M | 1 |
| Zoubovsky, S | 1 |
| Cassella, SN | 1 |
| Scheimann, JR | 1 |
| Ghosal, S | 1 |
| Mahbod, P | 1 |
| Packard, BA | 1 |
| Myers, B | 1 |
| Baccei, ML | 1 |
| Herman, JP | 1 |
| Pochwat, B | 1 |
| Nowak, G | 1 |
| Szewczyk, B | 1 |
| Shepard, R | 1 |
| Page, CE | 1 |
| Coutellier, L | 1 |
| Ward, RE | 1 |
| Veerula, VL | 1 |
| Ezra, N | 1 |
| Travers, JB | 1 |
| Mousdicas, N | 1 |
| Cohen, SM | 2 |
| Misono, S | 2 |
| Rosa, AS | 1 |
| Freitas, MF | 1 |
| Rocha, IR | 1 |
| Chacur, M | 1 |
| Seidel, K | 1 |
| Helmeke, C | 1 |
| Poeggel, G | 1 |
| Braun, K | 1 |
| De Smedt, RH | 1 |
| Jaarsma, T | 1 |
| van den Broek, SA | 1 |
| Haaijer-Ruskamp, FM | 1 |
| Rossi, S | 1 |
| De Chiara, V | 1 |
| Musella, A | 1 |
| Kusayanagi, H | 1 |
| Mataluni, G | 1 |
| Bernardi, G | 1 |
| Usiello, A | 1 |
| Centonze, D | 1 |
| Forde, G | 2 |
| Stanos, S | 1 |
| Levy, BS | 1 |
| Apgar, BS | 1 |
| Liu, YH | 1 |
| Huang, YG | 1 |
| Chen, LW | 1 |
| El-faramawy, YA | 1 |
| El-banouby, MH | 1 |
| Sergeev, P | 1 |
| Mortagy, AK | 1 |
| Amer, MS | 1 |
| Abdel-tawab, AM | 1 |
| Yamamoto, T | 1 |
| Fürst, Z | 1 |
| Blicher, JU | 1 |
| Jakobsen, J | 1 |
| Andersen, G | 1 |
| Nielsen, JF | 1 |
| Wolfe, D | 1 |
| Mata, M | 1 |
| Fink, DJ | 1 |
| Chiechio, S | 1 |
| Zammataro, M | 1 |
| Caraci, F | 1 |
| Rampello, L | 1 |
| Copani, A | 1 |
| Sabato, AF | 2 |
| Nicoletti, F | 1 |
| Gustafsson, H | 1 |
| Sandin, J | 1 |
| Landry, M | 1 |
| Nagy, F | 1 |
| Recla, JM | 1 |
| Sarantopoulos, CD | 1 |
| Sen, H | 3 |
| Sizlan, A | 2 |
| Yanarateş, O | 2 |
| Senol, MG | 1 |
| Inangil, G | 1 |
| Sücüllü, I | 1 |
| Ozkan, S | 2 |
| Dağli, G | 2 |
| Gatti, A | 1 |
| Carucci, A | 1 |
| Bertini, L | 1 |
| Mammucari, M | 1 |
| Occhioni, R | 1 |
| Clarke, H | 1 |
| Pereira, S | 1 |
| Kennedy, D | 1 |
| Andrion, J | 1 |
| Mitsakakis, N | 1 |
| Gollish, J | 1 |
| Katz, J | 1 |
| Kay, J | 1 |
| Straube, S | 1 |
| McQuay, HJ | 5 |
| Jensen, TS | 1 |
| Finnerup, NB | 1 |
| Emirkadi, H | 1 |
| Turan, A | 2 |
| Buvanendran, A | 1 |
| Kroin, JS | 1 |
| Della Valle, CJ | 1 |
| Kari, M | 1 |
| Moric, M | 1 |
| Tuman, KJ | 1 |
| Romanò, CL | 1 |
| Romanò, D | 1 |
| Bonora, C | 1 |
| Mineo, G | 1 |
| Tsuda, M | 1 |
| Inoue, K | 1 |
| Bandiera, FC | 1 |
| Arheart, KL | 1 |
| Caban-Martinez, AJ | 1 |
| Fleming, LE | 1 |
| McCollister, K | 1 |
| Dietz, NA | 1 |
| Leblanc, WG | 1 |
| Davila, EP | 1 |
| Lewis, JE | 1 |
| Serdar, B | 1 |
| Lee, DJ | 1 |
| Tayoshi, S | 1 |
| Nakataki, M | 1 |
| Sumitani, S | 1 |
| Taniguchi, K | 1 |
| Shibuya-Tayoshi, S | 1 |
| Numata, S | 1 |
| Iga, J | 1 |
| Ueno, S | 1 |
| Harada, M | 1 |
| Ohmori, T | 1 |
| Yildirim, K | 1 |
| Deniz, O | 1 |
| Gureser, G | 1 |
| Karatay, S | 1 |
| Ugur, M | 1 |
| Erdal, A | 1 |
| Senel, K | 1 |
| Morris-Stiff, G | 1 |
| Lewis, MH | 1 |
| Collins, S | 2 |
| Carroll, D | 2 |
| Jadad, A | 2 |
| Strauss, AC | 1 |
| Dimitrakov, JD | 1 |
| Greene, SM | 1 |
| Simpson, CB | 1 |
| Lampl, C | 1 |
| Schweiger, C | 1 |
| Haider, B | 1 |
| Lechner, A | 1 |
| Badawy, RA | 1 |
| Macdonell, RA | 1 |
| Jackson, GD | 1 |
| Berkovic, SF | 1 |
| Flatters, SJ | 1 |
| Bender, G | 1 |
| Florian, JA | 1 |
| Bramwell, S | 1 |
| Field, MJ | 2 |
| Tan, KK | 1 |
| Marshall, S | 1 |
| DeJongh, J | 1 |
| Bies, RR | 1 |
| Danhof, M | 1 |
| D'Amico, D | 1 |
| Amr, YM | 1 |
| Yousef, AA | 1 |
| Bar Ad, V | 1 |
| Hasbargen, T | 1 |
| Ahmed, MM | 1 |
| Miranpuri, G | 1 |
| Li, L | 1 |
| Kahle, KT | 1 |
| Resnick, D | 1 |
| Sun, D | 1 |
| Heidelbaugh, JJ | 1 |
| Llanes, M | 1 |
| Weadock, WJ | 1 |
| Ongür, D | 1 |
| Prescot, AP | 1 |
| McCarthy, J | 1 |
| Cohen, BM | 1 |
| Renshaw, PF | 1 |
| Millecamps, M | 1 |
| Tajerian, M | 1 |
| Sage, EH | 1 |
| Stone, LS | 1 |
| Wamsteeker, JI | 1 |
| Kuzmiski, JB | 1 |
| Bains, JS | 1 |
| Pontari, MA | 1 |
| Krieger, JN | 1 |
| Litwin, MS | 1 |
| White, PC | 1 |
| Anderson, RU | 1 |
| McNaughton-Collins, M | 1 |
| Nickel, JC | 1 |
| Shoskes, DA | 1 |
| Alexander, RB | 1 |
| O'Leary, M | 1 |
| Zeitlin, S | 1 |
| Chuai, S | 1 |
| Landis, JR | 1 |
| Cen, L | 1 |
| Propert, KJ | 1 |
| Kusek, JW | 1 |
| Nyberg, LM | 1 |
| Schaeffer, AJ | 2 |
| Vaysse, L | 1 |
| Sol, JC | 1 |
| Lazorthes, Y | 1 |
| Courtade-Saidi, M | 1 |
| Eaton, MJ | 1 |
| Jozan, S | 1 |
| Durkin, B | 1 |
| Page, C | 1 |
| Glass, P | 1 |
| Tsukumo, Y | 1 |
| Matsumoto, Y | 1 |
| Miura, H | 1 |
| Yano, H | 1 |
| Manabe, H | 1 |
| Lassen, CL | 1 |
| Kleinjung, T | 1 |
| Strutz, J | 1 |
| Graf, BM | 1 |
| Wiese, CH | 1 |
| Ucak, A | 1 |
| Onan, B | 1 |
| Selcuk, I | 1 |
| Yilmaz, AT | 1 |
| Pal'tsev, AI | 1 |
| Torgashov, MN | 1 |
| Vorontsova, IuS | 1 |
| Baiandina, EV | 1 |
| Luniakina, SB | 1 |
| Bockbrader, HN | 1 |
| Burger, P | 1 |
| Knapp, L | 1 |
| Corrigan, BW | 1 |
| Leke, R | 1 |
| Bak, LK | 1 |
| Iversen, P | 1 |
| Sørensen, M | 1 |
| Keiding, S | 1 |
| Vilstrup, H | 1 |
| Ott, P | 1 |
| Portela, LV | 1 |
| Schousboe, A | 1 |
| Waagepetersen, HS | 1 |
| Edwards, J | 1 |
| Hey, M | 1 |
| Wilson, I | 1 |
| Johnson, MI | 1 |
| Kanehira, T | 1 |
| Nakamura, Y | 1 |
| Nakamura, K | 1 |
| Horie, K | 1 |
| Horie, N | 1 |
| Furugori, K | 1 |
| Sauchi, Y | 1 |
| Yokogoshi, H | 1 |
| Buetefisch, C | 1 |
| Heger, R | 1 |
| Schicks, W | 1 |
| Seitz, R | 1 |
| Netz, J | 1 |
| Obata, H | 2 |
| Ogino, Y | 1 |
| Hoekstra, CE | 1 |
| Rynja, SP | 1 |
| van Zanten, GA | 1 |
| Rovers, MM | 1 |
| Lantos, PM | 1 |
| Gunduz, O | 1 |
| Oltulu, C | 1 |
| Guven, R | 1 |
| Buldum, D | 1 |
| Ulugol, A | 1 |
| Lua, J | 1 |
| Bellamy, CO | 1 |
| Whitworth, C | 1 |
| Dhaun, N | 1 |
| Zhang, Z | 1 |
| Cai, YQ | 1 |
| Zou, F | 1 |
| Bie, B | 1 |
| Pan, ZZ | 1 |
| Miklós, IH | 1 |
| Kovács, KJ | 1 |
| Park, JM | 1 |
| Jwa, SW | 1 |
| Song, M | 1 |
| Ko, HC | 1 |
| Kim, MB | 1 |
| Kwon, KS | 1 |
| Kim, BS | 1 |
| Komoly, S | 1 |
| Derks, NM | 1 |
| Pintér, O | 1 |
| Zuure, W | 1 |
| Ledent, C | 1 |
| Watanabe, M | 1 |
| Molnár, CS | 1 |
| Wei, Y | 1 |
| Roubos, EW | 1 |
| Wu, S | 1 |
| Hrabovszky, E | 1 |
| Zelena, D | 1 |
| Kozicz, T | 1 |
| Shavit, L | 1 |
| Grenader, T | 1 |
| Lifschitz, M | 1 |
| Slotki, I | 1 |
| Aboumarzouk, OM | 1 |
| Nelson, RL | 1 |
| Birring, SS | 1 |
| Llano, DA | 1 |
| Turner, J | 1 |
| Caspary, DM | 1 |
| Liu, HY | 1 |
| Li, YX | 1 |
| Hao, YJ | 1 |
| Wang, HY | 1 |
| Dai, XY | 1 |
| Yu, JQ | 1 |
| Wielage, R | 1 |
| Bansal, M | 1 |
| Wilson, K | 1 |
| Klein, R | 1 |
| Happich, M | 1 |
| Wu, F | 1 |
| Yang, N | 1 |
| Touré, A | 1 |
| Jin, Z | 1 |
| Xu, X | 1 |
| Diop, L | 1 |
| Raymond, F | 1 |
| Fargeau, H | 1 |
| Petoux, F | 1 |
| Chovet, M | 1 |
| Doherty, AM | 1 |
| Laughlin, TM | 1 |
| Tram, KV | 1 |
| Wilcox, GL | 1 |
| Birnbaum, AK | 1 |
| Surges, R | 1 |
| Feuerstein, TJ | 1 |
| Fassoulaki, A | 2 |
| Patris, K | 1 |
| Sarantopoulos, C | 2 |
| Hogan, Q | 1 |
| Bortalanza, LB | 1 |
| Ferreira, J | 1 |
| Hess, SC | 1 |
| Delle Monache, F | 1 |
| Yunes, RA | 1 |
| Calixto, JB | 1 |
| Xi, ZX | 1 |
| Ramamoorthy, S | 1 |
| Shen, H | 1 |
| Lake, R | 1 |
| Samuvel, DJ | 1 |
| Kalivas, PW | 1 |
| Duvilanski, BH | 1 |
| Alvarez, MP | 1 |
| Castrillón, PO | 1 |
| Cano, P | 1 |
| Esquifino, AI | 1 |
| Agostoni, E | 1 |
| Frigerio, R | 1 |
| Santoro, P | 1 |
| Polgár, E | 1 |
| Hughes, DI | 1 |
| Riddell, JS | 1 |
| Maxwell, DJ | 1 |
| Puskár, Z | 1 |
| Todd, AJ | 1 |
| Haller, H | 1 |
| Leblhuber, F | 1 |
| Trenkler, J | 1 |
| Schmidhammer, R | 1 |
| Laurén, HB | 1 |
| Pitkänen, A | 1 |
| Nissinen, J | 1 |
| Soini, SL | 1 |
| Korpi, ER | 2 |
| Holopainen, IE | 1 |
| Oefelein, MG | 1 |
| Bayazit, Y | 1 |
| Lockwood, PA | 1 |
| Cook, JA | 1 |
| Ewy, WE | 1 |
| Mandema, JW | 1 |
| Heinz, A | 1 |
| Schäfer, M | 1 |
| Higley, JD | 1 |
| Krystal, JH | 1 |
| Goldman, D | 1 |
| Spira, PJ | 1 |
| Beran, RG | 1 |
| von Orelli, F | 1 |
| White, WT | 1 |
| Patel, N | 1 |
| Drass, M | 1 |
| Nalamachu, S | 1 |
| Nicholson, BD | 1 |
| Lotery, HE | 1 |
| McClure, N | 1 |
| Galask, RP | 1 |
| Hong-Ju, Y | 1 |
| He, L | 1 |
| Wei-Guo, S | 1 |
| Nan, Z | 1 |
| Wei-Xiu, Y | 1 |
| Zhong-Wei, J | 1 |
| Jun-Wei, W | 1 |
| Zheng-Hua, G | 1 |
| Bo-Hua, Z | 1 |
| Zhi-Pu, L | 1 |
| Zhe-Hui, G | 1 |
| Stahl, SM | 1 |
| Loeliger, M | 1 |
| Briscoe, T | 1 |
| Lambert, G | 1 |
| Caddy, J | 1 |
| Rehn, A | 1 |
| Dieni, S | 1 |
| Rees, S | 1 |
| Di, S | 1 |
| Tasker, JG | 1 |
| Allen, NJ | 1 |
| Káradóttir, R | 1 |
| Attwell, D | 1 |
| Verkuyl, JM | 1 |
| Hemby, SE | 1 |
| Joëls, M | 2 |
| Baldassano, CF | 1 |
| Ballas, CA | 1 |
| O'Reardon, JP | 1 |
| Lin, TB | 1 |
| Lo, MJ | 1 |
| Huang, CY | 1 |
| Ting, H | 1 |
| Lee, SD | 1 |
| Urban, MO | 1 |
| Ren, K | 1 |
| Park, KT | 1 |
| Campbell, B | 1 |
| Anker, N | 1 |
| Stearns, B | 1 |
| Aiyar, J | 1 |
| Belley, M | 1 |
| Cohen, C | 1 |
| Bristow, L | 1 |
| Garber, K | 1 |
| Lauder, GR | 1 |
| White, MC | 1 |
| Heartsill, LG | 1 |
| Brown, TM | 1 |
| Karst, H | 1 |
| Alfarez, D | 1 |
| Heine, VM | 1 |
| Qin, Y | 1 |
| van Riel, E | 1 |
| Verkuyl, M | 1 |
| Lucassen, PJ | 1 |
| Krugers, HJ | 1 |
| Wiffen, P | 1 |
| McQuay, H | 1 |
| Moore, A | 1 |
| Edwards, JE | 1 |
| Weissenbacher, S | 1 |
| Ring, J | 1 |
| Hofmann, H | 1 |
| Coderre, TJ | 1 |
| Lefebvre, CD | 1 |
| Yu, JS | 1 |
| Triga, A | 1 |
| Melemeni, A | 1 |
| Toru, M | 1 |
| Sator-Katzenschlager, SM | 1 |
| Scharbert, G | 1 |
| Kress, HG | 2 |
| Frickey, N | 1 |
| Ellend, A | 1 |
| Gleiss, A | 1 |
| Kozek-Langenecker, SA | 1 |
| Persaud, R | 1 |
| Frosh, A | 1 |
| Baghdoyan, HA | 1 |
| Baron, R | 1 |
| Lu, VB | 1 |
| Moran, TD | 1 |
| Balasubramanyan, S | 1 |
| Alier, KA | 1 |
| Dryden, WF | 1 |
| Colmers, WF | 1 |
| Smith, PA | 1 |
| Son, BC | 1 |
| Choi, ES | 1 |
| Sung, JH | 1 |
| Hong, JT | 1 |
| Vieira, DS | 1 |
| Naffah-Mazacoratti, MG | 1 |
| Zukerman, E | 1 |
| Senne Soares, CA | 1 |
| Alonso, EO | 1 |
| Faulhaber, MH | 1 |
| Cavalheiro, EA | 1 |
| Peres, MF | 1 |
| Mintz, S | 2 |
| Lee, JK | 2 |
| Kehlet, H | 1 |
| Cohen, SP | 1 |
| Sireci, A | 1 |
| Wu, CL | 1 |
| Larkin, TM | 1 |
| Williams, KA | 1 |
| Hurley, RW | 1 |
| Bichuetti, DB | 1 |
| Yamaoka, WY | 1 |
| Bastos, JR | 1 |
| Carvalho, Dde S | 1 |
| Potes, CS | 1 |
| Neto, FL | 2 |
| Castro-Lopes, JM | 2 |
| Cauli, O | 2 |
| Llansola, M | 2 |
| Erceg, S | 1 |
| Felipo, V | 2 |
| Kimos, P | 1 |
| Biggs, C | 1 |
| Mah, J | 1 |
| Heo, G | 1 |
| Rashiq, S | 1 |
| Thie, NM | 1 |
| Major, PW | 1 |
| Bergasa, NV | 1 |
| McGee, M | 1 |
| Ginsburg, IH | 1 |
| Engler, D | 1 |
| Lefaucheur, JP | 1 |
| Drouot, X | 1 |
| Ménard-Lefaucheur, I | 1 |
| Keravel, Y | 1 |
| Nguyen, JP | 1 |
| Ferreira-Gomes, J | 1 |
| Pawlik, MT | 1 |
| Ittner, KP | 1 |
| Vadalouca, A | 1 |
| Siafaka, I | 1 |
| Argyra, E | 1 |
| Vrachnou, E | 1 |
| Moka, E | 1 |
| Hauer, JM | 1 |
| Wical, BS | 1 |
| Charnas, L | 1 |
| Yokoyama, T | 1 |
| Maeda, Y | 1 |
| Audette, KM | 1 |
| Sluka, KA | 1 |
| Manenti, L | 1 |
| Vaglio, A | 1 |
| Jatzko, A | 1 |
| Stegmeier-Petroianu, A | 3 |
| Petroianu, GA | 1 |
| Melrose, HL | 1 |
| Kinloch, RA | 1 |
| Cox, PJ | 1 |
| Collins, D | 1 |
| Williams, D | 1 |
| Mlili, N | 1 |
| Solak, O | 2 |
| Metin, M | 1 |
| Esme, H | 1 |
| Yaman, M | 1 |
| Pekcolaklar, A | 1 |
| Gurses, A | 1 |
| Kavuncu, V | 1 |
| Wu, DC | 1 |
| Zhang, Q | 1 |
| Wallace, JM | 1 |
| Sinclair, AM | 1 |
| Miller, B | 1 |
| Lee, LK | 1 |
| Petroianu, G | 3 |
| Jerome, L | 1 |
| Knake, S | 1 |
| Klein, KM | 1 |
| Hattemer, K | 1 |
| Wellek, A | 1 |
| Oertel, WH | 1 |
| Hamer, HM | 1 |
| Rosenow, F | 1 |
| Kong, VK | 1 |
| Irwin, MG | 1 |
| Obermann, M | 1 |
| Yoon, MS | 1 |
| Sensen, K | 1 |
| Maschke, M | 1 |
| Diener, HC | 1 |
| Katsarava, Z | 1 |
| Hayashida, K | 1 |
| Schuchmann, JA | 1 |
| Browne, BA | 1 |
| Zeilhofer, HU | 1 |
| Ehrchen, J | 1 |
| Ständer, S | 1 |
| Tanimoto-Mori, S | 1 |
| Toide, K | 1 |
| Kita, Y | 1 |
| Ketz, AK | 1 |
| Rudick, CN | 1 |
| Thumbikat, P | 1 |
| Benbouzid, M | 1 |
| Choucair-Jaafar, N | 1 |
| Yalcin, I | 1 |
| Waltisperger, E | 1 |
| Muller, A | 1 |
| Freund-Mercier, MJ | 1 |
| Barrot, M | 1 |
| Bras, M | 1 |
| Haslam, C | 1 |
| Nurmikko, T | 1 |
| Logothetis, J | 1 |
| Paraschos, A | 1 |
| Frangos, E | 1 |
| Snyder, SH | 1 |
| Kausen, J | 1 |
| Zimmermann, P | 1 |
| Fünfgeld, EW | 1 |
| Klenke, D | 1 |
| Henkel, H | 1 |
| Puca, FM | 1 |
| Genco, S | 1 |
| Minervini, MG | 1 |
| Specchio, LM | 1 |
| Napoletano, V | 1 |
| Brancasi, B | 1 |
| Reggio, F | 1 |
| Skerritt, JH | 1 |
| Trisdikoon, P | 1 |
| Johnston, GA | 2 |
| Eninia, GI | 1 |
| Smeltere, ES | 1 |
| Godlevska, MA | 1 |
| Uzulinia, IP | 1 |
| McCarthy, BW | 1 |
| Gomes, UR | 1 |
| Neethling, AC | 1 |
| Shanley, BC | 1 |
| Taljaard, JJ | 1 |
| Potgieter, L | 1 |
| Roux, JT | 1 |
| Nazaretian, RA | 1 |
| Babaian, EA | 1 |
| Sarukhanian, ZhG | 1 |
| Martirosian, AS | 1 |
| Darbinian, GV | 1 |
| Maddison, JE | 1 |
| Watson, WE | 1 |
| Acosta, GB | 1 |
| Otero Losada, ME | 1 |
| Rubio, MC | 1 |
| Suh, TS | 1 |
| Shinn, KS | 1 |
| Lee, CW | 1 |
| Lee, C | 1 |
| Paik, IH | 1 |
| Walker, MC | 1 |
| Li, LM | 1 |
| Sander, JW | 4 |
| Hunter, JC | 1 |
| Gogas, KR | 1 |
| Hedley, LR | 1 |
| Jacobson, LO | 1 |
| Kassotakis, L | 1 |
| Thompson, J | 1 |
| Fontana, DJ | 1 |
| Wilson, EA | 1 |
| Brodie, MJ | 1 |
| Nicolodi, M | 1 |
| Del Bianco, PL | 1 |
| Sicuteri, F | 1 |
| Terranova, R | 1 |
| Gilotta, SM | 1 |
| Luca, S | 1 |
| García-Albea, E | 1 |
| Gibbs, JW | 1 |
| Morton, LD | 1 |
| Amaker, B | 1 |
| Ward, JD | 1 |
| Holloway, KL | 1 |
| Coulter, DA | 1 |
| Yamashiro, K | 1 |
| Tomiyama, N | 1 |
| Ishida, A | 1 |
| Terada, Y | 1 |
| Mukawa, J | 1 |
| Yoshii, Y | 1 |
| Tasker, RR | 1 |
| Albe-Fessard, D | 1 |
| Hein, G | 2 |
| Petroianu, A | 1 |
| Bergler, W | 2 |
| Rüfer, R | 2 |
| Schwartzkroin, PA | 1 |
| Langan, Y | 1 |
| Duncan, JS | 1 |
| Ylinen, A | 1 |
| Salmenperä, T | 1 |
| Mumford, JP | 1 |
| Riekkinen, PJ | 1 |
| Hansen, HC | 1 |
| Wasterlain, CG | 1 |
| Mazarati, AM | 1 |
| Shirasaka, Y | 1 |
| Thompson, KW | 1 |
| Penix, L | 1 |
| Katsumori, H | 1 |
| Law, RO | 1 |
| Wong, IC | 2 |
| Chadwick, DW | 1 |
| Fenwick, PB | 1 |
| Mawer, GE | 1 |
| Ben-David, B | 1 |
| Friedman, M | 1 |
| Moretti, R | 1 |
| Torre, P | 1 |
| Antonello, RM | 1 |
| Nasuelli, D | 1 |
| Cazzato, G | 1 |
| Kapadia, NP | 1 |
| Harden, N | 1 |
| Fragoso, YD | 1 |
| Carrazana, EJ | 1 |
| Grachev, ID | 1 |
| Fredrickson, BE | 1 |
| Apkarian, VA | 1 |
| Lhatoo, SD | 1 |
| Polizzi, G | 1 |
| Ueda, Y | 1 |
| Doi, T | 1 |
| Tokumaru, J | 1 |
| Yokoyama, H | 1 |
| Nakajima, A | 1 |
| Mitsuyama, Y | 1 |
| Ohya-Nishiguchi, H | 1 |
| Kamada, H | 1 |
| Willmore, LJ | 1 |
| Hulsebosch, CE | 2 |
| Xu, GY | 1 |
| Perez-Polo, JR | 1 |
| Westlund, KN | 1 |
| Taylor, CP | 1 |
| McAdoo, DJ | 1 |
| Guyot, LL | 1 |
| Diaz, FG | 1 |
| O'Regan, MH | 1 |
| Song, D | 1 |
| Phillis, JW | 1 |
| Haywood, JR | 1 |
| Mifflin, SW | 1 |
| Craig, T | 1 |
| Calderon, A | 1 |
| Hensler, JG | 1 |
| Hinojosa-Laborde, C | 1 |
| Mills, CD | 1 |
| Grady, JJ | 1 |
| Farrar, JT | 1 |
| Young, JP | 1 |
| LaMoreaux, L | 1 |
| Werth, JL | 1 |
| Poole, MR | 1 |
| Mtchedlishvili, Z | 1 |
| Bertram, EH | 1 |
| Kapur, J | 1 |
| Suzuki, T | 1 |
| Sundman-Eriksson, I | 1 |
| Blennow, K | 1 |
| Davidsson, P | 1 |
| Dandenell, AK | 1 |
| Marcusson, J | 1 |
| Gustorff, B | 1 |
| Nahlik, G | 1 |
| Spacek, A | 1 |
| Hamani, C | 1 |
| Söderpalm, B | 1 |
| Boz, C | 1 |
| Velioglu, S | 1 |
| Bulbul, I | 1 |
| Ozmenoglu, M | 1 |
| To, TP | 1 |
| Lim, TC | 1 |
| Hill, ST | 1 |
| Frauman, AG | 1 |
| Cooper, N | 1 |
| Kirsa, SW | 1 |
| Brown, DJ | 1 |
| Bruins Slot, LA | 1 |
| Tarayre, JP | 1 |
| Koek, W | 1 |
| Ribet, JP | 1 |
| Colpaert, FC | 1 |
| Tamminga, CA | 2 |
| Neophytides, A | 1 |
| Chase, TN | 1 |
| Frohman, LA | 1 |
| Garkusha, LG | 1 |
| Kukhtevich, II | 1 |
| Proskurkina, OA | 1 |
| Smythies, JR | 1 |
| Bradley, RJ | 1 |
| Linton, PH | 1 |
| Sytinsky, IA | 1 |
| Guzikov, BM | 1 |
| Gomanko, MV | 1 |
| Eremin, VP | 1 |
| Konovalova, NN | 1 |
| Cassady, SL | 1 |
| Thaker, GK | 1 |
| Moran, M | 1 |
| Birt, A | 1 |
| Rönnbäck, L | 1 |
| Hansson, E | 1 |
| Mishunina, TM | 1 |
| Kononenko, VIa | 1 |
| Komissarenko, IV | 1 |
| Smith, KA | 1 |
| Bierkamper, GG | 1 |
| Sil'vestrov, VP | 1 |
| Kinitin, AV | 1 |
| Chesnokova, IV | 1 |
| Thirlby, RC | 1 |
| Fenster, LF | 1 |
| Coatsworth, JJ | 1 |
| Petty, F | 1 |
| Esclapez, M | 1 |
| Trottier, S | 1 |
| Levy, LJ | 1 |
| Losowsky, MS | 1 |
| Monteleone, P | 3 |
| Maj, M | 2 |
| Iovino, M | 2 |
| Forziati, D | 1 |
| Veltro, F | 1 |
| Steardo, L | 3 |
| Kleinman, JE | 1 |
| Goodman, SI | 1 |
| Wyatt, RJ | 1 |
| Zontini, G | 1 |
| Ramade, F | 1 |
| Baylé, JD | 1 |
| Bode, JC | 1 |
| Schäfer, K | 1 |
| Minuk, GY | 1 |
| Winder, A | 1 |
| Burgess, ED | 1 |
| Sarjeant, EJ | 1 |
| Van Leuven, F | 1 |
| Weyne, J | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients[NCT04855578] | 160 participants (Actual) | Interventional | 2021-05-28 | Completed | |||
| The Treatment Effect of Chinese Medicine Formula on Uremic Pruritus[NCT04650750] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2020-12-01 | Not yet recruiting | ||
| Effectiveness of Sertraline in Alleviating Uremic Pruritis in Hemodialysis Patients[NCT05341843] | Phase 2 | 60 participants (Actual) | Interventional | 2022-05-01 | Completed | ||
| Biperiden for Prevention of Epilepsy in Patients With Traumatic Brain Injury[NCT04945213] | Phase 3 | 312 participants (Anticipated) | Interventional | 2023-01-10 | Recruiting | ||
| A Double-Blind, Placebo-Controlled Study of Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors[NCT03530800] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
| Phenomics and Genomics of Clinically Relevant Chronic Postsurgical Pain: A Multicenter Prospective Study[NCT04798573] | 10,000 participants (Anticipated) | Observational | 2012-08-03 | Active, not recruiting | |||
| Pre-Emptive Analgesia in Ano-Rectal Surgery[NCT02402543] | 90 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Use of Single Dose Pre-Operative Pregabalin for Post-Operative Analgesia in Bilateral Head and Neck Cancer Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial[NCT03714867] | Phase 4 | 0 participants (Actual) | Interventional | 2019-03-22 | Withdrawn (stopped due to Inability to recruit patients) | ||
| Cannabidiol for Fibromyalgia -The CANNFIB Trial Protocol for a Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-center Trial[NCT04729179] | Phase 3 | 200 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| The Effect of Intravenous Infusions of Lidocaine and Magnesium Versus Lidocaine and Ketamine Versus Lidocaine Alone on Recovery Profile and Postoperative Pain After Elective Gynecological Surgery[NCT04622904] | 90 participants (Anticipated) | Interventional | 2020-11-14 | Recruiting | |||
| Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia[NCT03066739] | Phase 2 | 105 participants (Anticipated) | Interventional | 2023-02-25 | Recruiting | ||
| A Prospective, Randomized Controlled Trial on Perioperative Pregabalin to Reduce Late-onset Complex Regional Pain Syndrome After Total Knee Arthroplasty[NCT00558753] | Phase 2 | 240 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Preemptive Analgesia With Amitryptyline for Prevention of Post-operative Pain in Women After Total Abdominal Hysterectomy: a Randomized Clinical Trial[NCT03587025] | Phase 3 | 150 participants (Actual) | Interventional | 2015-06-01 | Completed | ||
| Efficacy of Different Doses of Pregabalin as a Multimodal Analgesic Agent in Postoperative Pain Control After Total Knee Arthroplasty - A Randomized Controlled Trial[NCT05447364] | Phase 4 | 82 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | ||
| Comparison of Oral Lamotrigine Versus Pregabalin for Control of Acute and Chronic Pain Following Modified Radical Mastectomy: Controlled Double-blind Study[NCT03419949] | 0 participants | Expanded Access | Available | ||||
| Diagnostic Challenges in IC (and Male CPPS)[NCT00672087] | 1,000 participants (Anticipated) | Observational | 2003-09-30 | Completed | |||
| The Effect of Lidocaine to Prevent the Development of Chronic Post-Surgical Pain[NCT01619852] | 148 participants (Actual) | Interventional | 2012-06-30 | Completed | |||
| Double Blind Trial Investigating the Role of Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients[NCT03847311] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-05-03 | Recruiting | ||
| A Randomized, Placebo-controlled Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)[NCT00371033] | Phase 3 | 318 participants (Anticipated) | Interventional | 2006-03-31 | Active, not recruiting | ||
| Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903] | Phase 4 | 77 participants (Actual) | Interventional | 2018-05-15 | Completed | ||
| STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis[NCT05603702] | Phase 1 | 24 participants (Anticipated) | Interventional | 2023-03-17 | Recruiting | ||
| Regional Anesthesia and Valproate Sodium for the Prevention of Chronic Post-Amputation Pain[NCT01928849] | Phase 2 | 128 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Clinical Trial of Etanercept (TNF-α Blocker) for Treatment of Blast-Induced Tinnitus[NCT04066348] | Phase 2 | 310 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
| Comparative Evaluation of Osteopathy Treatment Efficacy in Pain Support After Breast Surgery in Oncology[NCT01403168] | 28 participants (Actual) | Interventional | 2011-04-30 | Terminated (stopped due to Recruitment difficulties) | |||
| Randomized Controlled Pilot Trial of Adjunct Group Acupuncture vs Usual Care Among Patients With Painful Diabetic Neuropathy[NCT02104466] | 40 participants (Actual) | Interventional | 2015-03-31 | Completed | |||
| Radiofrequency Thoracic Sympathectomy for Chronic Postmastectomy Pain; Randomized Placebo Controlled Study[NCT03494426] | 70 participants (Actual) | Interventional | 2018-04-01 | Completed | |||
| Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)[NCT05162027] | Phase 2 | 5 participants (Actual) | Interventional | 2022-04-01 | Terminated (stopped due to Low enrollment rate) | ||
| Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain[NCT02339662] | Phase 4 | 50 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
| Study of Gabapentin for the Pruritus of Cholestasis[NCT00058890] | Phase 3 | 15 participants (Actual) | Interventional | 2000-11-30 | Completed | ||
| Comparison of the Analgesic Effect Between the Motor Cortex Stimulation (tDCS and rTMS) and the Trans-spinal Stimulation (tsDCS ) in the Algoneurodystrophy of Members. A Randomised Clinical Trial. tDCS : Transcranial Direct-current Stimulation rTMS : Repe[NCT02817880] | 36 participants (Actual) | Interventional | 2016-07-25 | Completed | |||
| Primary Motor Cortex Plasticity and the Bottom up Effect of Deep Intramuscular Needling Stimulation Therapy (DIMST)in Osteoarthritis Chronic Pain[NCT01855958] | 26 participants (Actual) | Interventional | 2012-02-29 | Completed | |||
| Effect of Transcranial Direct Current Stimulation and Electro Acupuncture in Pain, Functional Capability and Cortical Excitability in Patients With Osteoarthritis.[NCT01747070] | 60 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| A Phase II, Randomized, Placebo-controlled, Double Blind, Cross-over, Study of the Effects of Gabapentin on Chronic Irritability in Neurologically Impaired Children[NCT01675960] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to unable to enroll) | ||
| The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair[NCT02419443] | Phase 4 | 100 participants (Anticipated) | Interventional | 2011-08-31 | Active, not recruiting | ||
| Effect of Preoperative Pregabalin on Propofol Induction Dose[NCT01158859] | Phase 4 | 50 participants (Anticipated) | Interventional | 2010-04-30 | Completed | ||
| The Effect of Gabapentin on Acute Pain and PONV in Bariatric Surgical Patients[NCT00886236] | 62 participants (Actual) | Interventional | 2008-02-29 | Completed | |||
| Phase III Study of the Use of Gabapentin and Osteopathic Manipulative Medicine to Treat Fibromyalgia[NCT01107574] | Phase 3 | 41 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| An Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy[NCT00522418] | Phase 4 | 122 participants (Actual) | Interventional | 2006-02-28 | Terminated (stopped due to Insufficient enrollment) | ||
| A Double-Blind, Randomized, Placebo-Controlled, Three-Arm Trial Examining Sublingual Cannabinoid Tablets for the Treatment of Pain From Osteoarthritis of the Knee.[NCT04992962] | Phase 2 | 66 participants (Anticipated) | Interventional | 2021-07-29 | Recruiting | ||
| An Open-label, Single-centre, Parallel-group Clinical Investigation, to Evaluate the Effectiveness and In-use Tolerability of a Range of Four Orthotic Insoles on Target Areas of Pain in the Lower Body, Associated With Musculoskeletal Stress, Experienced b[NCT04746755] | 145 participants (Actual) | Interventional | 2019-06-21 | Terminated (stopped due to Participants experienced data collection issues when using the eDiary, these issues increased the burden and lowered compliance. Updates to the eDiary were unsuccessful at resolving the issues so the decision was taken to terminate the Investigation.) | |||
| Effects of a Self-management Program for Temporomandibular Myalgia in Subjects With Fibromyalgia: a Single Arm Study[NCT05426655] | 40 participants (Anticipated) | Interventional | 2022-06-16 | Recruiting | |||
| Side Effects of Two Different Mandibular Advancement Devices (MAD) in the Treatment of Snoring and Obstructive Sleep Apnea Syndrome (OSAS)[NCT04050514] | 65 participants (Actual) | Interventional | 2019-12-01 | Completed | |||
| The Effect of Repetitive Transcranial Magnetic Stimulation on Diabetic Peripheral Neuropathic Pain: A Randomized Controlled Trial[NCT04833660] | 22 participants (Anticipated) | Interventional | 2021-04-30 | Not yet recruiting | |||
| Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy[NCT04920097] | 240 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | |||
| The Effectiveness of Radial Shockwave Therapy on Myofascial Pain Syndrome: A Mixed Method Study That Combines a Randomised Control Trial and Semi-Structured Interview.[NCT05381987] | 120 participants (Anticipated) | Interventional | 2022-04-21 | Recruiting | |||
| Ultrasound Guided Platelet Rich Plasma Injections for Post Traumatic Greater Occipital Neuralgia: A Randomized Controlled Pilot Study[NCT04051203] | Phase 1 | 35 participants (Anticipated) | Interventional | 2019-02-01 | Active, not recruiting | ||
| NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial[NCT04808531] | Phase 3 | 360 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| Assessment and Treatment Responses to Patient Education and Basic Body Awareness Therapy in Hip Osteoarthritis: a Randomized Controlled Trial[NCT02884531] | 101 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| Effect of Muscle Energy Technique on Craniovertebral and Shoulder Angles in Forward Head Posture[NCT05642130] | 60 participants (Anticipated) | Interventional | 2022-09-22 | Active, not recruiting | |||
| Multicentre Observational Study on the Wound Pain Relief Properties of ORTODERMINA®[NCT03720119] | 78 participants (Actual) | Observational | 2015-01-27 | Completed | |||
| Erenumab as a Therapeutic Approach for the Management of Trigeminal Neuropathic Pain (TNP)[NCT05142228] | Phase 2 | 5 participants (Actual) | Interventional | 2022-04-01 | Terminated (stopped due to Low enrollment rate) | ||
| The Use of Virtual Reality for Lumbar Pain Management in an Outpatient Spine Clinic: An Exploratory Comparative Randomized Trial[NCT03819907] | 45 participants (Actual) | Interventional | 2019-04-08 | Completed | |||
| A Double Blind, Randomized Crossover Study of Efficacy and Safety of Topical Menthol, With and Without Mannitol, in the Treatment of Painful Diabetic Peripheral Neuropathy[NCT02728687] | Phase 1/Phase 2 | 72 participants (Actual) | Interventional | 2017-03-15 | Completed | ||
| Randomized Controlled Trial of Fractional CO2 Laser vs Sham Laser for Women With Provoked Vestibulodynia Who Have Failed Conservative Management[NCT03390049] | 0 participants (Actual) | Interventional | 2018-08-31 | Withdrawn (stopped due to No funding) | |||
| Clinical Validation of a Decompression Prototype Splint for Patients With Carpal Tunel Syndrome: a Multicentric Randomized Controlled Trial[NCT04043780] | 60 participants (Actual) | Interventional | 2019-09-24 | Completed | |||
| Addressing Opioid Use Disorder With an External Multimodal Neuromodulation Device: Clinical Evaluation of DuoTherm for Opioid-Sparing in Chronic Low Back Pain[NCT04494698] | 100 participants (Anticipated) | Interventional | 2022-06-23 | Recruiting | |||
| Addressing Opioid Use Disorder With an External Multimodal Neuromodulation Device: Clinical Evaluation of DuoTherm for Opioid-Sparing in Acute Low Back Pain[NCT04491175] | 60 participants (Anticipated) | Interventional | 2022-06-23 | Recruiting | |||
| Effects of Tele-prehabilitation on Clinical and Muscular Recover in Patients Waiting for Knee Replacement: a Randomized Controlled Trial[NCT05668312] | 58 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | |||
| Trigger Point Dry Needling vs Trigger Point Dry Needling With Intramuscular Electrical Stimulation for the Treatment of Sub-acute and Chronic Low Back Pain in a Military Population: A Randomized Crossover Design[NCT03539588] | 30 participants (Actual) | Interventional | 2017-04-12 | Completed | |||
| A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Multiple-Dose, Active and Placebo-Controlled Efficacy Study of Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars[NCT03785756] | Phase 3 | 280 participants (Anticipated) | Interventional | 2019-04-29 | Recruiting | ||
| Perioperative Visual Therapy May Help Prevent Phantom Limb Pain[NCT02383979] | Phase 4 | 115 participants (Anticipated) | Interventional | 2010-08-31 | Recruiting | ||
| Acupuncture for Female Interstitial Cystitis/Painful Bladder Syndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial[NCT02232282] | 22 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
| Does the Addition of Massage to Manual Therapy and Exercise Improve Outcome in Chronic Neck Pain?[NCT02313480] | 39 participants (Actual) | Interventional | 2013-04-30 | Completed | |||
| A Retrospective Longitudinal Cohort Study to Determine the Effectiveness of Integrated a Clinical Pathway Approach for Chronic Pain Treatment With Acupuncture in a Pain Clinic[NCT04490798] | 3,245 participants (Actual) | Observational | 2020-06-12 | Completed | |||
| A Randomised, Double-blind, Double-dummy, Parallel-group, Single Dose, Active and Placebo-controlled Efficacy and Pharmacokinetics/Pharmacodynamics Study of 2 x 200 mg Ibuprofen Liquid Capsules for the Treatment of Pain After Surgical Removal of Impacted [NCT05484401] | Phase 3 | 294 participants (Actual) | Interventional | 2022-08-09 | Completed | ||
| Evaluation of Pain Before and After Removal of Non-obstructive Kidney Stones[NCT03657667] | 43 participants (Actual) | Interventional | 2018-08-28 | Completed | |||
| Efficacy of an Internet-based Intervention for Dental Anxiety[NCT03680755] | Phase 2 | 450 participants (Anticipated) | Interventional | 2019-07-24 | Active, not recruiting | ||
| Cryoneurolysis Outcome on Pain Experience (COPE) in Patients With Low-back Pain - a Single-blinded Randomized Controlled Trial[NCT04786145] | 120 participants (Anticipated) | Interventional | 2020-02-15 | Active, not recruiting | |||
| Celiac Plexus Radiosurgery for Pain Management in Advanced Cancer Patients - a Phase II Trial[NCT02356406] | Phase 2 | 52 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| Effect of Scapula-focused Treatment With Additional Motor Control Exercises on Pain and Disability in Patients With Subacromial Pain Syndrome: A Randomized Controlled Trial[NCT02695524] | 60 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The entire study lasts 10 weeks. Every two weeks subjects will take the NIMH-TSS. The change in scores from baseline to after 10 weeks will be assessed. The scale itself assesses severity of trichotillomania symptoms. The NIMH-TSS score ranges from 0 to 20, with 0 being no symptoms and 20 being the most severe. (NCT03530800)
Timeframe: Assessed every two weeks up to 10 weeks, baseline data reported
| Intervention | score on a scale (Mean) |
|---|---|
| Dronabinol | 12.38 |
| Placebo | 10.63 |
The entire study lasts 10 weeks. Every two weeks subjects will take the SP-SAS. The change in scores from baseline to after 10 weeks will be assessed. The scale itself assesses severity of skin-picking symptoms. The SP-SAS score ranges from 0 to 48, with 0 being no symptoms and 48 being the most severe. (NCT03530800)
Timeframe: Assessed every two weeks up to 10 weeks, baseline reported
| Intervention | score on a scale (Mean) |
|---|---|
| Dronabinol | 24.44 |
| Placebo | 28.5 |
Epidural medication consumption was recorded for each 4-h interval from the completion of surgery to the time that the epidural was discontinued (same as the time to achieve hospital discharge criteria). Because the discontinuation time varied from patient to patient (as they achieved physical therapy criteria), the average hourly consumption (total analgesic used divided by the total infusion time) was used as the measure of epidural drug use. (NCT00558753)
Timeframe: 36 h
| Intervention | mL/h (Mean) |
|---|---|
| 1 Placebo | 6.40 |
| 2 Pregabalin | 5.77 |
(NCT00558753)
Timeframe: 1-30 days
| Intervention | Degrees (Least Squares Mean) | |||
|---|---|---|---|---|
| Day 1 | Day 2 | Day 3 | Day 30 | |
| 1 Placebo | 75.6 | 76.7 | 80.4 | 103.0 |
| 2 Pregabalin | 77.8 | 81.0 | 84.2 | 107.2 |
Patients will be evaluated in blinded fashion for lower extremity Complex Regional Pain Syndrome(CRPS) at pre-op, 1, 3, and 6 months postsurgery based initially on telephone interviews. An S-LANSS score of 12 or more was an indication of chronic neuropathic pain. Patients with an Self-report version of the Leeds Assessment of Neuropathic Symptoms and Signs(S-LANSS) score of 12 or more at 6 mo came to the physician's office for a standardized physical examination, which included the S-LANSS examination items (allodynia and hyperalgesia) directly assessed by the physician, plus a pinprick evaluation. (NCT00558753)
Timeframe: 3 and 6 months post-surgery
| Intervention | participants (Number) | |
|---|---|---|
| Neuropathic pain at 3 Month Follow up | Neuropathic pain at 6 Month Follow up | |
| 1 Placebo | 10 | 6 |
| 2 Pregabalin | 0 | 0 |
The participants development of chronic persistent pain 3 months after surgery as determined by character severity (yes/no). (NCT01619852)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Group L | 2 |
| .9% Normal Saline Placebo | 6 |
The amount of opioid analgesics consumed was converted to an equivalent dose of intravenous morphine. (NCT01619852)
Timeframe: 24 hours
| Intervention | equivalent dose of intravenous morphine (Median) |
|---|---|
| Group L | 34 |
| .9% Normal Saline Placebo | 39 |
Postoperative pain within the first 24 hours. Area under the numeric rating scale for pain versus time curve during the first 24 hours after surgery (score * hr). Numeric rating scale for pain on a scale of 0-10 (0 is no pain and 10 is high pain) versus time curve during the first 24 hours ( score * hr). The pain scores were collected upon arrival to recovery area, 30 minutes, 1 hour and every 6 hours up to 24 hours following the procedure. Minimum score is 60, Maximum score is 170. A higher value indicates more pain. (NCT01619852)
Timeframe: 24 hours
| Intervention | score on a scale (Median) |
|---|---|
| Group L | 116 |
| .9% Normal Saline Placebo | 119 |
Quality of recovery (QoR-40 instrument) is a 40-item questionnaire that provides a global score and sub-scores across five dimensions: patient support, comfort, emotions, physical independence, and pain. Score range: 40 to 200. A score of 40 demonstrates poor recovery and a maximum score of 200 represents good recovery. The higher the score the better recovery after surgery. (NCT01619852)
Timeframe: 24 hours post operative
| Intervention | units on a scale (Median) |
|---|---|
| Lidocaine (Group L) | 158 |
| .9% Normal Saline Placebo | 169 |
The development of chronic pain 3 months after surgery determined by the Leads Assessment of Neuropathic Symptoms and Signs (LANSS) scale, a valid 7-item tool for identifying patients whose pain is dominated by neuropathic mechanisms. Each item is a binary response (yes or no) to the presence of symptoms (5 items) or clinical signs (2 items), range 0-24 points. A score ≥ 12, neuropathic mechanisms are likely to be contributing to the patient's pain. A score < 12 is unlikely to be contributing. McGill questionnaire (Sensory domain) - 11 descriptors rated on an intensity scale as 0=none, 1=mild, 2=moderate, 3=severe. The higher the score, greater the pain (range 0-33). McGill questionnaire (Motivational-affective) 4 affect descriptors rated on an intensity scale as 0=none, 1=mild, 2=moderate, 3=severe.The higher the score the greater the pain (range 0-12) Brief pain inventory - pain severity (0, no pain, 10 excruciating pain); Greater the score; greater the pain (range 0-10). (NCT01619852)
Timeframe: 3 months
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| S-LANNS | McGill Questionaire-Sensory Discrimation | McGill Questionaire-Motivational-affective | Brief Pain Inventory | |
| .9% Normal Saline Placebo | 3 | 3 | 0 | 1 |
| Group L | 3 | 4 | 0 | 1 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)
| Intervention | score on 10-point scale (Mean) |
|---|---|
| Standard of Care | 2.26 |
| Postoperative Gabapentin Regimen | 2.46 |
Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 3.84 |
| Postoperative Gabapentin Regimen | 3.54 |
Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 5.73 |
| Postoperative Gabapentin Regimen | 6.38 |
Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 0.36 |
| Postoperative Gabapentin Regimen | 0.17 |
Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | score on a 10-point scale (Mean) |
|---|---|
| Standard of Care | 7.83 |
| Postoperative Gabapentin Regimen | 8.48 |
Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).
| Intervention | days (Mean) |
|---|---|
| Standard of Care | 14.8 |
| Postoperative Gabapentin Regimen | 18.7 |
Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).
| Intervention | morphine equivalents (Mean) |
|---|---|
| Standard of Care | 287.0 |
| Postoperative Gabapentin Regimen | 281.1 |
The S-LANSS is a self-reported version of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale. It aims to differentiate neuropathic pain from somatic or nociceptive pain. We will analyze the change in numeric average pain score during the past week (range from 0-10) from baseline. Higher scores indicate greater pain. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | score on a scale (Median) |
|---|---|
| Cherry Syrup | -2 |
| Valproic Acid | -2 |
The primary endpoint is the incidence of chronic pain after surgery. The study team will use the average pain score over the past week as noted on the Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) for the assessment of pain, and define chronic pain as a score greater than or equal to 3. (NCT01928849)
Timeframe: 3 months or time of final adjudication assessment, up to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Cherry Syrup | 37 |
| Valproic Acid | 36 |
The BPI short form is a multidimensional patient-completed measure that assesses the sensory component of pain intensity. We will analyze the change in average pain score question (ranges 0-10) and the sum of the 7 interference questions (total range 0-70) from baseline. Higher score indicates greater pain and interference. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | score on a scale (Median) | |
|---|---|---|
| BPI Average Pain Score | BPI interference question sum | |
| Cherry Syrup | -2 | -15 |
| Valproic Acid | -1 | -7 |
The DVPRS is a pain assessment tool developed by the military in an effort to improve reliability and interpretability of pain assessment in the military population. It has been found to be an effective and valid tool in this population. We will analyze the change in numeric pain response (range 0-10) and the sum of the four supplemental questions (range 0-40) from baseline. Higher scores indicate greater pain and functional limitations. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | score on a scale (Median) | |
|---|---|---|
| DVPRS numeric pain | DVPRS Supplemental Question Sum | |
| Cherry Syrup | -2 | -9 |
| Valproic Acid | 0 | -4.5 |
The effect of study drug on perioperative analgesic consumption and corresponding analysis of pain/sedation scales. Outcome defined as total opioid consumption (mg) during each 24-hour periods following surgery. (NCT01928849)
Timeframe: Assessments during hospitalization (0-24 hours and 24-48 hours post-surgery)
| Intervention | morphine milligram equivalents (Median) | |
|---|---|---|
| Postoperative hours 0-24 | Postoperative hours 24-48 | |
| Cherry Syrup | 59 | 49 |
| Valproic Acid | 33 | 45 |
The incidence of neuropathic limb or post-amputation pain sub-types as defined by adjudication classification at each assessment time point. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Residual limb pain | Phantom limb | |
| Cherry Syrup | 29 | 22 |
| Valproic Acid | 31 | 26 |
The RASS is a commonly used, valid and reliable assessment tool for use in hospitalized patients. Validity testing reveals good inter-rater reliability among medical, surgical, and intensive care units. We will analyze the numeric score at each assessment (range -5 (unarousable) to 4 (combative)). (NCT01928849)
Timeframe: during hospitalization (0-24 hours and 24-48 hours post-surgery)
| Intervention | score on a scale (Median) | |
|---|---|---|
| Post-op hours 0-24 | Post-op hours 24-48 | |
| Cherry Syrup | 0 | 0 |
| Valproic Acid | 0 | 0 |
"PPT during cold water immersion (PPT+CPM): By measuring PPT during cold water immersion, we evaluated the degree to which pain perception is modulated by conditioned pain modulation (CPM) following the presentation of an initial heterotopic noxious stimulus. Subjects immersed their left hands into cold water (zero to 1°C) for 1 minute. During the last 30 seconds of cold-water immersion, the PPT procedure was administered at the right forearm. The temperature was held constant across during the experiment for each subject.~# Below the data after intervention." (NCT01855958)
Timeframe: Before and within one hour after intervention.
| Intervention | Kgf / cm2 (Mean) |
|---|---|
| DIMST | 12.62 |
| Placebo-sham | 9.15 |
"To determine the cortical silent period (CSP), subjects were instructed to squeeze the dynamometer using their fingers at 20% of maximal force when a single pulse stimulus (130% rMT) was applied. The result was the average of five consecutive measurements. The CSP was determined by the interval between the stimulus and the motor response elicited in the subject.~# Below the data after intervention." (NCT01855958)
Timeframe: Evaluated before and within one hour after intervention.
| Intervention | ms (milliseconds). (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 50.93 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 48.92 |
"ICF was evaluated using an inter-stimuli intervals (ISIs) of 12 ms with paired-pulse and similar parameters for the conditioning and test stimuli. After a randomized protocol, thirty stimuli were assessed using a 2ms interval (ICI), a 12ms interval (ICF) and test-only trials (MEP). The resulting MEP amplitude was converted into the mean amplitude, and paired-pulse parameters were expressed as the amount of inhibition or facilitation. The calculation result of ICF was done by the ratio of the mean ICF by the mean MEP.~# Below the data after intervention." (NCT01855958)
Timeframe: Before and within one hour after intervention.
| Intervention | ratio of amplitude (mV). (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 1.20 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 0.78 |
"ICI was evaluated using inter-stimuli intervals (ISIs) of 2 ms with paired-pulse stimulation. The subthreshold stimulus was set at 80% of rMT (conditioning stimulus) , and the suprathreshold test stimulus was set at 130% of rMT. After a randomized protocol, thirty stimuli were assessed using a 2ms interval (ICI), a 12ms interval (ICF) and test-only trials (MEPs). The resulting MEP amplitude was converted into the mean amplitude, and paired-pulse parameters were expressed as the amount of inhibition or facilitation. The calculation result of ICI was done by the ratio of the mean ICI by the mean MEP.~# Below the data after intervention." (NCT01855958)
Timeframe: Evaluated in one day. The cortical excitability before and within an hour after intervention.
| Intervention | ratio of amplitude (mV). (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 0.75 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 0.57 |
"Cortical excitability was assessed using a MagPro X100 (MagVenture Company, Lucernemarken, Denmark) and a figure-of-8 coil centered over the left motor cortex (M1). Subjects were seated in a comfortable reclining chair with their arms and hands lying relaxed on the armrests. The investigators measured the resting motor threshold (rMT) of the right first dorsal interosseous (FDI) muscle. The MEPs were recorded by surface electromyography (EMG) using Ag-AgCl cup electrodes in a belly tendon montage. Resting motor threshold (rMT) was defined as the stimulus intensity at which peak-to-peak MEP amplitude of 50 µV (microvolts) was obtained in at least 5 of 10 consecutive trials.~MEP was defined as approximately 130% of the rMT or the stimulus intensity at which peak-to-peak MEP amplitude of at least 1 mV was obtained in 10 consecutive trials. The result of the MEP was the average of 10 curves (unconditioned MEP).~# Below the data after intervention." (NCT01855958)
Timeframe: Before and within one hour after intervention.
| Intervention | mV (millivolts). (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 1.14 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 1.12 |
"The intensity of pain was measured by a 10-cm VAS. VAS scores ranged from no pain (zero) to the worst possible pain possible (10 cm). The pain score on VAS during the last 24 hours was used to classify the subjects into two groups: (1) absence of pain or mild pain (scores equal to or lower than 4 cm) and (2) moderate, intense, or worst possible pain (scores higher than 4 cm).~# Below the data after intervention." (NCT01855958)
Timeframe: Evaluated within twenty four hours before and within one hour after the intervention.
| Intervention | cm ( mean). (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 0.88 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 3.36 |
"PPT (alone): The patient was instructed to verbally report the perception of pain onset. The investigator assessed PPT using an electronic algometer (J Tech Medical Industries, USA). The device had a 1-cm2 hard-rubber probe, which was applied over structures at L1- L5 dermatome at the knee and at the contralateral forearm. The average values of PPT in kgf/cm2 for three successive readings taken at intervals of 3-5 min were used as the outcomes.~# Below, the data after intervention." (NCT01855958)
Timeframe: Before and within one hour after intervention.
| Intervention | Kgf / cm2 (Mean) |
|---|---|
| DIMST, Deep Intramuscular Stimulation Therapy | 8.82 |
| Placebo-sham, Rubber Electrodes With Electrostimulation | 6.66 |
(NCT00886236)
Timeframe: 48 hours
| Intervention | % oxygen saturation (Mean) |
|---|---|
| 1 Preoperative Gabapentin Liquid | 93 |
| 2 Preoperative and Postoperative Gabapentin Liquid | 94 |
| 3 Preoperative and Postoperative Placebo Liquid | 95 |
The amount of intraoperative and postoperative opioids used will be collected and analyzed for the three different arms. (NCT00886236)
Timeframe: 120 hours
| Intervention | ml (Mean) |
|---|---|
| 1 Preoperative Gabapentin Liquid | 11.035 |
| 2 Preoperative and Postoperative Gabapentin Liquid | 8.7 |
| 3 Preoperative and Postoperative Placebo Liquid | 12.4 |
(NCT00886236)
Timeframe: 120 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Preoperative Gabapentin Liquid | 12 |
| 2 Preoperative and Postoperative Gabapentin Liquid | 11 |
| 3 Preoperative and Postoperative Placebo Liquid | 12 |
Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Mean change from baseline AEP Score at 12 months
| Intervention | Units on a scale (Mean) |
|---|---|
| VNS Therapy | -6.0 |
| Best Medical Practice | -3.2 |
The Center for Epidemiologic Studies Depression Scale (CES-D) includes 20 items comprising six scales reflecting major dimensions of depression: depressed mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, psychomotor retardation, loss of appetite, and sleep disturbance. Possible range of scores is 0 to 60, higher scores indicate more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline CES-D Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -2.2 |
| Best Medical Practice | 0.5 |
The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) is a 6-item questionnaire validated to screen for depression in people with epilepsy. Scores range from 6 to 24, with higher scores indicating more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline NDDI-E Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -1.0 |
| Best Medical Practice | -0.2 |
Change from baseline in number of AED medications by visit (NCT00522418)
Timeframe: Change from baseline in number of AEDs at 12 months
| Intervention | Number of AEDs Taken (Median) |
|---|---|
| VNS Therapy | 0 |
| Best Medical Practice | 0 |
The Clinical Global Impression scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention Scores range from 1-7: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT00522418)
Timeframe: Mean change from baseline CGI-I Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -0.8 |
| Best Medical Practice | -0.3 |
Percent change in total seizuires per week from baseline at 12 months (NCT00522418)
Timeframe: Mean percent change from baseline in seizure frequency at 12 months
| Intervention | Percent Change (Mean) |
|---|---|
| VNS Therapy | -19.1 |
| Best Medical Practice | -1.0 |
QOLIE-89 contains 17 multi-item measures of overall quality of life, emotional well-being, role limitations due to emotional problems, social support, social isolation, energy/fatigue, worry about seizure, medication effects, health discouragement, work/driving/social function, attention/concentration, language, memory, physical function, pain, role limitations due to physical problems, and health perceptions. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. (NCT00522418)
Timeframe: Mean change from baseline QOLIE-89 Overall Score at 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| VNS Therapy | 5.5 |
| Best Medical Practice | 1.2 |
Response Rate is defined as the percent of participants who are responders. A Responder is defined as participants with a reduction of at least 50% or 75% in seizure frequency from baseline to the seizure count evaluation period. (NCT00522418)
Timeframe: Number of Responders at 12 Months
| Intervention | participants (Number) |
|---|---|
| VNS Therapy | 10 |
| Best Medical Practice | 7 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| VNS Therapy | Best Medical Practice | |
| Baseline Adverse Event Profile Score < 40 | 3.3 | 0.5 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
| Intervention | Units on a Scale (Least Squares Mean) | |
|---|---|---|
| VNS Therapy | Best Medical Practice | |
| Baseline Adverse Event Profile Score >= 40 | 3.3 | 0.7 |
"The evaluation of the pain intensity was based on a 11-point Numerical Pain Rating Scale (NPRS score from 0= no pain to 10= the most intense pain imaginable). Patients recorded the NPRS score every day of treatment in their diary.~The improvement in the pain intensity is defined as a decrease in NPRS scores from baseline to the end of treatment." (NCT03720119)
Timeframe: Every day for 15 days
| Intervention | Score on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NPRS score of Day 1 | NPRS score of Day 2 | NPRS score of Day 3 | NPRS score of Day 4 | NPRS score of Day 5 | NPRS score of Day 6 | NPRS score of Day 7 | NPRS score of Day 8 | NPRS score of Day 9 | NPRS score of Day 10 | NPRS score of Day 11 | NPRS score of Day 12 | NPRS score of Day 13 | NPRS score of Day 14 | NPRS score of Day 15 | |
| Single Cohort | 6.7 | 5.4 | 5.0 | 4.7 | 4.1 | 3.9 | 3.6 | 3.6 | 3.6 | 3.4 | 3.2 | 3.2 | 3.3 | 3.0 | 2.8 |
"The evaluation of wound pain relief was based on a 5-point Visual Rating Scale (0 = none improvement; 4 = total relief).~Patients recorded the VRS score every day of treatment in their diary. The improvement in the pain relief was defined as a VRS scores at end of treatment significantly greater than 0." (NCT03720119)
Timeframe: Every day for 15 days
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 272404424 | Day 372404424 | Day 472404424 | Day 572404424 | Day 672404424 | Day 772404424 | Day 872404424 | Day 972404424 | Day 1072404424 | Day 1172404424 | Day 1272404424 | Day 1372404424 | Day 1472404424 | Day 1572404424 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| None relief | Mild | Complete relief | Moderate | A lot | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 30 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 31 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 39 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 33 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 35 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Single Cohort | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Change in worst pain as measured by the Brief Pain Inventory-Short Form. Scores range from 0 to 10 and higher scores indicate more pain. Change is calculated as the 6 weeks score minus the baseline score. (NCT02232282)
Timeframe: 0 weeks, 6 weeks
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Minimal Acupuncture | -2.08 |
| Standard Acupuncture Treatment | -2.91 |
The total number of adverse events experienced by women receiving acupuncture (NCT02232282)
Timeframe: 0 weeks, 12 weeks
| Intervention | total number of adverse events (Number) |
|---|---|
| Minimal Acupuncture | 0 |
| Standard Acupuncture Treatment | 0 |
The total number of acupuncture sessions stopped due to poor tolerability of acupuncture (NCT02232282)
Timeframe: 0 weeks, 6 weeks
| Intervention | total number of sessions (Number) |
|---|---|
| Minimal Acupuncture | 0 |
| Standard Acupuncture Treatment | 0 |
The Brazilian version of Shoulder Pain and Disability Index ranging 0 to 100 points. Lower scores indicate better functionality (NCT02695524)
Timeframe: baseline, four and eight weeks and sixteen weeks after randomization
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| baseline | 4 weeks | 8 weeks | 16 weeks | |
| Motor Control Exercises | 65.7 | 43.5 | 39.7 | 34.2 |
| Scapula-focused Exercises | 63.3 | 49.8 | 37.1 | 32.8 |
Pain Numerical Rating Scale from 0 to 10. Lower values indicate improvement in pain (NCT02695524)
Timeframe: baseline, four and eight weeks and sixteen weeks after randomization
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | 4 weeks | 8 weeks | 16 weeks | |
| Motor Control Exercises | 3.9 | 1.5 | 1.3 | 1.2 |
| Scapula-focused Exercises | 3.7 | 2.7 | 1.8 | 0.5 |
Tampa Scale of Kinesiophobia ranging 17 to 68 points. High scores indicate high degree kinesiophobia (NCT02695524)
Timeframe: baseline, four and eight weeks and sixteen weeks after randomization
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Kinesiophobia baseline | Kinesiophobia 4 weeks | Kinesiophobia 8 weeks | Kinesiophobia 16 weeks | |
| Motor Control Exercises | 42.8 | 40.7 | 38.9 | 37.5 |
| Scapula-focused Exercises | 42.1 | 39.8 | 40.2 | 38.7 |
Strength of serratus anterior, trapezius muscles, abduction, adduction, internal and external rotation movements the arm with hand held Dynamometer. (NCT02695524)
Timeframe: baseline, four and eight weeks and sixteen weeks after randomization
| Intervention | Kilogram-force (Mean) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shoulder abduction baseline | Shoulder abduction 4 weeks | Shoulder abduction 8 weeks | Shoulder abduction 16 weeks | Shoulder adduction baseline | Shoulder adduction 4 weeks | Shoulder adduction 8 weeks | Shoulder adduction 16 weeks | Shoulder external rotation baseline | Shoulder external rotation 4 weeks | Shoulder external rotation 8 weeks | Shoulder external rotation 16 weeks | Shoulder Internal rotation baseline | Shoulder Internal rotation 4 weeks | Shoulder Internal rotation 8 weeks | Shoulder Internal rotation 16 weeks | Serratus Anterior Baseline | Serratus Anterior 4 weeks | Serratus Anterior 8 weeks | Serratus Anterior 16 weeks | Upper Trapezius Baseline | Upper Trapezius 4 weeks | Upper Trapezius 8 weeks | Upper Trapezius 16 weeks | Middle Trapezius Baseline | Middle Trapezius 4 weeks | Middle Trapezius 8 weeks | Middle Trapezius 16 weeks | Lower Trapezius baseline | Lower Trapezius 4 weeks | Lower Trapezius 8 weeks | Lower Trapezius 16 weeks | |
| Motor Control Exercises | 5.5 | 6.3 | 7.1 | 7 | 7.9 | 9 | 9.2 | 9 | 5.7 | 6.1 | 6.5 | 6.4 | 9.4 | 10.4 | 11.4 | 10.7 | 6.8 | 10 | 10.8 | 10.6 | 8.8 | 11.1 | 12.1 | 11.4 | 3.3 | 4.1 | 4.4 | 4.6 | 3.1 | 4 | 4 | 4.1 |
| Scapula-focused Exercises | 6.2 | 7.1 | 7.9 | 7.8 | 7.8 | 8.8 | 9.2 | 8.5 | 5.8 | 5.9 | 6.5 | 6.9 | 8.6 | 9.1 | 10.4 | 10.3 | 7.2 | 9.1 | 10.3 | 11.1 | 8.3 | 9.8 | 11.1 | 11 | 4.4 | 4.9 | 5.1 | 5.4 | 4.3 | 4.6 | 5 | 5 |
Global Perceived Effect Scale ranging -5 to +5 points. Positive values indicate improvement and negative values indicate worsening of symptoms (NCT02695524)
Timeframe: four, eight weeks and sixteen weeks of randomization
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| 4 weeks | 8 weeks | 16 weeks | |
| Motor Control Exercises | 2.8 | 3.3 | 3.1 |
| Scapula-focused Exercises | 2 | 2.9 | 3.3 |
abduction, adduction, internal and external rotation of the shoulder (NCT02695524)
Timeframe: baseline, four and eight weeks and sixteen weeks after randomization
| Intervention | degrees (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shoulder Flexion Baseline | Shoulder Flexion 4 weeks | Shoulder Flexion 8 weeks | Shoulder Flexion 16 weeks | Shoulder Abduction Baseline | Shoulder Abduction 4 weeks | Shoulder Abduction 8 weeks | Shoulder Abduction 16 weeks | Shoulder External Rotation Baseline | Shoulder External Rotation 4 weeks | Shoulder External Rotation 8 weeks | Shoulder External Rotation 16 weeks | Shoulder Internal Rotation Baseline | Shoulder Internal Rotation 4 weeks | Shoulder Internal Rotation 8 weeks | Shoulder Internal Rotation 16 weeks | |
| Motor Control Exercises | 129 | 148.5 | 147.8 | 149.9 | 120.2 | 145.2 | 145.5 | 141.3 | 60.9 | 66.7 | 68.3 | 70 | 48.6 | 53.4 | 54.6 | 54.8 |
| Scapula-focused Exercises | 132.5 | 140.4 | 148 | 146.6 | 125.3 | 139 | 147.8 | 143.2 | 60.1 | 66.4 | 73.7 | 71.4 | 49.2 | 53.9 | 59.2 | 57.1 |
Medrisk Questionnaire ranging 13 to 80 points. High scores indicate satisfaction with treatment (NCT02695524)
Timeframe: four, eight weeks and sixteen weeks after randomization
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Medrisk 4 weeks | Medrisk 8 weeks | Medrisk 16 weeks | |
| Motor Control Exercises | 63.1 | 63.6 | 63.8 |
| Scapula-focused Exercises | 60.8 | 61.3 | 62 |
upward rotation and tilt of the scapula (NCT02695524)
Timeframe: baseline, four and eight weeks and sixteen weeks after randomization
| Intervention | degrees (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upward Rotation 0º Baseline | Upward Rotation 0º 4 weeks | Upward Rotation 0º 8 weeks | Upward Rotation 0º 16 weeks | Upward Rotation 90º baseline | Upward Rotation 90º 4 weeks | Upward Rotation 90º 8 weeks | Upward Rotation 90º 16 weeks | Upward Rotation 180º baseline | Upward Rotation 180º 4 weeks | Upward Rotation 180º 8 weeks | Upward Rotation 180º 16 weeks | Anterior Tilt 0º baseline | Anterior Tilt 0º 4 weeks | Anterior Tilt 0º 8 weeks | Anterior Tilt 0º 16 weeks | Anterior Tilt 90º baseline | Anterior Tilt 90º 4 weeks | Anterior Tilt 90º 8 weeks | Anterior Tilt 90º 16 weeks | Anterior Tilt 180º baseline | Anterior Tilt 180º 4 weeks | Anterior Tilt 180º 8 weeks | Anterior Tilt 180º 16 weeks | |
| Motor Control Exercises | 7 | 5.7 | 5.7 | 6.5 | 13.6 | 14.5 | 17.6 | 20.6 | 35.5 | 39.3 | 44.3 | 44.5 | 19 | 19 | 19.4 | 19.6 | 14.2 | 13.6 | 12.3 | 11.7 | 4.2 | 3.2 | 0.1 | 0.7 |
| Scapula-focused Exercises | 5.6 | 5.3 | 5 | 5.1 | 12.8 | 13.3 | 15 | 16.8 | 30.7 | 37.3 | 40.9 | 39.7 | 18.4 | 18.4 | 19.7 | 18.7 | 15 | 14.6 | 15.1 | 13.2 | 4.3 | 2 | 3.1 | 0.6 |
64 reviews available for gamma-aminobutyric acid and Chronic Disease
| Article | Year |
|---|---|
Mechanisms and mode of action of spinal cord stimulation in chronic neuropathic pain.
Topics: Chronic Disease; gamma-Aminobutyric Acid; Ganglia, Spinal; Humans; Neuralgia; Serotonin; Spinal Cord | 2020 |
The Role of HPA Axis and Allopregnanolone on the Neurobiology of Major Depressive Disorders and PTSD.
Topics: Adaptation, Physiological; Animals; Antidepressive Agents; Chronic Disease; Corticosterone; Depressi | 2021 |
Gabapentin for chronic neuropathic pain in adults.
Topics: Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; Diabetic Neur | 2017 |
Chronic Hiccups: An Underestimated Problem.
Topics: Amines; Anesthesiology; Baclofen; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Am | 2017 |
End-Stage Renal Disease Chronic Itch and Its Management.
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Antipruritics; Chronic Disease; Cyclohexanecarboxylic A | 2018 |
Clinical practice. Chronic pruritus.
Topics: Amines; Antidepressive Agents, Tricyclic; Behavior Therapy; Chronic Disease; Cyclohexanecarboxylic A | 2013 |
Prurigo nodularis: an update on etiopathogenesis and therapy.
Topics: Amines; Chronic Disease; Cyclohexanecarboxylic Acids; Dermatologic Agents; Epidermis; Female; Gabape | 2013 |
Gabapentin for chronic neuropathic pain and fibromyalgia in adults.
Topics: Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; Fibromyalgia; | 2014 |
A systematic review of pharmacoeconomic studies for pregabalin.
Topics: Amines; Analgesics; Anticonvulsants; Chronic Disease; Cost-Benefit Analysis; Cyclohexanecarboxylic A | 2015 |
A review on the efficacy and safety of gabapentin in the treatment of chronic cough.
Topics: Amines; Antitussive Agents; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2015 |
Gabapentin in chronic cough.
Topics: Amines; Animals; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagoni | 2015 |
Ammonia and Its Role in the Pathogenesis of Hepatic Encephalopathy.
Topics: Ammonia; Animals; Astrocytes; Blood-Brain Barrier; Chronic Disease; gamma-Aminobutyric Acid; Glutami | 2015 |
Management of chronic refractory cough.
Topics: Adaptation, Psychological; Amines; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; | 2015 |
Gabapentin and pregabalin for the treatment of chronic pruritus.
Topics: Amines; Anti-Anxiety Agents; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma | 2016 |
Are neuromodulating medications effective for the treatment of chronic neurogenic cough?
Topics: Amines; Amitriptyline; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminob | 2017 |
Practical management strategies for the chronic pain patient.
Topics: Administration, Cutaneous; Amines; Analgesics; Antidepressive Agents, Tricyclic; Carbamazepine; Chro | 2007 |
The complex nature of chronic pelvic pain.
Topics: Adult; Amines; Anti-Anxiety Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, | 2007 |
[Mechanisms of the development of neuropathic pain and its treatment].
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Calcium Channel Block | 2008 |
[Central and peripheral mechanisms in antinociception: current and future perspectives].
Topics: Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Bridged Bicyclo Compounds, Heterocycl | 2008 |
A human trial of HSV-mediated gene transfer for the treatment of chronic pain.
Topics: Animals; Chronic Disease; Clinical Trials, Phase I as Topic; Enkephalins; gamma-Aminobutyric Acid; G | 2009 |
Pregabalin in the treatment of chronic pain: an overview.
Topics: Amines; Analgesics, Non-Narcotic; Animals; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic | 2009 |
[GABA(B) receptors and sensitization to pain].
Topics: 14-3-3 Proteins; Allosteric Regulation; Animals; Baclofen; Calcium Channels; Calcium-Binding Protein | 2009 |
Pregabalin for acute and chronic pain in adults.
Topics: Acute Disease; Adult; Analgesics; Chronic Disease; Diabetic Neuropathies; Fibromyalgia; gamma-Aminob | 2009 |
Pregabalin for acute and chronic pain in adults.
Topics: Acute Disease; Adult; Analgesics; Chronic Disease; Diabetic Neuropathies; Fibromyalgia; gamma-Aminob | 2009 |
Pregabalin for acute and chronic pain in adults.
Topics: Acute Disease; Adult; Analgesics; Chronic Disease; Diabetic Neuropathies; Fibromyalgia; gamma-Aminob | 2009 |
Pregabalin for acute and chronic pain in adults.
Topics: Acute Disease; Adult; Analgesics; Chronic Disease; Diabetic Neuropathies; Fibromyalgia; gamma-Aminob | 2009 |
[Role of extracellular nucleotides and their receptors in chronic pain].
Topics: Adenosine Triphosphate; Animals; Brain-Derived Neurotrophic Factor; Chronic Disease; Drug Design; ga | 2009 |
WITHDRAWN. Anticonvulsant drugs for acute and chronic pain.
Topics: Acute Disease; Amines; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topic; Cycloh | 2010 |
New treatments for chronic prostatitis/chronic pelvic pain syndrome.
Topics: Amines; Chronic Disease; Cognitive Behavioral Therapy; Cyclohexanecarboxylic Acids; Gabapentin; gamm | 2010 |
Evidence for sensory neuropathy and pharmacologic management.
Topics: Adrenergic Uptake Inhibitors; Amines; Amitriptyline; Anticonvulsants; Chronic Disease; Cough; Cycloh | 2010 |
Gabapentin for the treatment of cancer-related pain syndromes.
Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2010 |
An algorithm for the treatment of chronic testicular pain.
Topics: Algorithms; Amines; Analgesics; Anesthetics; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive | 2010 |
Pregabalin for the treatment of postsurgical pain.
Topics: Acute Disease; Analgesics; Analgesics, Opioid; Chronic Disease; Dose-Response Relationship, Drug; ga | 2010 |
WITHDRAWN: Gabapentin for acute and chronic pain.
Topics: Acute Disease; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; ga | 2011 |
Gabapentin for chronic neuropathic pain and fibromyalgia in adults.
Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Fibromyalgia; Gabapentin; gamma-Am | 2011 |
[Molecular mechanisms and clinical pharmacology of chronic pain].
Topics: Amines; Animals; Anterior Horn Cells; Antidepressive Agents; Brain; Chronic Disease; Cyclohexanecarb | 2010 |
Anticonvulsants for tinnitus.
Topics: Administration, Oral; Amines; Anticonvulsants; Carbamazepine; Chronic Disease; Cyclohexanecarboxylic | 2011 |
Pregabalin for chronic prostatitis.
Topics: Analgesics; Chronic Disease; gamma-Aminobutyric Acid; Humans; Male; Pelvic Pain; Pregabalin; Prostat | 2012 |
Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
Topics: Age Factors; Aged; Amitriptyline; Analgesics; Cardiovascular Diseases; Celecoxib; Chronic Disease; C | 2013 |
Use of specific neuromodulators in the treatment of chronic, idiopathic cough: a systematic review.
Topics: Amines; Amitriptyline; Baclofen; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; ga | 2013 |
Germinated brown rice and its role in human health.
Topics: Amino Acids, Essential; Antihypertensive Agents; Chronic Disease; Coumaric Acids; Dietary Fiber; Foo | 2013 |
Mode of action of gabapentin in chronic neuropathic pain syndromes. A short review about its cellular mechanisms in nociceptive neurotransmission.
Topics: Acetates; Amines; Animals; Biogenic Monoamines; Calcium Channels; Chronic Disease; Cyclohexanecarbox | 2002 |
Antiepileptic drugs in the treatment of chronic headaches.
Topics: Anticonvulsants; Chronic Disease; gamma-Aminobutyric Acid; Headache; Humans; Meta-Analysis as Topic | 2003 |
Neurobiological correlates of the disposition and maintenance of alcoholism.
Topics: Acute Disease; Alcoholism; Brain; Chronic Disease; Dopamine; Drug Tolerance; Ethanol; gamma-Aminobut | 2003 |
[Nonorganic pain -- only psychogenic?].
Topics: Acetates; Adult; Amines; Analgesics; Analgesics, Opioid; Anesthetics, Local; Back Pain; Chronic Dise | 2003 |
Diagnosis and management of neuropathic pain: a balanced approach to treatment.
Topics: Acetates; Amines; Antidepressive Agents; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; g | 2003 |
Reversal or reduction of glutamate and GABA transport in CNS pathology and therapy.
Topics: Acute Disease; Animals; Central Nervous System Diseases; Chronic Disease; gamma-Aminobutyric Acid; G | 2004 |
Rethinking the treatment paradigm for bipolar depression: the importance of long-term management.
Topics: Amines; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Ch | 2004 |
Effects of chronic stress on structure and cell function in rat hippocampus and hypothalamus.
Topics: Animals; Chronic Disease; Dentate Gyrus; gamma-Aminobutyric Acid; Glutamates; Hippocampus; Hypothala | 2004 |
Anticonvulsant drugs for acute and chronic pain.
Topics: Acute Disease; Amines; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topic; Cycloh | 2005 |
Gabapentin for acute and chronic pain.
Topics: Acute Disease; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Ga | 2005 |
[Brain of patients with chronic schizophrenia and neurotransmitters].
Topics: Animals; Brain Chemistry; Chromatography, High Pressure Liquid; Chronic Disease; gamma-Aminobutyric | 2005 |
Bilateral SUNCT syndrome associated to chronic maxillary sinus disease.
Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2006 |
Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment.
Topics: Amines; Analgesics; Antidepressive Agents, Tricyclic; Chronic Disease; Cyclohexanecarboxylic Acids; | 2006 |
Adjuvant analgesics for the treatment of neuropathic pain: evaluating efficacy and safety profiles.
Topics: Administration, Cutaneous; Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents; Arthritis; | 2007 |
Update on pharmacotherapy guidelines for treatment of neuropathic pain.
Topics: Analgesics; Animals; Cannabidiol; Chronic Disease; Dronabinol; Duloxetine Hydrochloride; gamma-Amino | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
Gabapentin: a multimodal perioperative drug?
Topics: Amines; Analgesics, Non-Narcotic; Anti-Anxiety Agents; Blood Pressure; Chronic Disease; Cyclohexanec | 2007 |
[Alpha2-adrenergic receptors in the dorsal horn of the spinal cord--their function and the descending inhibitory systems].
Topics: Acetylcholine; Adrenergic alpha-2 Receptor Agonists; Amines; Analgesics; Animals; Brain-Derived Neur | 2007 |
Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature.
Topics: Aged; Amines; Anti-Anxiety Agents; Anticonvulsants; Cerebral Infarction; Chlorpromazine; Chronic Dis | 2007 |
Loss of glycinergic and GABAergic inhibition in chronic pain--contributions of inflammation and microglia.
Topics: Animals; Chronic Disease; Dinoprostone; gamma-Aminobutyric Acid; Glycine; Humans; Inflammation; Micr | 2008 |
Pain management in the traumatic amputee.
Topics: Acute Disease; Afghanistan; Amines; Amputation, Traumatic; Analgesia; Analgesics; Benchmarking; Caus | 2008 |
[Psychopharmacotherapy in psychiatric comorbidities among patients with chronic pain].
Topics: Amines; Analgesics; Anticonvulsants; Bupropion; Chronic Disease; Cyclohexanecarboxylic Acids; Dopami | 2007 |
Treatment of chronic pain with antiepileptic drugs: a new era.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapen | 1999 |
[Modification of morphine dependence under chronic pain and its mechanism].
Topics: Animals; Brain; Chronic Disease; gamma-Aminobutyric Acid; Male; Morphine Dependence; Pain; Rats; Rat | 2001 |
Anticonvulsants: aspects of their mechanisms of action.
Topics: Animals; Anticonvulsants; Central Nervous System; Chronic Disease; Epilepsy; gamma-Aminobutyric Acid | 2002 |
Pathophysiology of chronic hepatic encephalopathy.
Topics: Amines; Amino Acids; Ammonia; Animals; Blood-Brain Barrier; Chronic Disease; Dogs; gamma-Aminobutyri | 1985 |
Baclofen: a preliminary report of its pharmacological properties and therapeutic efficacy in spasticity.
Topics: Adolescent; Adult; Aminobutyrates; Animals; Chlorobenzenes; Chronic Disease; Clinical Trials as Topi | 1974 |
39 trials available for gamma-aminobutyric acid and Chronic Disease
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Acute Kidney Injury; Adult; Aged; Albumins; Alloys; Amides; Amino Acids; Animals; Antineoplastic Com | 2023 |
GaPP2, a multicentre randomised controlled trial of the efficacy of gabapentin for the management of chronic pelvic pain in women: study protocol.
Topics: Adolescent; Adult; Amines; Analgesics; Chronic Disease; Chronic Pain; Cyclohexanecarboxylic Acids; D | 2018 |
An open labeled randomized controlled trial of pregabalin versus amitriptyline in chronic low backache.
Topics: Adolescent; Adult; Aged; Amitriptyline; Analgesics, Non-Narcotic; Chronic Disease; Disability Evalua | 2014 |
Gabapentin Superadded to a Pre-Existent Regime Containing Amytriptyline for Chronic Sciatica.
Topics: Adult; Aged; Aged, 80 and over; Amines; Amitriptyline; Analgesics; Chronic Disease; Cohort Studies; | 2016 |
The effects of gabapentin on acute and chronic pain after inguinal herniorrhaphy.
Topics: Adult; Amines; Analgesics; Anesthesia, Spinal; Chronic Disease; Cyclohexanecarboxylic Acids; Double- | 2009 |
Adequacy assessment of oxycodone/paracetamol (acetaminophen) in multimodal chronic pain : a prospective observational study.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; | 2009 |
Adding gabapentin to a multimodal regimen does not reduce acute pain, opioid consumption or chronic pain after total hip arthroplasty.
Topics: Acute Disease; Aged; Amines; Analgesics; Analgesics, Opioid; Anesthesia, Spinal; Arthroplasty, Repla | 2009 |
Adding gabapentin to a multimodal regimen does not reduce acute pain, opioid consumption or chronic pain after total hip arthroplasty.
Topics: Acute Disease; Aged; Amines; Analgesics; Analgesics, Opioid; Anesthesia, Spinal; Arthroplasty, Repla | 2009 |
Adding gabapentin to a multimodal regimen does not reduce acute pain, opioid consumption or chronic pain after total hip arthroplasty.
Topics: Acute Disease; Aged; Amines; Analgesics; Analgesics, Opioid; Anesthesia, Spinal; Arthroplasty, Repla | 2009 |
Adding gabapentin to a multimodal regimen does not reduce acute pain, opioid consumption or chronic pain after total hip arthroplasty.
Topics: Acute Disease; Aged; Amines; Analgesics; Analgesics, Opioid; Anesthesia, Spinal; Arthroplasty, Repla | 2009 |
A comparison of gabapentin and ketamine in acute and chronic pain after hysterectomy.
Topics: Acute Disease; Administration, Oral; Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analg | 2009 |
A comparison of gabapentin and ketamine in acute and chronic pain after hysterectomy.
Topics: Acute Disease; Administration, Oral; Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analg | 2009 |
A comparison of gabapentin and ketamine in acute and chronic pain after hysterectomy.
Topics: Acute Disease; Administration, Oral; Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analg | 2009 |
A comparison of gabapentin and ketamine in acute and chronic pain after hysterectomy.
Topics: Acute Disease; Administration, Oral; Adult; Amines; Analgesia, Patient-Controlled; Analgesics; Analg | 2009 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial.
Topics: Aged; Analgesics; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Chronic Disease; Double-Bli | 2010 |
Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain.
Topics: Adult; Aged; Analgesics; Celecoxib; Chronic Disease; Cyclooxygenase 2 Inhibitors; Drug Therapy, Comb | 2009 |
Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality.
Topics: Administration, Oral; Adult; Amines; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; | 2009 |
Pregabalin as mono- or add-on therapy for patients with refractory chronic neuropathic pain: a post-marketing prescription-event monitoring study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Chronic Disease; Cohort Studies; Drug Prescriptions; Dru | 2010 |
Evaluation of efficacy of the perioperative administration of Venlafaxine or gabapentin on acute and chronic postmastectomy pain.
Topics: Acute Disease; Adult; Amines; Analgesics; Breast Neoplasms; Chronic Disease; Cyclohexanecarboxylic A | 2010 |
Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial.
Topics: Adult; Aged; Analgesics; Canada; Chronic Disease; Double-Blind Method; gamma-Aminobutyric Acid; Hosp | 2010 |
The effects of gabapentin on acute and chronic postoperative pain after coronary artery bypass graft surgery.
Topics: Acute Disease; Aged; Amines; Analgesics; Analgesics, Opioid; Chronic Disease; Chronic Pain; Coronary | 2011 |
Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures.
Topics: Adult; Aged; Algorithms; Analgesics; Anticonvulsants; Chronic Disease; Databases, Factual; Dose-Resp | 2011 |
Use of pregabalin in the management of chronic uremic pruritus.
Topics: Aged; Analgesics; Anticonvulsants; Chronic Disease; Female; gamma-Aminobutyric Acid; Humans; Male; P | 2013 |
Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Amines; Anticonvulsants; Central Nervous System; Chronic Disease; Cough; Cyclohex | 2012 |
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr | 2002 |
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr | 2002 |
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr | 2002 |
The analgesic effect of gabapentin and mexiletine after breast surgery for cancer.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Breast Neoplasms; Chr | 2002 |
Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Analgesics; Anticonvulsants; Ataxia; Chronic Disease; Cro | 2003 |
Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain.
Topics: Acetates; Activities of Daily Living; Aged; Aged, 80 and over; Amines; Analgesics; Anesthetics, Loca | 2003 |
Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage lyme borreliosis: a pilot study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amines; Chronic Disease; Cyclohexanecarboxylic Acids; | 2005 |
Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer.
Topics: Acute Disease; Adult; Amines; Analgesia; Anesthetics, Local; Breast Neoplasms; Chronic Disease; Cycl | 2005 |
Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study.
Topics: Adult; Amines; Amitriptyline; Austria; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Combinatio | 2005 |
Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial.
Topics: Adolescent; Adult; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids | 2007 |
Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial.
Topics: Adolescent; Adult; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids | 2007 |
Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial.
Topics: Adolescent; Adult; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids | 2007 |
Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial.
Topics: Adolescent; Adult; Amines; Analgesics; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids | 2007 |
Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Amines; Analgesics; Cholestasis; Chronic Disease; Cyclohexanecarboxylic Acids; Double-Blind M | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Motor cortex rTMS restores defective intracortical inhibition in chronic neuropathic pain.
Topics: Adult; Aged; Analgesia; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; ga | 2006 |
Effectiveness of gabapentin in the treatment of chronic post-thoracotomy pain.
Topics: Adult; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-A | 2007 |
Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy.
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Creatine; Female; Follow-Up Studies; Front | 1996 |
Clinical evaluation of the efficacy of pivagabine in the treatment of mood and adjustment disorders.
Topics: Adjustment Disorders; Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Double-Blind Meth | 1997 |
An audit of the perceived efficacy and tolerability of gabapentin therapy in an out-patient cohort with chronic epilepsy.
Topics: Acetates; Adult; Ambulatory Care; Amines; Anticonvulsants; Chronic Disease; Cohort Studies; Cyclohex | 1999 |
Treatment of chronic: new perspectives.
Topics: Acetates; Aged; Amines; Cerebral Infarction; Chronic Disease; Cyclohexanecarboxylic Acids; Excitator | 1999 |
Low doses of gabapentin may be helpful in the management of chronic daily headache.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic | 2000 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topi | 2001 |
Baclofen is effective in intractable hiccups induced by brainstem lesions.
Topics: Adult; Aged; Baclofen; Brain Stem; Brain Stem Infarctions; Chronic Disease; GABA Agonists; gamma-Ami | 2001 |
GABA agonist-induced changes in motor, oculomotor, and attention measures correlate in schizophrenics with tardive dyskinesia.
Topics: Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Dyskinesia, Drug-Induc | 1992 |
Baclofen-induced growth hormone secretion is blunted in chronic schizophrenics: neuroendocrine evidence for a GABA disturbance in schizophrenia.
Topics: Adult; Aged; Baclofen; Brain; Chronic Disease; gamma-Aminobutyric Acid; Growth Hormone; Humans; Male | 1988 |
Growth hormone response to sodium valproate in chronic schizophrenia.
Topics: Adult; Brain; Chronic Disease; Double-Blind Method; gamma-Aminobutyric Acid; Growth Hormone; Humans; | 1986 |
Baclofen: a preliminary report of its pharmacological properties and therapeutic efficacy in spasticity.
Topics: Adolescent; Adult; Aminobutyrates; Animals; Chlorobenzenes; Chronic Disease; Clinical Trials as Topi | 1974 |
192 other studies available for gamma-aminobutyric acid and Chronic Disease
| Article | Year |
|---|---|
Saturation transfer MRI is sensitive to neurochemical changes in the rat brain due to chronic unpredictable mild stress.
Topics: 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; Animals; Cerebral Cortex; Chronic Disease | 2021 |
Electroacupuncture alleviates the relapse of pain-related aversive memory by activating KOR and inhibiting GABAergic neurons in the insular cortex.
Topics: Animals; Carrageenan; Chronic Disease; Chronic Pain; Electroacupuncture; GABAergic Neurons; gamma-Am | 2023 |
The molecular mechanism underlying GABAergic dysfunction in nucleus accumbens of depression-like behaviours in mice.
Topics: Animals; Behavior, Animal; Chronic Disease; Depressive Disorder; GABAergic Neurons; gamma-Aminobutyr | 2019 |
Moderate maternal separation mitigates the altered synaptic transmission and neuronal activation in amygdala by chronic stress in adult mice.
Topics: Aging; Amygdala; Animals; Anxiety; Behavior, Animal; Chronic Disease; Excitatory Postsynaptic Potent | 2019 |
Anxiolytic Effects of 8-O-Acetyl Shanzhiside Methylester on Acute and Chronic Anxiety via Inflammatory Response Inhibition and Excitatory/Inhibitory Transmission Imbalance.
Topics: Acute Disease; Animals; Anti-Anxiety Agents; Anxiety; Chronic Disease; Dose-Response Relationship, D | 2020 |
Dysregulation of REV-ERBα impairs GABAergic function and promotes epileptic seizures in preclinical models.
Topics: Acute Disease; Animals; Basic-Leucine Zipper Transcription Factors; Chronic Disease; Disease Models, | 2021 |
Topical ketamine-amitriptyline-lidocaine for chronic pruritus: A retrospective study assessing efficacy and tolerability.
Topics: Aged; Amines; Amitriptyline; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Therapy, | 2017 |
Alpha7 nicotinic acetylcholine receptor agonist promotes retinal ganglion cell function via modulating GABAergic presynaptic activity in a chronic glaucomatous model.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzamides; Bridged Bicyclo Compounds; Cell Surviv | 2017 |
JIEYUANSHEN DECOCTION EXERTS ANTIDEPRESSANT EFFECTS ON DEPRESSIVE RAT MODEL VIA REGULATING HPA AXIS AND THE LEVEL OF AMINO ACIDS NEUROTRANSMITTER.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Chronic Disease; Corticosterone; Cortic | 2017 |
Haloperidol Decreases Hyperalgesia and Allodynia Induced by Chronic Constriction Injury.
Topics: Amines; Analgesics; Animals; Antipsychotic Agents; Chronic Disease; Constriction, Pathologic; Cycloh | 2017 |
Unilateral Laryngoscopic Findings Associated With Response to Gabapentin in Patients With Chronic Cough.
Topics: Amines; Calcium Channel Blockers; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Female; Gabap | 2017 |
International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.
Topics: Aged; Aged, 80 and over; Amines; Antipruritics; Chronic Disease; Cyclohexanecarboxylic Acids; Female | 2017 |
International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.
Topics: Aged; Aged, 80 and over; Amines; Antipruritics; Chronic Disease; Cyclohexanecarboxylic Acids; Female | 2017 |
International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.
Topics: Aged; Aged, 80 and over; Amines; Antipruritics; Chronic Disease; Cyclohexanecarboxylic Acids; Female | 2017 |
International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.
Topics: Aged; Aged, 80 and over; Amines; Antipruritics; Chronic Disease; Cyclohexanecarboxylic Acids; Female | 2017 |
Modification of the natural progression of epileptogenesis by means of biperiden in the pilocarpine model of epilepsy.
Topics: Action Potentials; Animals; Autonomic Nervous System; Biperiden; Chronic Disease; Cytokines; Disease | 2017 |
The sinonasal microbiota, neural signaling, and depression in chronic rhinosinusitis.
Topics: Adult; Aged; Bacteria; Bacterial Load; Chronic Disease; Depression; DNA, Bacterial; Dopamine; Female | 2018 |
Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.
Topics: Amines; Analgesics; Autoantibodies; Biomarkers; Chronic Disease; Cyclohexanecarboxylic Acids; Female | 2018 |
The Influence of Primary Motor Cortex Inhibition on Upper Limb Impairment and Function in Chronic Stroke: A Multimodal Study.
Topics: Aged; Aged, 80 and over; Chronic Disease; Electromyography; Evoked Potentials, Motor; Female; gamma- | 2019 |
Targeted hippocampal GABA neuron ablation by Stable Substance P-saporin causes hippocampal sclerosis and chronic epilepsy in rats.
Topics: Animals; Chronic Disease; Dentate Gyrus; Epilepsy, Temporal Lobe; GABAergic Neurons; gamma-Aminobuty | 2019 |
Persistent
Topics: Animals; Brain; Chemokine CX3CL1; Chronic Disease; Complement Activation; Disease Models, Animal; Fe | 2019 |
[Survival of calbindin, calretinin and parvalbumin positive neurons in mouse hippocampal CA area at chronic stage of pilocarpine-induced epilepsy].
Topics: Animals; Calbindin 2; Calbindins; Cell Survival; Chronic Disease; Epilepsy; gamma-Aminobutyric Acid; | 2013 |
Nanoscale intracortical iron injection induces chronic epilepsy in rodent.
Topics: Animals; Anticonvulsants; Cell Count; Cerebral Cortex; Cerebrovascular Circulation; Chronic Disease; | 2014 |
Downregulated GABA and BDNF-TrkB pathway in chronic cyclothiazide seizure model.
Topics: 4-Aminobutyrate Transaminase; Animals; Behavior, Animal; Benzothiadiazines; Brain-Derived Neurotroph | 2014 |
Chronic stress impairs GABAergic control of amygdala through suppressing the tonic GABAA receptor currents.
Topics: Action Potentials; Amygdala; Animals; Chronic Disease; Corticosterone; gamma-Aminobutyric Acid; Immo | 2014 |
Chronic repetitive transcranial magnetic stimulation enhances GABAergic and cholinergic metabolism in chronic unpredictable mild stress rat model: ¹H-NMR spectroscopy study at 11.7T.
Topics: Animals; Choline; Chronic Disease; Depression; Food Preferences; gamma-Aminobutyric Acid; Hippocampu | 2014 |
Gabapentin as a potential treatment for cough syncope.
Topics: Amines; Antitussive Agents; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2015 |
Altered levels of brain neurotransmitter from new born rabbits with intrauterine restriction.
Topics: Animals; Animals, Newborn; Brain; Cerebral Cortex; Chronic Disease; Corpus Striatum; Dopamine; Fetal | 2015 |
The role of calcitonin gene-related peptide in post-stroke depression in chronic mild stress-treated ischemic rats.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain Ischemia; Calcitonin Gene-Related Peptide; Chronic | 2015 |
Chronic stress shifts the GABA reversal potential in the hippocampus and increases seizure susceptibility.
Topics: Acute Disease; Animals; Bumetanide; Chronic Disease; Corticosterone; Disease Models, Animal; gamma-A | 2015 |
Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus.
Topics: Acute Disease; Amino Acids; Animals; Anticonvulsants; Aspartic Acid; Bridged Bicyclo Compounds, Hete | 2014 |
[Cognitive and emotional impairments in patients with protracted anxiety-phobic disorders].
Topics: Acute Disease; Adolescent; Adult; Chronic Disease; Cognition Disorders; gamma-Aminobutyric Acid; Hum | 2014 |
Chronic progressive polyarthritis in a domestic shorthair cat.
Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Buprenorphine; Cat Diseases; Cats; | 2015 |
Increased extracellular levels of glutamate in the hippocampus of chronically epileptic rats.
Topics: Animals; Chromatography, High Pressure Liquid; Chronic Disease; Disease Models, Animal; Electroencep | 2015 |
Pharmacological characteristics of the hind paw weight bearing difference induced by chronic constriction injury of the sciatic nerve in rats.
Topics: Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Disease Models, Animal; G | 2009 |
BMSCs transplantation improves cognitive impairment via up-regulation of hippocampal GABAergic system in a rat model of chronic cerebral hypoperfusion.
Topics: Animals; Bone Marrow Transplantation; Brain Ischemia; Carotid Artery Diseases; Cell Movement; Chroni | 2015 |
[On the Differential Diagnosis of Intractable Psychogenic Chronic Cough: Neuropathic Larynx Irritable - Gabapentin's Antitussive Action].
Topics: Aged; Amines; Avitaminosis; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; Depressive Disorder | 2015 |
IV and V cranial nerves dysfunction as initial manifestations of superficial siderosis of the central nervous system.
Topics: Aged; Amines; Angiography, Digital Subtraction; Atrophy; Central Nervous System Diseases; Cerebellum | 2016 |
Reduced tonic inhibition in the dentate gyrus contributes to chronic stress-induced impairments in learning and memory.
Topics: Animals; Chronic Disease; Dentate Gyrus; Female; gamma-Aminobutyric Acid; Learning; Learning Disabil | 2016 |
Chronic Stress Increases Prefrontal Inhibition: A Mechanism for Stress-Induced Prefrontal Dysfunction.
Topics: Animals; Behavior, Animal; Chronic Disease; Disease Models, Animal; gamma-Aminobutyric Acid; Glutami | 2016 |
Brain glutamic acid decarboxylase-67kDa alterations induced by magnesium treatment in olfactory bulbectomy and chronic mild stress models in rats.
Topics: Animals; Antidepressive Agents; Brain; Chronic Disease; Depression; Disease Models, Animal; gamma-Am | 2016 |
Sensitivity of the prefrontal GABAergic system to chronic stress in male and female mice: Relevance for sex differences in stress-related disorders.
Topics: Amygdala; Animals; Anxiety; Chronic Disease; Depression; Disease Models, Animal; Female; gamma-Amino | 2016 |
Multilevel symmetric neuropathic pruritus (MSNP) presenting as recalcitrant "generalized" pruritus.
Topics: Age Distribution; Aged; Amines; Chronic Disease; Cohort Studies; Cyclohexanecarboxylic Acids; Diseas | 2016 |
Gabapentin decreases microglial cells and reverses bilateral hyperalgesia and allodynia in rats with chronic myositis.
Topics: Amines; Animals; Astrocytes; Behavior, Animal; Cell Count; Chronic Disease; Cyclohexanecarboxylic Ac | 2017 |
Repeated neonatal separation stress alters the composition of neurochemically characterized interneuron subpopulations in the rodent dentate gyrus and basolateral amygdala.
Topics: Amygdala; Animals; Animals, Newborn; Brain; Calbindins; Chronic Disease; Dentate Gyrus; gamma-Aminob | 2008 |
Decompensation of chronic heart failure associated with pregabalin in a 73-year-old patient with postherpetic neuralgia: a case report.
Topics: Aged; Anticonvulsants; Bumetanide; Chronic Disease; gamma-Aminobutyric Acid; Heart Failure; Herpes Z | 2008 |
Chronic psychoemotional stress impairs cannabinoid-receptor-mediated control of GABA transmission in the striatum.
Topics: Animals; Chronic Disease; Corpus Striatum; Dronabinol; Excitatory Amino Acid Antagonists; Excitatory | 2008 |
Challenges of fragmented care in long-term management of pelvic pain.
Topics: Acetaminophen; Adult; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Anxiety Agents; Chr | 2007 |
Time-course of neuronal death in the mouse pilocarpine model of chronic epilepsy using Fluoro-Jade C staining.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Brain; Cerebral Cortex; Chronic Disease; Convulsa | 2008 |
Changes in glutamate decarboxylase enzyme activity and tau-protein phosphorylation in the hippocampus of old rats exposed to chronic mild stress: reversal with the neuronal nitric oxide synthase inhibitor 7-nitroindazole.
Topics: Aging; Animals; Blotting, Western; Chromatography, High Pressure Liquid; Chronic Disease; Enzyme Inh | 2009 |
Cortical excitability in chronic stroke and modulation by training: a TMS study.
Topics: Adult; Aged; Brain Mapping; Cerebral Cortex; Chronic Disease; Electromyography; Evoked Potentials, M | 2009 |
Oral pregabalin reverses cold allodynia in two distinct models of peripheral neuropathic pain.
Topics: Administration, Oral; Analgesics; Animals; Behavior, Animal; Chronic Disease; Cold Temperature; Dise | 2009 |
Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: a novel analgesic and neuroprotective strategy?
Topics: Analgesics; Chronic Disease; Drug Therapy, Combination; Fibromyalgia; gamma-Aminobutyric Acid; Human | 2009 |
Fibromyalgia: poorly understood; treatments are disappointing.
Topics: Acetaminophen; Acupuncture Therapy; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2009 |
Neuropathic pain treatment: a further step forward.
Topics: Amines; Analgesics; Antidepressive Agents, Tricyclic; Chronic Disease; Cyclohexanecarboxylic Acids; | 2009 |
Secondhand smoke exposure and depressive symptoms.
Topics: Air Pollution, Indoor; Chronic Disease; Cotinine; Depression; Depressive Disorder, Major; Environmen | 2010 |
GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study.
Topics: Adult; Antipsychotic Agents; Brain; Chronic Disease; Female; gamma-Aminobutyric Acid; Humans; Magnet | 2010 |
Gabapentin (Neurontin) improves pain scores of patients with critical limb ischaemia: an observational study.
Topics: Aged; Amines; Analgesics; Analgesics, Opioid; Chronic Disease; Cyclohexanecarboxylic Acids; Female; | 2010 |
Can changes in cortical excitability distinguish progressive from juvenile myoclonic epilepsy?
Topics: Adult; Anticonvulsants; Cerebral Cortex; Chronic Disease; Diagnosis, Differential; Drug Resistance; | 2010 |
Effect of analgesic standards on persistent postoperative pain evoked by skin/muscle incision and retraction (SMIR).
Topics: Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Dermatologic Surgical Pro | 2010 |
Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain.
Topics: Analgesics; Animals; Calcium Channels; Chronic Disease; Drug Interactions; gamma-Aminobutyric Acid; | 2010 |
Pharmacological prophylaxis of chronic migraine: a review of double-blind placebo-controlled trials.
Topics: Amines; Analgesics; Chronic Disease; Clonidine; Cyclohexanecarboxylic Acids; Diagnosis, Differential | 2010 |
Role of NKCC1 and KCC2 in the development of chronic neuropathic pain following spinal cord injury.
Topics: Animals; Bumetanide; Chronic Disease; gamma-Aminobutyric Acid; Hyperalgesia; Inflammation; K Cl- Cot | 2010 |
Elevated gamma-aminobutyric acid levels in chronic schizophrenia.
Topics: Adult; Analysis of Variance; Aspartic Acid; Case-Control Studies; Chronic Disease; Creatine; Female; | 2010 |
Behavioral signs of chronic back pain in the SPARC-null mouse.
Topics: Age Factors; Amines; Analgesics; Animals; Anti-Inflammatory Agents; Behavior, Animal; Chronic Diseas | 2011 |
Repeated stress impairs endocannabinoid signaling in the paraventricular nucleus of the hypothalamus.
Topics: Animals; Cannabinoid Receptor Modulators; Chronic Disease; Endocannabinoids; gamma-Aminobutyric Acid | 2010 |
GABAergic pathway in a rat model of chronic neuropathic pain: modulation after intrathecal transplantation of a human neuronal cell line.
Topics: Animals; Cell Line; Chronic Disease; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamate Deca | 2011 |
Gabapentin and pregabalin inhibit the itch-associated response induced by the repeated application of oxazolone in mice.
Topics: Amines; Animals; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic Acids; Disease Models, Ani | 2011 |
[Glossopharyngeal neuralgia after resection of a glossopharyngeal schwannoma].
Topics: Administration, Oral; Adult; Analgesics; Analgesics, Opioid; Autonomic Nerve Block; Buprenorphine; C | 2011 |
[The role of combat stress in the development of chronic pain syndrom in veterans and its treatment by pantogam active].
Topics: Adult; Aged; Chronic Disease; Combat Disorders; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; | 2010 |
Synthesis of neurotransmitter GABA via the neuronal tricarboxylic acid cycle is elevated in rats with liver cirrhosis consistent with a high GABAergic tone in chronic hepatic encephalopathy.
Topics: Acetates; Ammonia; Animals; Astrocytes; Brain Chemistry; Chromatography, High Pressure Liquid; Chron | 2011 |
Stellate ganglion blockade (SGB) for refractory index finger pain - a case report.
Topics: Abdominal Pain; Accidental Falls; Acetaminophen; Adult; Amines; Autonomic Nerve Block; Chronic Disea | 2011 |
Relieving occupational fatigue by consumption of a beverage containing γ-amino butyric acid.
Topics: Adult; Beverages; Chromogranin A; Chronic Disease; Fatigue; Female; gamma-Aminobutyric Acid; Humans; | 2011 |
Hebbian-type stimulation during robot-assisted training in patients with stroke.
Topics: Aged; Chronic Disease; Evoked Potentials, Motor; Female; Functional Laterality; gamma-Aminobutyric A | 2011 |
Chronic Lyme disease: the controversies and the science.
Topics: Amines; Analgesics; Anti-Bacterial Agents; Arthritis, Rheumatoid; Borrelia burgdorferi; Chronic Dise | 2011 |
Pharmacological and behavioral characterization of the saphenous chronic constriction injury model of neuropathic pain in rats.
Topics: Amines; Amitriptyline; Analgesics; Animals; Benzoxazines; Chronic Disease; Constriction; Cyclohexane | 2011 |
Quiz Page October 2011: An under-recognized cause of CKD.
Topics: Acidosis; Amines; Anorexia Nervosa; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Creati | 2011 |
Epigenetic suppression of GAD65 expression mediates persistent pain.
Topics: Animals; Chronic Disease; Epigenesis, Genetic; gamma-Aminobutyric Acid; Gene Expression Regulation, | 2011 |
Reorganization of synaptic inputs to the hypothalamic paraventricular nucleus during chronic psychogenic stress in rats.
Topics: Animals; Behavioral Symptoms; Chronic Disease; Corticosterone; Corticotropin-Releasing Hormone; Depr | 2012 |
Efficacy and safety of pregabalin for the treatment of chronic pruritus in Korea.
Topics: Adult; Aged; Antipruritics; Chronic Disease; Female; gamma-Aminobutyric Acid; Humans; Male; Middle A | 2012 |
[About the neuropathic component of back pain].
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Chroni | 2012 |
Cannabinoid modulation of midbrain urocortin 1 neurones during acute and chronic stress.
Topics: Acute Disease; Animals; Anxiety; Behavior, Animal; Chronic Disease; Endocannabinoids; gamma-Aminobut | 2012 |
Diminished cortical inhibition in an aging mouse model of chronic tinnitus.
Topics: Acoustic Stimulation; Aging; Animals; Auditory Cortex; Auditory Threshold; Cerebral Cortex; Chronic | 2012 |
Effects of oxymatrine on the neuropathic pain induced by chronic constriction injury in mice.
Topics: Alkaloids; Animals; Chronic Disease; Constriction; Disease Models, Animal; Dose-Response Relationshi | 2012 |
Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat.
Topics: Analgesics, Opioid; Animals; Chronic Disease; Colon; Colonic Diseases; gamma-Aminobutyric Acid; Hype | 2002 |
Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception.
Topics: Acetates; Acute Disease; Adrenergic alpha-Agonists; Amines; Analgesics, Non-Narcotic; Analgesics, Op | 2002 |
Anti-allodynic action of the tormentic acid, a triterpene isolated from plant, against neuropathic and inflammatory persistent pain in mice.
Topics: Acetates; Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Freund' | 2002 |
GABA transmission in the nucleus accumbens is altered after withdrawal from repeated cocaine.
Topics: Animals; Binding, Competitive; Chronic Disease; Cocaine; Cocaine-Related Disorders; Disease Models, | 2003 |
Daily changes of GABA and taurine concentrations in various hypothalamic areas are affected by chronic hyperprolactinemia.
Topics: Animals; Chronic Disease; Circadian Rhythm; gamma-Aminobutyric Acid; Hyperprolactinemia; Hypothalamu | 2003 |
Selective loss of spinal GABAergic or glycinergic neurons is not necessary for development of thermal hyperalgesia in the chronic constriction injury model of neuropathic pain.
Topics: Animals; Chronic Disease; gamma-Aminobutyric Acid; Glycine; Hot Temperature; Hyperalgesia; Male; Pai | 2003 |
Treatment of chronic neuropathic pain after traumatic central cervical cord lesion with gabapentin.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Arm; Carbamazepine; Central Cord Syndrome; Cervical Ver | 2003 |
Selective changes in gamma-aminobutyric acid type A receptor subunits in the hippocampus in spontaneously seizing rats with chronic temporal lobe epilepsy.
Topics: Animals; Chronic Disease; Disease Models, Animal; Epilepsy; Epilepsy, Temporal Lobe; gamma-Aminobuty | 2003 |
Chronic pain syndrome after laparoscopic radical nephrectomy.
Topics: Acetates; Aged; Amines; Analgesics; Analgesics, Opioid; Carcinoma, Renal Cell; Carcinoma, Transition | 2003 |
[Unclear chronic aches. Often depression plays a part therein].
Topics: Acetates; Amines; Analgesics, Opioid; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Age | 2003 |
The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain.
Topics: Acetates; Amines; Analgesics; Chronic Disease; Clinical Trials, Phase II as Topic; Computer Simulati | 2003 |
Vulvodynia.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents, Tricyclic; Biofeedback, Psychology; Chroni | 2004 |
Gabapentin (Neurontin) for chronic pain.
Topics: Acetates; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Costs; Drug Interac | 2004 |
Effect of gabapentin derivates on mechanical allodynia-like behaviour in a rat model of chronic sciatic constriction injury.
Topics: Amines; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Cyclohexanols; Disease Models, Animal | 2004 |
Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels.
Topics: Acetates; Amines; Anticonvulsants; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic Acids; G | 2004 |
Chronic placental insufficiency affects retinal development in the guinea pig.
Topics: Amacrine Cells; Animals; Blotting, Western; Body Weight; Calbindin 2; Calbindins; Catecholamines; Ch | 2004 |
Dehydration-induced synaptic plasticity in magnocellular neurons of the hypothalamic supraoptic nucleus.
Topics: Animals; Chronic Disease; Dehydration; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; | 2004 |
Chronic stress attenuates GABAergic inhibition and alters gene expression of parvocellular neurons in rat hypothalamus.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Anim | 2004 |
GABAergic modulation of ventilatory response to acute and sustained hypoxia in obese Zucker rats.
Topics: Acute Disease; Animals; Bicuculline; Carbon Dioxide; Chronic Disease; GABA Antagonists; gamma-Aminob | 2005 |
Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action.
Topics: Acetates; Acute Disease; Amines; Analgesics; Animals; Benzylamines; Chronic Disease; Cyclohexanecarb | 2005 |
Peptide leads new class of chronic pain drugs.
Topics: Calcium Channel Blockers; Calcium Channels, N-Type; Chronic Disease; gamma-Aminobutyric Acid; Humans | 2005 |
Neuropathic pain following multilevel surgery in children with cerebral palsy: a case series and review.
Topics: Adolescent; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Cerebral Palsy; Chi | 2005 |
Use of gabapentin for rest pain in chronic critical limb ischemia.
Topics: Amines; Analgesics; Bed Rest; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminob | 2005 |
Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate.
Topics: Amines; Analgesics; Animals; Aspartic Acid; Chronic Disease; Cyclohexanecarboxylic Acids; Excitatory | 2005 |
[Refractory chronic backache. Neuropathic pain contributions ignored?].
Topics: Algorithms; Analgesics; Anticonvulsants; Back Pain; Chronic Disease; Cross-Sectional Studies; Diagno | 2005 |
The aetiology of chronic cough: a review of current theories for the otorhinolaryngologists.
Topics: Amines; Anticonvulsants; Chronic Disease; Cough; Cranial Nerve Diseases; Cyclohexanecarboxylic Acids | 2006 |
Hyperalgesia induced by REM sleep loss: a phenomenon in search of a mechanism.
Topics: Acetylcholine; Adenosine; Anxiety; Chronic Disease; Depression; Drug Therapy; Drug-Related Side Effe | 2006 |
[Pregabalin--clinical evidence and experiences].
Topics: Anticonvulsants; Chronic Disease; Controlled Clinical Trials as Topic; Drug Interactions; Epilepsy; | 2005 |
Substantia Gelatinosa neurons in defined-medium organotypic slice culture are similar to those in acute slices from young adult rats.
Topics: Action Potentials; Afferent Pathways; Aging; Animals; Chronic Disease; Culture Media; Electric Stimu | 2006 |
Motor cortex stimulation for central pain following a traumatic brain injury.
Topics: Accidental Falls; Adult; Amines; Amitriptyline; Analgesics, Non-Narcotic; Aphasia, Broca; Brain Inju | 2006 |
Cerebrospinal fluid GABA levels in chronic migraine with and without depression.
Topics: Brain; Chromatography, High Pressure Liquid; Chronic Disease; Comorbidity; Depressive Disorder; Fema | 2006 |
Gabapentin in the treatment of intractable idiopathic chronic cough: case reports.
Topics: Adult; Aged; Amines; Calcium Channel Blockers; Chronic Disease; Cough; Cyclohexanecarboxylic Acids; | 2006 |
Perioperative analgesia to prevent chronic postmastectomy pain.
Topics: Amines; Anesthetics, Local; Breast Neoplasms; Chronic Disease; Cyclohexanecarboxylic Acids; Female; | 2006 |
Pulsed radiofrequency of the dorsal root ganglia is superior to pharmacotherapy or pulsed radiofrequency of the intercostal nerves in the treatment of chronic postsurgical thoracic pain.
Topics: Adult; Amines; Analgesics; Anticonvulsants; Carbamazepine; Catheter Ablation; Chronic Disease; Cyclo | 2006 |
Inhibition of pain behavior by GABA(B) receptors in the thalamic ventrobasal complex: effect on normal rats subjected to the formalin test of nociception.
Topics: Acute Disease; Analgesics; Animals; Baclofen; Behavior, Animal; Chronic Disease; Disease Models, Ani | 2006 |
Hypolocomotion in rats with chronic liver failure is due to increased glutamate and activation of metabotropic glutamate receptors in substantia nigra.
Topics: Animals; Basal Ganglia; Chromones; Chronic Disease; GABA Antagonists; gamma-Aminobutyric Acid; Gluta | 2006 |
GABA(B2) receptor subunit mRNA decreases in the thalamus of monoarthritic animals.
Topics: Afferent Pathways; Animals; Arthralgia; Arthritis; Chronic Disease; Disease Models, Animal; Down-Reg | 2006 |
[Post-operative pain therapy of a chronic pain patient].
Topics: Adult; Amines; Analgesics; Analgesics, Opioid; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Co | 2006 |
Chronic cough as a sign of laryngeal sensory neuropathy: diagnosis and treatment.
Topics: Amines; Chronic Disease; Cough; Cranial Nerve Diseases; Cyclohexanecarboxylic Acids; Diagnosis, Diff | 2006 |
Gabapentin successfully manages chronic unexplained irritability in children with severe neurologic impairment.
Topics: Adolescent; Adult; Amines; Analgesics; Child; Child, Preschool; Chronic Disease; Cyclohexanecarboxyl | 2007 |
Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats.
Topics: Analgesics; Animals; Carrageenan; Chronic Disease; Disease Models, Animal; Dose-Response Relationshi | 2007 |
Gabapentin use in chronic uraemic itch is in line with emerging pathogenetic hypothesis.
Topics: Amines; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; P | 2007 |
Alpha-2-delta ligands for singultus (hiccup) treatment: three case reports.
Topics: Aged; Amines; Anticonvulsants; Calcium Channels; Chronic Disease; Cyclohexanecarboxylic Acids; Gabap | 2007 |
[3H] pregabalin binding is increased in ipsilateral dorsal horn following chronic constriction injury.
Topics: Afferent Pathways; Analgesics; Animals; Binding, Competitive; Calcium Channel Blockers; Calcium Chan | 2007 |
Motor activity is modulated via different neuronal circuits in rats with chronic liver failure than in normal rats.
Topics: Animals; Behavior, Animal; Brain; Chronic Disease; Dopamine; Excitatory Amino Acid Agonists; Excitat | 2007 |
[Effects of acute maximal electroshock and chronic transauricular kindled seizures on learning abilities in Sprague-Dawley rats].
Topics: Animals; Chronic Disease; Electric Stimulation; Electrodes; Electroshock; gamma-Aminobutyric Acid; H | 2007 |
Chronic orchialgia: consider gabapentin or nortriptyline before considering surgery.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Amines; Calcium Channel Blockers; Chronic Disease; Cycloh | 2007 |
[The 10-minute-consultation: chronic singultus].
Topics: Aged; Amines; Anti-Ulcer Agents; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Diag | 2007 |
Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia.
Topics: Amitriptyline; Analgesics; Anti-Ulcer Agents; Anticoagulants; Antidepressive Agents; Anxiety; Cardio | 2007 |
Pregabalin-induced generalized myoclonic status epilepticus in patients with chronic pain.
Topics: Aged, 80 and over; Analgesics; Chronic Disease; Electroencephalography; Epilepsies, Myoclonic; Femal | 2007 |
Efficacy of pregabalin in the treatment of trigeminal neuralgia.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Chronic Disease; Dose-Response Relationship, Drug; Facia | 2008 |
Pregabalin in the treatment of chronic pruritus.
Topics: Anticonvulsants; Chronic Disease; gamma-Aminobutyric Acid; Humans; Pregabalin; Pruritus | 2008 |
Pharmacologic investigation of the mechanism underlying cold allodynia using a new cold plate procedure in rats with chronic constriction injuries.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Calcium Channel Blockers; Chronic Disease; Cold Tempe | 2008 |
Experimental autoimmune prostatitis induces chronic pelvic pain.
Topics: Amines; Analgesics; Anesthetics, Local; Animals; Autoimmune Diseases; Chronic Disease; Cyclohexaneca | 2008 |
Chronic, but not acute, tricyclic antidepressant treatment alleviates neuropathic allodynia after sciatic nerve cuffing in mice.
Topics: Amines; Amitriptyline; Animals; Anticonvulsants; Antidepressive Agents, Tricyclic; Brain; Chronic Di | 2008 |
Pharmacological treatment of neuropathic pain in older persons.
Topics: Aged; Amines; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; Chronic Disease | 2008 |
Side effects in preventive maintenance therapy with neuroleptics with special emphasis on tardive dyskinesia.
Topics: Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Humans; Pa | 1981 |
Neurotransmitters and CNS disease. Schizophrenia.
Topics: Antipsychotic Agents; Atrophy; Brain; Cerebral Ventricles; Chronic Disease; Dopamine; Endorphins; GA | 1982 |
Effects of a GABA-mimetic drug (sodium valproate) on visually evoked potentials in chronic schizophrenics.
Topics: Adult; Brain; Brief Psychiatric Rating Scale; Chronic Disease; Clozapine; Dibenzazepines; Drug Thera | 1984 |
[Sleep in chronic chorea patients after therapy with sodium valproate].
Topics: Adult; Chorea; Chronic Disease; Female; gamma-Aminobutyric Acid; Humans; Huntington Disease; Male; M | 1984 |
Increased GABA binding in mouse brain following acute swim stress.
Topics: Acute Disease; Analgesia; Animals; Brain; Chronic Disease; Female; gamma-Aminobutyric Acid; Kinetics | 1981 |
[Effect of gamma-aminobutyric acid preparations on cerebral circulation in chronic cerebrovascular insufficiency].
Topics: Blood Pressure; Brachial Artery; Cerebrovascular Circulation; Cerebrovascular Disorders; Chronic Dis | 1982 |
gamma-Aminobutyric acid concentration in cerebrospinal fluid in schizophrenia.
Topics: Acute Disease; Adult; Chronic Disease; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; R | 1981 |
[Possibility of using gamma-aminobutyric acid for treating chronic xanthate poisoning].
Topics: Animals; Carbonates; Chronic Disease; Drug Evaluation, Preclinical; Environmental Exposure; gamma-Am | 1980 |
L-glutamate and gamma-aminobutyric acid uptake in synaptosomes from the cerebral cortex of dogs with congenital chronic hepatic encephalopathy.
Topics: Ammonia; Animals; Cerebral Cortex; Chronic Disease; Dogs; gamma-Aminobutyric Acid; Glutamic Acid; He | 1995 |
Area-dependent changes in GABAergic function after acute and chronic cold stress.
Topics: Acute Disease; Animals; Cerebral Cortex; Chronic Disease; Cold Temperature; gamma-Aminobutyric Acid; | 1993 |
Long-term use of lamotrigine and vigabatrin in severe refractory epilepsy: audit of outcome.
Topics: Chronic Disease; Clinical Trials as Topic; Epilepsy; Follow-Up Studies; gamma-Aminobutyric Acid; Hum | 1996 |
The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain.
Topics: Acetates; Acute Disease; Amines; Analgesics; Animals; Anticonvulsants; Chronic Disease; Cyclohexanec | 1997 |
Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions.
Topics: Adult; Anticonvulsants; Chronic Disease; Epilepsy; gamma-Aminobutyric Acid; Humans; Male; Vigabatrin | 1997 |
Modulation of excitatory amino acids pathway: a possible therapeutic approach to chronic daily headache associated with analgesic drugs abuse.
Topics: Acetates; Adult; Amines; Chronic Disease; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagon | 1997 |
[Prophylactic treatment with gabapentin in chronic daily headache resistant to other drugs].
Topics: Acetates; Adult; Aged; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Drug Resist | 1998 |
Physiological analysis of Rasmussen's encephalitis: patch clamp recordings of altered inhibitory neurotransmitter function in resected frontal cortical tissue.
Topics: Cell Size; Cells, Cultured; Cerebral Cortex; Child; Chronic Disease; Clonazepam; Dose-Response Relat | 1998 |
Characteristics of neurons with high-frequency discharge in the central nervous system and their relationship to chronic pain. Experimental and clinical investigations.
Topics: Animals; Calcium Channel Blockers; Chronic Disease; Denervation; Disease Models, Animal; Electric St | 1997 |
[ETICS Study: Empirical therapy of idiopathic chronic singultus].
Topics: Acetates; Aged; Aged, 80 and over; Amines; Baclofen; Chronic Disease; Cisapride; Cyclohexanecarboxyl | 1998 |
GABA synapses enter the molecular big time.
Topics: Chronic Disease; Epilepsy; gamma-Aminobutyric Acid; Humans; Neural Inhibition; Neuronal Plasticity; | 1998 |
Long-term treatment with vigabatrin - 10 years of clinical experience.
Topics: Anticonvulsants; Chronic Disease; Cohort Studies; Epilepsy; Female; Follow-Up Studies; gamma-Aminobu | 1999 |
Seizure-induced hippocampal damage and chronic epilepsy: a hebbian theory of epileptogenesis.
Topics: Animals; Chronic Disease; Dentate Gyrus; Epilepsy; gamma-Aminobutyric Acid; Hippocampus; Interneuron | 1999 |
Amino acid efflux and cell volume regulation in cerebrocortical minislices prepared from chronically hyponatraemic and hypernatraemic rats.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Amino Acids; Animals; Aspartic Acid; Biological Tr | 1999 |
The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy.
Topics: Acetates; Ambulatory Care; Amines; Anticonvulsants; Chronic Disease; Clinical Trials as Topic; Cyclo | 1999 |
Gabapentin therapy for vulvodynia.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic | 1999 |
Gabapentin "add-on therapy" for idiopathic chronic hiccup (ICH).
Topics: Acetates; Aged; Amines; Baclofen; Chronic Disease; Cisapride; Cyclohexanecarboxylic Acids; Drug Admi | 2000 |
Gabapentin for chronic pain in spinal cord injury: a case report.
Topics: Acetates; Adult; Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Female; Gabapenti | 2000 |
Abnormal brain chemistry in chronic back pain: an in vivo proton magnetic resonance spectroscopy study.
Topics: Adult; Anxiety; Aspartic Acid; Back Pain; Brain Chemistry; Choline; Chronic Disease; Creatine; Femal | 2000 |
Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy.
Topics: Acetates; Adolescent; Adult; Age of Onset; Aged; Amines; Anticonvulsants; Chronic Disease; Cyclohexa | 2000 |
Collapse of extracellular glutamate regulation during epileptogenesis: down-regulation and functional failure of glutamate transporter function in rats with chronic seizures induced by kainic acid.
Topics: Amino Acid Transport System X-AG; Animals; ATP-Binding Cassette Transporters; Carrier Proteins; Chro | 2001 |
Rodent model of chronic central pain after spinal cord contusion injury and effects of gabapentin.
Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Chronic Disease; Contusions; Cyclohexanecar | 2000 |
The effect of streptozotocin-induced diabetes on the release of excitotoxic and other amino acids from the ischemic rat cerebral cortex.
Topics: Acute Disease; Amino Acids; Animals; Blood Glucose; Brain Ischemia; Cerebral Cortex; Chronic Disease | 2001 |
gamma-Aminobutyric acid (GABA)--A function and binding in the paraventricular nucleus of the hypothalamus in chronic renal-wrap hypertension.
Topics: Animals; Bicuculline; Binding Sites; Blood Pressure; Chronic Disease; GABA Antagonists; GABA-A Recep | 2001 |
Changes in exploratory behavior as a measure of chronic central pain following spinal cord injury.
Topics: Acetates; Amines; Analgesics; Animals; Chronic Disease; Cyclohexanecarboxylic Acids; Exploratory Beh | 2001 |
Diminished allopregnanolone enhancement of GABA(A) receptor currents in a rat model of chronic temporal lobe epilepsy.
Topics: Animals; Anticonvulsants; Chronic Disease; Diazepam; Electric Conductivity; Epilepsy, Temporal Lobe; | 2001 |
Increased [(3)H]tiagabine binding to GAT-1 in the cingulate cortex in schizophrenia.
Topics: Aged; Aged, 80 and over; Brain; Carrier Proteins; Case-Control Studies; Caudate Nucleus; Chronic Dis | 2002 |
[Gabapentin in the treatment of chronic intractable pain].
Topics: Acetates; Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non | 2002 |
Spontaneous recurrent seizures and neuropathology in the chronic phase of the pilocarpine and picrotoxin model epilepsy.
Topics: Acetylcholine; Action Potentials; Aggression; Animals; Behavior, Animal; Brain; Chronic Disease; Dis | 2002 |
Gabapentin for neuropathic pain following spinal cord injury.
Topics: Acetates; Acute Disease; Adolescent; Adult; Aged; Amines; Chronic Disease; Cyclohexanecarboxylic Aci | 2002 |
Experimental conditions for the continuous subcutaneous infusion of four central analgesics in rats.
Topics: Acetates; Amines; Analgesics; Anesthetics, Dissociative; Animals; Anticonvulsants; Antidepressive Ag | 2002 |
Stimulation of prolactin and growth hormone secretion by muscimol, a gamma-aminobutyric acid agonist.
Topics: Adult; Aged; Chronic Disease; Female; gamma-Aminobutyric Acid; Growth Hormone; Humans; Huntington Di | 1978 |
[Treatment of chronic diffuse arachnoiditis with aminalon].
Topics: Adult; Aminobutyrates; Arachnoiditis; Chronic Disease; Drug Evaluation; Female; gamma-Aminobutyric A | 1978 |
Meeting report: Biochemical aspects of schizophrenia. Alabama, April 1975.
Topics: Acute Disease; Blood Platelets; Chronic Disease; Dopamine; Folic Acid; gamma-Aminobutyric Acid; Hall | 1975 |
The gamma-aminobutyric acid (GABA) system in brain during acute and chronic ethanol intoxication.
Topics: 1-Propanol; 4-Aminobutyrate Transaminase; Acute Disease; Alcoholic Intoxication; Aminobutyrates; Ani | 1975 |
Chronic encephalopathies induced by mercury or lead: aspects of underlying cellular and molecular mechanisms.
Topics: Astrocytes; Brain Diseases; Cells, Cultured; Chronic Disease; gamma-Aminobutyric Acid; Glutamates; L | 1992 |
[The gamma-aminobutyric acid content of the blood plasma in patients with Itsenko-Cushing disease and its dependence on clinical and hormonal indices].
Topics: 11-Hydroxycorticosteroids; 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenalectomy; Adrenocorticot | 1991 |
Paradoxical role of GABA in a chronic model of petit mal (absence)-like epilepsy in the rat.
Topics: Animals; Anticonvulsants; Chronic Disease; Disease Models, Animal; Dose-Response Relationship, Drug; | 1990 |
[Immunological and metabolic disorders and the means for their correction in patients with chronic bronchitis].
Topics: Adolescent; Adult; Antibody Formation; Antioxidants; Bronchitis; Chronic Disease; Drug Evaluation; F | 1991 |
Reversal of chronic hepatic encephalopathy by colonic exclusion: poor correlation with blood GABA levels.
Topics: Ammonia; Chronic Disease; Electroencephalography; Female; gamma-Aminobutyric Acid; Hepatic Encephalo | 1990 |
Changes in GABA-immunoreactive cell density during motor focal epilepsy induced by cobalt in the rat.
Topics: Animals; Cell Count; Chronic Disease; Cobalt; Epilepsies, Partial; gamma-Aminobutyric Acid; Male; Mo | 1989 |
Plasma gamma aminobutyric acid concentrations provide evidence of different mechanisms in the pathogenesis of hepatic encephalopathy in acute and chronic liver disease.
Topics: Acute Disease; Adult; Chronic Disease; Delta Rhythm; Female; gamma-Aminobutyric Acid; Hepatic Enceph | 1989 |
Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients.
Topics: Adult; Aged; Amino Acids; Amygdala; Brain Chemistry; Chronic Disease; Female; gamma-Aminobutyric Aci | 1987 |
Failure of the GABAergic drug, sodium valproate, to reduce basal plasma prolactin secretion in chronic schizophrenia.
Topics: Adult; Chronic Disease; Female; gamma-Aminobutyric Acid; Humans; Hypothalamo-Hypophyseal System; Mid | 1985 |
Effects of chronic intracerebroventricular GABAergic treatment on basal and chronic or acute stress-induced adrenocortical activities in the thalamic pigeon.
Topics: Acute Disease; Adrenal Cortex; Animals; Chronic Disease; Columbidae; Corticosterone; Decerebrate Sta | 1986 |
Serum gamma-aminobutyric acid (GABA) levels in patients with hepatic encephalopathy.
Topics: Ammonia; Chronic Disease; gamma-Aminobutyric Acid; Hepatic Encephalopathy; Humans; Kidney Failure, C | 1985 |
Proceedings: Ammonia and amino acids in the brain of the rat with chronic hepatic failure.
Topics: Amino Acids; Ammonia; Animals; Aspartic Acid; Brain; Carbon Tetrachloride Poisoning; Chronic Disease | 1974 |